Sensitive assays are needed for detection of residual HIV in patients with undetectable plasma viral loads to determine if eradication strategies are effective. The gold standard quantitative viral outgrowth assay (QVOA) underestimates the magnitude of the viral reservoir, while sensitive PCR‐based assays lack the ability to distinguish replication competent from defective virus. We sought to determine whether xenograft of leukocytes from HIV‐1 infected patients with undetectable plasma viral loads into severely immunocompromised mice would result in viral amplification and measurable viral loads within the aberrant murine host. We evaluated whether xenograft of 1) peripheral blood mononuclear cells (PBMCs) from five HIV‐1+ patients on suppressive antiretroviral therapy (ART), 2) PBMCs or purified resting CD4+ T cells from 5 HIV‐1+ elite suppressors (ES), or 3) PBMCs from a Simian Immunodeficiency Virus (SIV)+ pigtailed macaque on suppressive ART, all with undetectable plasma viral loads, into NOD. Cg‐PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice resulted in viral amplification in the mouse. Successful xenograft of mice was confirmed by flow cytometry. Human CD8+ T cells were depleted in humanized mice with depleting antibody, and CD4+ T cells were activated in a subset of mice with activating anti‐CD3. Plasma viral loads in xenografted mice were quantified using qRT‐PCR, and compared to plasma viral load and QVOA results from the human or macaque donor. With this murine viral outgrowth assay (MVOA), we amplified HIV‐1 from all 10 HIV+ subjects with undetectable plasma viral load, including an ES from whom we were unable to recover virus by QVOA. We detected HIV in mice an average of 20 days after xenograft with PBMCs from patients on suppressive ART, and an average of 28 days after xenograft with PBMCs or resting CD4+ T cells from ES. For two of the mice xenografted with CD4+ T cells from ES, we detected HIV only after activation with anti‐CD3. We similarly detected SIV in macaquized mice by seven days post‐xenograft. The MVOA has the potential to serve as a powerful tool to identify residual HIV‐1 in patients with undetectable viral loads, such as those who have undergone promising cure therapies. Abstract MOAA0101–Figure 1. MVOA for detection of residual virus. Abstract MOAA0101–Figure 1. MVOA for detection of residual virus. 10.7448/IAS.18.5.20320 © 2015 Pate K M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: kpate5@jhmi.edu Antiretroviral therapy (ART) does not eradicate HIV and the virus rebounds upon treatment interruption. Recently, a sustained control of HIV replication in the absence of ART has been achieved in a subset of patients starting ART early after infection, defined as post‐ART treatment controllers (PTC). Unfortunately, the virologic and immunologic determinants of post‐ART control of HIV replication are still unclear, particularly in tissues. Here, we used the well‐established model of SIV‐infection in rhesus macaques (RMs) to investigate the existence of PTC in this model and the features associated with post‐ART SIV control. Fifteen RMs (B*08‐ and B*17) were infected (i.v.) with SIVmac239. All 15 animals initiated a five‐drug ART regimen 60 days after infection, which was maintained for seven months. ART was then interrupted and RMs monitored for eight additional months. Blood (PB), lymph node (LN) and colorectal (RB) biopsies were collected throughout the study. Quantitative assessment of total SIV‐DNA and RNA was performed on purified blood CD4 T cells and mucosal tissues by quantitative PCR; immunological parameters were determined by flow cytometry. ART suppressed SIV‐RNA to <60 copies/mL in all RMs. After ART interruption, six RMs controlled SIV viremia at <103 copies/mL up to eight months off‐ART (PTC), while nine RMs rebounded to pre‐ART levels (non‐controllers, NC). At pre‐ART, PTC had significantly lower plasma viremia and SIV‐DNA content, as well as higher CD4 T cell counts as compared to NC. Levels of intestinal CD4 T cells were similar, but PTC had higher frequencies of Th17 cells than NC. On‐ART, PTC had significantly lower levels of residual plasma viremia (3 copies/mL, limit of detection) and SIV‐DNA content (both in blood and colorectum). After ART interruption, SIV‐DNA content rapidly increased in NC while it progressively decreased in PTC. Finally, in PTC control of SIV rebound associated with higher CD4 T cell levels and reduced immune activation in PB and RB during the entire off‐ART period. Lower set point viremia, reduced cell‐associated SIV‐DNA and preserved Th17 cell homeostasis associate with improved virologic response to ART and sustained viral control post‐ART interruption in SIV‐infected RMs. 10.7448/IAS.18.5.20321 © 2015 Micci L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mirko.paiardini@emory.edu A major challenge to HIV eradication strategies is accurate measurement of the latent HIV reservoir. We assessed whether the host response to residual virus may be a sensitive measure of reservoir size by comparing anti‐HIV antibody profiles in relation to several HIV reservoir assays. Using a luciferase immunoprecipitation systems (LIPS) assay, we quantitatively analyzed seven anti‐HIV antibody profiles from 61 patients who initiated long‐term (≥3 years) antiretroviral therapy (ART) during chronic HIV infection. HIV antibody levels were evaluated in relation to 12 HIV reservoir measures: total, integrated and 2‐LTR DNA (rtPCR, n=48); unspliced RNA (rtPCR, n=44), total and 2‐LTR DNA (droplet digital PCR, n=27); integrated DNA (aluPCR, n=16); viral outgrowth assay (VOA, n=27) and plasma HIV RNA (single copy assay, SCA, n=27). Summary estimates of the overall association between HIV reservoir measures and HIV antibody levels adjusted for multiple comparisons were obtained using permutation testing. Participants were mostly male (96%) with a median age of 56, median nadir and proximal CD4+ T cell counts of 210 and 670 cells/mm3, respectively, and ART‐suppression for a median of 11 years. Individual correlations showed that integrated and total HIV DNA levels by aluPCR and ddPCR were significantly associated with all antibody levels except p24 (nor matrix, for ddPCR, Figure 1). HIV reservoir size measured by viral outgrowth assay (VOA) was associated with gp120 and gp41 levels (r=0.45, p=0.02; r=0.43, p=0.02) while HIV RNA by SCA and HIV DNA by rtPCR were not correlated with any HIV antibody responses. Permutation testing demonstrated a strong overall association between HIV reservoir size and anti‐HIV antibody responses (r=0.82, p=0.04, Table 1), in particular with gp120 (r=0.80, p=0.009), gp41 (r=0.73, p=0.04) and reverse transcriptase (r=0.82, p=0.007). Further adjustment for age, proximal CD4+ T cell count and years of ART suppression did not significantly alter these results. Anti‐HIV antibody responses correlate with quantifiable reservoir size during chronic ART‐mediated suppression. Epitope location (envelope proteins and reverse transcriptase, an enzyme involved in the early steps of viral replication) may determine the strength of this association. Future studies are needed to evaluate whether viral RNA or proteins are produced in cells with defective proviruses. Abstract MOAA0103–Figure 1. Individual correlations matrix. Abstract MOAA0103–Figure 1. Individual correlations matrix. Abstract MOAA0103–Table 1. Adjusted summary correlations Anti‐HIV antibody response R P loggp120 0.80 0.009 loggp41 0.73 0.042 logrt 0.82 0.007 logintegrase 0.70 0.053 logpr 0.60 0.199 logma 0.54 0.340 logp24 0.41 0.679 All 0.82 0.039 10.7448/IAS.18.5.20322 © 2015 Lee S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: sulggi.lee@ucsf.edu To identify mechanisms that control immune reconstitution and the size of the inducible HIV reservoir, we performed whole blood transcriptional and metabolic profiling of subjects from the CLIF and UCSF SCOPE cohorts. These cohorts included subjects who increased CD4 counts post cART (IR) or stayed <350/mm3 after three years of cART (INR). We performed unsupervised analysis of gene expression data using hierarchical clustering to identify class and supervised analysis using statistical filtering to identify gene signatures and pathway activity differentially expressed between classes. Multivariate analysis based on Sparse Partial Least Regression was used to determine if Group membership correlated with plasma metabolites measured by LC‐MS/GC‐MS. A gene‐based classifier was developed to identify INR groups using the pamr package. Two groups of INR subjects were identified by whole blood gene expression and pathway analysis. INR‐A had the highest levels of IL‐6, sCD14, FOXO3 and STAT1 expression, and highest levels of oxidative stress and mitochondrial dysfunction. Pathway analysis showed that INR‐A failed to activate the NF‐κB pathway, TLR‐MyD88 signalling and proinflammatory modules yet upregulated expression of the p38 MAPK pathway, IRF‐3, IRF‐4 and IL‐10 associated with a tolerogenic myeloid response. In contrast, INR‐B was characterized by an unrestrained proinflammatory response including the upregulation of multiple TLRs, STAT1, IRF1 and IRF8 associated with Type I/II IFN responses. Plasma metabolites including carnitines, bacterial metabolites and cholesterol also segregated between the two INR groups and correlated with gene expression including FOXO3A and STAT‐1. TILDA, a measure of the inducible HIV reservoir; revealed that INR‐A subjects had higher levels than INR‐B and IR's. As CD4 counts and plasma biomarkers of inflammation/immune activation fail to distinguish the two INR groups, we developed a 352 gene‐based classifier that accurately identified patient groups (AUC of 0.81 by ROC analysis) in an independent test cohort (UCSF SCOPE) including those that had the highest levels of HIV reservoir. Identifying pathways that control immune reconstitution and the size of the inducible HIV reservoir paves the way to the development of therapeutic strategies that can lead to eradication of HIV. 10.7448/IAS.18.5.20323 © 2015 Ghneim K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: khader.ghneim@case.edu Durable HIV‐1 remission after interruption of combined antiretroviral therapy (cART) has been reported in some adults who started cART during primary HIV‐1 infection. The in utero HIV‐1‐infected “Mississippi child” exhibited transient viral control after interrupting very early‐initiated cART. However, viraemia rebounded 27 months later, leaving unclear the possibility of obtaining long‐term post‐treatment remission in vertically infected children. Here, we report the case of a perinatally HIV‐1‐infected adolescent who shows unprecedented virological remission more than 11 years after cART discontinuation. HIV‐RNA and CD4+ T‐cell counts have been monitored since birth. Ultrasensitive HIV‐RNA, peripheral blood mononuclear cell (PBMC)‐associated HIV‐DNA, flow‐cytometry‐assessed frequency of HIV‐specific CD8+ T cells, CD8+ T‐cell‐mediated HIV suppression, reactivation of the CD4+ T‐cell reservoir were evaluated after 10 and 11 years of control off therapy. Plasma concentrations of antiretrovirals were determined by tandem mass spectrometry. One infant born for a woman with uncontrolled HIV‐1 viraemia received zidovudine‐based prophylaxis during six weeks. HIV‐RNA and DNA were not detected 3 and 14 days after birth. HIV‐DNA was detected at four weeks of age. HIV‐RNA reached a peak of 2.1×106 copies/mL at three months of age when cART (zidovudine, lamivudine, didanosine and ritonavir) was initiated. HIV‐RNA was undetectable one month later and remained below assay‐detection limits while on cART, except at 15 and 21 months of age. Between 5.8 and 6.8 years of age, cART was discontinued by the family. HIV‐RNA was undetectable at 6.8 years of age and cART was not resumed. HIV‐RNA has remained <50 copies/mL through 18.3 years of age, except for one blip (515 copies/mL). CD4+ T‐cell counts remained stable. After 11 years of control off therapy (confirmed by undetectable plasma concentrations of antiretrovirals), HIV‐RNA was below four copies/mL and HIV‐DNA was 2.2 log copies/106 PBMC. Low levels of HIV‐RNA and p24 were detected upon the activation of CD4+ T cells with PHA. HLA genotype showed homozygosity at several loci (A*2301‐;B*1503/4101;C*0210/0802;DRB1*1101‐;DQB1*0602‐). HIV‐specific CD8+ T‐cell responses and T‐cell activation were very weak. HIV‐1 western blot was positive with the absence of antibodies against gp110 and p18. This case provides first‐time evidence that very long‐term HIV‐1 remission is possible in perinatally infected early‐treated children, with similar characteristics as reported in adult post‐treatment controllers. 10.7448/IAS.18.5.20566 © 2015 Frange P et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: asier.saez‐cirion@pasteur.fr Cell‐associated unspliced (CA‐US) HIV RNA is an important marker of the HIV reservoir and a common primary endpoint in clinical trials of latency reversing agents in HIV‐infected subjects on antiretroviral therapy (ART). We observed large baseline variation in CA‐US HIV RNA in a recent clinical trial of disulphiram and hypothesized that these changes were due to circadian‐related alterations in CD4+ T‐cell composition, gene regulation or anticipatory stress. Blood was collected on three occasions (B1, B2 and B3) from HIV‐infected subjects (n=30) on suppressive ART prior to any intervention. B3 was collected immediately prior to administration of disulphiram. We measured CA‐US HIV RNA and DNA by real‐time PCR and plasma HIV RNA (using a single copy assay) by droplet digital PCR. Plasma cortisol and thyroid‐stimulating hormone (TSH) levels were quantified by ELISA. PBMC were stained with live‐dead dye and antibodies to CD3, CD4, CD8, CD45RA, CCR7, CD27, CD38, HLA‐DR, acetylated lysine and acetylated histone‐3 and were analyzed by flow cytometry. Data were assessed for normality and then analyzed with Wilcoxon matched‐pairs signed rank tests and paired t‐tests. CA‐US RNA was higher in blood collected at B3 compared to B1 and B2 (median 85.63 vs. 28.14 and 34.87 copies/million CD4+ T‐cell equivalents; both, p<0.001). There were little differences in HIV DNA or plasma HIV RNA at these times. B3 was collected earlier in the day compared to B1 and B2 (mean 8.28 am vs. 11.38 am and 10.21 am; both, p<0.001). Other parameters that were significantly higher at B3 compared to B1 and B2 were cortisol (p=0.001 and 0.011); TSH (p=0.023 and 0.004); CD8+CD38+HLA‐DR– T cells (both, p50 years old (ageing), or (2) <35 years old (young adult) and (3) healthy age‐matched uninfected women. We also examine correlations between dysbiosis of the salivary microbiome, disease progression and opportunistic oral infections. HIV infection results in dysbiosis of the salivary microbiome that is enhanced in ageing individuals and characterized by increased abundance of pathogenic bacteria and a decline in healthy probiotic microbes. Higher proportions of Prevotella, Staphylococcus, Moryella, Peptostreptococcus, Ruminococcus and Oribacterium were detected in both ageing and young adult HIV infected women than in uninfected controls. Prevotella, Moryella and Oribacterium increases were higher in ageing than in young HIV patients. HIV infection in older patients was associated with greater salivary shedding of Epstein Barr Virus (EBV). Increased EBV shedding, higher peripheral HIV burden and reduced CD4+ T cell counts correlated with increases in Prevotella and decreases in probiotic Lactobacillus. Patients with opportunistic oral infections also showed enhanced salivary levels of Porphyromonas, Lachnospira and Actinobacillus, and reduced Streptococcus. Age, severity of disease progression and emergence of opportunistic infections all contribute to various degrees in increasing the pathogenic footprint of the oral microbiome during chronic HIV infection. The study findings provide new insights into age‐related dysbiosis of the salivary microbiome and its role in HIV pathogenesis and lay critical groundwork for future expanded investigations. 10.7448/IAS.18.5.20325 © 2015 George M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mdgeorge@ucdavis.edu A multi‐centre trial in HIV‐enteropathy was conducted to evaluate the impact of serum‐derived bovine immunoglobulin isolate (SBI) on markers of peripheral and mucosal immunity and gastrointestinal (GI) symptoms as previously reported. Patients (pts) on long‐term suppressive antiretroviral treatment (ART) with HIV‐enteropathy were randomized to receive SBI 2.5 vs. 5.0 g BID or placebo (PBO) during a four‐week lead‐in phase followed by SBI 2.5 vs. 5.0 g BID for 20 weeks. Evaluations included plasma biomarkers for inflammation, peripheral CD4 counts and pt‐reported surveys on GI symptoms. Eight pts underwent duodenal biopsies to examine mucosal immunity. A total of 103 pts (SBI 2.5 g; n=34; SBI 5.0 g; n=33; PBO: n=36 continued 2.5 vs. 5.0 g (n=18 each)) were enrolled (31% female; 61% black; mean age 51 years). Mean duration of HIV, ART and enteropathy was over 15, 5 and 5 years, respectively. All cohorts showed a reduction in abnormal stool frequency (p=0.0001) from baseline (BL) to week 4; however between group analysis was not significant. This reduction was maintained for pts receiving SBI through 24 weeks. The 2.5 and 5.0 g cohorts were combined for zonulin and CD4 analysis. The mean plasma zonulin levels significantly increased (p<0.0001) for pts receiving SBI through 24 weeks. Median peripheral CD4 counts increased significantly from BL to week 24 in patients in the lowest baseline CD4 quartile (308 to 386 cells/mL, p=0.002), while no significant change was observed among subjects in the combined SBI cohorts during this time period. This compromised subgroup also experienced greater increases in CD4 counts at week‐4 than PBO pts (median +42 vs. −17 cells/mL, p=0.02). Duodenal CD4 densities increased from 217 to 329 cells/mm2 (median increase of 145 cells/mm2 (p=0.02)) in biopsies obtained from eight pts, consistent with earlier findings. Duodenal crypt cells expressing Ki67 decreased in 6/7 pts from 41 to 24% (p=0.08, n=7) which correlated with the decreased number of Paneth cells per crypt (p=0.048). Oral SBI may be a novel strategy to restore mucosal immunity and systemic immune reconstitution among pts who have not achieved normal CD4 counts despite prolonged suppressive ART. 10.7448/IAS.18.5.20326 © 2015 Asmuth D et al; licensee International AIDS Society Published 22 July 2015 The gut microbiome is crucial for mucosal and systemic immune development. In mice, certain bacteria are required for induction of Treg and Th17 cell development in the gut. Likewise, gut microbiota enhance immune responses to influenza vaccination in the mouse model. HIV‐infected women have altered vaginal and gut microbiome, and HIV‐exposed infants (HEU) and their mothers receive antibiotics for pneumocystis pneumonia prophylaxis, therefore HEU may have altered gut microbiota. HEU have higher morbidity and mortality than HIV‐unexposed (HU) infants, and respond poorly to certain infant vaccinations. We hypothesized that the aetiology of this relative immune deficiency is mediated by gut dysbiosis. HEU and HU infants were recruited at birth from informal settlements of Cape Town. Blood and stool were collected after informed consent was obtained. Stool DNA was extracted using MoBio PowerFecal DNA kit and 454 or Illumina sequencing was performed. Data was pre‐processed using QIIME and UPARSE and imported into R for further analyses using phyloseq. Differential abundance testing was performed at Operational Taxonomic Unit (OTU) level using the R metagenomeSeq package. Whole blood was incubated with BCG, positive and negative controls, and proliferation and cytokine expression measured using multi‐parameter flow cytometry. We found substantial differences in bacterial diversity between HEU and HU infants by Shannon index. Moreover, at all taxonomic levels, there were differences between the HIV exposure groups via PCoA analysis. Several OTUs of the phylum Firmicutes were differentially abundant between HEU and HU infants, three of which were of the genus Veillonella. Several key species were significantly correlated with both proliferative and cytokine responses to BCG. For example, at six weeks of age, significantly decreased abundance of Bacteroides species, and in particular B. fragilis, were present in infants with high CD4+IL‐2+, CD8+ki67+ and CD8+IL‐17+ responses to BCG vaccination at six weeks of age. Gut microbial composition could explain the immunological differences between HU and HEU infants. These differences should be considered in development of HIV vaccines for exposed neonates. 10.7448/IAS.18.5.20327 © 2015 Viljoen K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: hbjaspan@gmail.com Disruption of the mucosal epithelium during immunodeficiency lentivirus infections permits translocation of microbial products into the circulation, causing systemic immune activation and driving disease progression. However, the specific effects of microbial products in liver, as a blood‐filtering organ, are unclear. In this study, we investigated the effects of simian immunodeficiency virus (SIV) infection of rhesus macaques on microbial translocation in the liver by immunohistochemistry. We also compared liver infiltration by myeloid dendritic cells (mDCs), trafficking to the liver by lymphocytes, and liver‐resident natural killer (NK) cell frequencies, phenotypes and functions in naïve and chronically SIVmac239‐ or SIVmac251‐infected rhesus macaques using flow cytometry. In livers of normal rhesus macaques, very low levels of bacteria and lipopolysaccharide (LPS) were detectable, but increased up to 20‐fold in chronically SIV‐infected animals. Increased microbial products in the liver of infected macaques was associated with the production of the chemoattractant, CXCL16, by mDCs. Subsequently, lymphocytes expressing the CXCL16 receptor, CXCR6, were mobilized in blood and hypercytotoxic NK cells were recruited to the liver. Microbial accumulation, mDC activation and hepatic cytotoxic NK cell frequency were all significantly correlated with markers of liver damage. Collectively, these data indicate that SIV‐associated accumulation of microbial products in the liver initiates a cascade of innate immune activation resulting in liver damage. These findings have implications for the liver pathology associated with HIV, especially in instances of coinfection with HCV. 10.7448/IAS.18.5.20568 © 2015 Schafer J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rreeves@bidmc.harvard.edu Provision of rapid early infant HIV diagnosis (EID) service remains a challenge for prevention of mother‐to‐child transmission programmes globally. Point‐of‐care (POC) EID testing may improve access and turnaround times, but while several POC technologies are in development there are few data on implementation. We conducted an implementation study of the Alere q Detect POC system for EID at two public sector health facilities. At a maternity hospital the POC device was used to test HIV‐exposed neonates soon after birth; at a primary care clinic the device was used for routine six‐week EID testing. At each site infants undergoing laboratory‐based HIV PCR testing per local protocols were tested on the POC device by doctors or nurses with results available within one hour. Analysis examined the performance of POC versus laboratory testing of the same specimen, and semi‐structured interviews with providers to assess implementation issues and acceptability. Overall 476 tests were conducted: 291 birth tests in the maternity hospital (mean child age, 99%) at both sites. In interviews, providers felt that the ease of use of the device coupled with the rapid turnaround time of POC EID results facilitated decision‐making in the management of infants, but many wanted to understand better the cause of errors on the POC device to assist in repeat testing. POC EID testing performs well in field implementation in health care facilities and is highly acceptable to health care providers. While further research is needed to understand POC EID implementation at scale, the rapid turnaround time of POC testing may allow immediate identification and management of HIV‐infected infants. 10.7448/IAS.18.5.20328 © 2015 Kroon M et al; licensee International AIDS Society Published 22 July 2015 Limited data exist on drug resistance and antiretroviral treatment (ART) outcomes in HIV‐1 infected children in West Africa. We determined the prevalence of baseline resistance, and correlates of virologic failure (VF) and on‐treatment resistance in a cohort of HIV‐1 infected children in Mali. Prospective observational study of HIV‐1 infected children <10 years of age initiating first‐line ART in Bamako, Mali. Assessments occurred at baseline and after six months of ART. Genotypic resistance testing on stored baseline and six‐month samples occurred at study end. Reverse transcriptase and protease genes were sequenced using in‐house methods. Resistance was defined as intermediate or high‐level according to the Stanford HIV Genotypic Resistance Algorithm v7.0. Virologic failure was defined as viral load (VL) ≥1000 copies/mL. Clinical and immunological failures were based on WHO criteria. Logistic regression was used to evaluate factors associated with VF and resistance. A total of 150 children were enrolled; 60% male and mean age 3.4 years. Ninety‐four percent reported no prevention of mother‐to‐child transmission (PMTCT) exposure. Median baseline CD4 count and VL were 633 cells/mm3 (IQR: 381–1039) and 675,651 copies/mL (IQR: 40,000–1,583,200). Initial ART regimens were lopinavir/ritonavir‐based (43%) or non‐nucleoside reverse transcriptase inhibitors (NNRTI) (efavirenz or nevirapine)‐based (57%). Of 141 children with amplifiable baseline samples, 28 (19.86%) had NNRTI resistance, only two of whom had PMTCT exposure and none had protease inhibitor (PI) resistance. Mean age of children with baseline NNRTI resistance was 2.3 years. By six months of ART, 11 died, 8 were lost to follow‐up and 6 had missing VL data. Among 125 remaining children, 41 (33%) had VF, 24 of whom (58%) had drug resistance (23 with NNRTI and one with PI mutations). A total of 93% of children with VF did not meet criteria for clinical or immunological failure. In multivariate analyses adjusting for age, gender, adherence and ART regimen, baseline NNRTI resistance was strongly associated with VF and six‐month resistance (OR: 6.7, p=0.001; OR: 20, p<0.001). Baseline NNRTI resistance was common in Malian children without prior NNRTI exposure and was associated with VF and a high resistance rate during ART. Clinical and immunologic criteria rarely detected VF. Our findings support WHO recommendations of PI‐based regimens in all children <3 years, and virological monitoring. 10.7448/IAS.18.5.20329 © 2015 Crowell C S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: claudia.crowell@seattlechildrens.org Chronic immune activation is associated with HIV disease progression in adults; however, data in children, especially infants, are limited. We determined levels and correlates of T‐cell activation and the effect of baseline activation on response to antiretroviral treatment (ART) in HIV‐infected infants. This investigation utilized specimens from the Optimizing Pediatric HAART study of early infant ART (NCT00428116). Kenyan infants less than five months of age were enrolled between 2007 and 2010 and started on ART. Peripheral blood mononuclear cell (PBMC) samples collected before ART initiation were analyzed using flow cytometry and the activated (HLA‐DR+/CD38high) T‐cell percentage quantified. Factors associated with T‐cell activation at baseline were identified using Mann‐Whitney U tests or linear regression. The effect of baseline activation on survival, CD4 reconstitution and HIV‐1 log10 viral load (VL) suppression was assessed using Cox proportional hazard models. Among 72 infants, median age at enrolment was 111 days, median VL was 6.6 log10 copies/mL and median CD4 was 19%. Most infants had symptomatic disease; 49% were WHO stage 3/4, median weight‐for‐age Z‐score (WAZ) was −2.5 and median length‐for‐age Z‐score (LAZ) was −2.1. Twenty infants died, including eight before ART initiation. Median CD8+ T‐cell activation at baseline pre‐ART was 17.0% (interquartile range (IQR) 10.4, 31.8) and median CD4+ T‐cell activation was 3.3% (IQR 1.6, 5.8). At enrolment, CD8+ T‐cell activation was associated with younger age (−0.15%/day (95% Confidence Interval (CI) −0.28, −0.01), p=0.05) and weight‐for‐age Z‐score (2.4%/WAZ standard deviation (95% CI 0.64–4.2), p=0.02), but not with CD4% or VL. CD4+ T‐cell activation at enrolment was inversely associated with CD4% (−0.20%/CD4% (95% CI −0.36, −0.05), p=0.01). T‐cell activation pre‐ART was not associated with time to CD4% reconstitution or VL suppression. Low CD8+ T‐cell activation (<5%) was associated with mortality (hazard ratio=3.8 (95% CI 1.3, 11.4), p=0.02). Contrary to findings in adults, low CD8+ T‐cell activation was strongly associated with mortality in this infant cohort. Among infants, low CD8+ T‐cell activation in symptomatic HIV infection may be a marker of ineffective immune response. Abstract MOAB0103–Figure 1. Survival to one year by CD8+ T‐cell activation. Abstract MOAB0103–Figure 1. Survival to one year by CD8+ T‐cell activation. 10.7448/IAS.18.5.20330 © 2015 Ásbjörnsdóttir K H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: kasbjorn@uw.edu EVG/COBI/FTC/TAF (E/C/F/TAF) and EVG/COBI/FTC/TDF (Stribild, STB) are integrase inhibitor (INSTI)‐based single‐tablet regimens (STRs) in clinical development for HIV‐1‐infected adolescents. Exposures of all components have been shown to be within the range associated with antiviral activity in adults. Preliminary comparative safety data through 24 weeks are reported. Treatment‐naïve 12 to 100 cells/µL and eGFR ≥90 mL/min/1.73 m2 received E/C/F/TAF or STB once daily in two ongoing 48‐week, single‐arm, open‐label trials. Adverse events (AE), laboratory tests, bone mineral density (BMD) by dual X‐ray absorptiometry and height‐age adjusted (HA) Z‐scores were assessed through Week 24. The E/C/F/TAF and STB trials enrolled 50 and 33 adolescents, respectively (median age 15 vs. 16 years, 56% vs. 30% female, 88% vs. 76% Black, 22% vs. 27% with baseline HIV‐1 RNA >100,000 copies/mL, median CD4 count 456 vs. 407 cells/µL median eGFR 156 vs. 143 mL/min/1.73 m2). Most AEs in both trials were mild and unrelated to treatment, with no deaths or AEs leading to treatment discontinuation. At Week 24, the median increase in serum creatinine was +0.08 mg/dL in E/C/F/TAF participants, with and +0.10 mg/dL in STB participants, with median eGFR decreases of −17.0 and −18.0 mL/min/1.73 m2, respectively, consistent with COBI's inhibition of renal tubular creatinine secretion. Proteinuria (any grade) occurred in 26% of E/C/F/TAF participants vs. 52% of STB participants, with Grade 2 or higher proteinuria occurring in 4% vs. 21% of participants, respectively. Of those participants with BMD measurements at Week 24, the median increase in spine BMD was +1.98% in E/C/F/TAF participants, with a decrease of ≥4% in 3/41 participants (7%), versus a median decrease of −1.29% in the STB cohort, with a decrease of ≥4% in 6/20 participants (30%). Spine HA Z‐scores decreased by −0.02 and −0.21 respectively. Compared with STB, E/C/F/TAF exhibited similar effects on eGFR, a lower incidence and severity of proteinuria, and a median increase in spine mineralization. Both STRs were well‐tolerated through 24 weeks. These findings support INSTI‐based STRs as initial HIV‐1 treatment in adolescents and suggest that TAF could offer safety advantages in paediatric populations. 10.7448/IAS.18.5.20331 © 2015 Kizito H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: aditya.gaur@stjude.org With limited paediatric third‐line antiretroviral therapy (ART) in resource‐limited settings, data on treatment efficacy and drug resistance following second‐line failure are needed to guide future management. HIV‐infected children 1000 copies/mL). Cox proportional hazards regression was used to evaluate factors predicting post‐switch VF. A total of 277 children were enrolled; 41% were female. Baseline values included median (interquartile range; IQR) age 7.5 (5.3–10.3) years, CD4 count 300 (146–562) cells/mm3, CD4 percentage 13 (7–20)%, HIV‐RNA 5 (4.4–5.5) log10 copies/mL. The median duration of first‐line ART was 2.7 (1.7–4.2) years. Resistance mutations at first‐line failure were available for 156 of 277 children (all had prior non‐nucleoside reverse transcriptase (NNRTI)‐based regimens) and included ≥4 thymidine analogue mutations (TAMs; 18%), Q151 M (8%), M184 V (82%) and ≥1 NNRTI mutation (92%). Current second‐line regimens contained lamivudine (90%), tenofovir (43%), zidovudine or abacavir (30%) and boosted lopinavir (LPV) or atazanavir (ATV; 98%). After a median of 3.3 (1.8–5.3) years on second‐line, the median CD4 was 767 (556–1060) cells/mm3 and 26 (20–31)%. Eighteen (7%) had WHO stage 3 or 4 events; 3 (2%) died from HIV‐related illnesses. VF occurred in 73 (27%; incidence 7 per 100 person‐years, 95% confidence interval (CI) 5.8–9.1), at which time 23% had 11 years (hazard ratio (HR) 4.06; 95% CI 2.15–7.66) and HIV‐RNA >5 log10 copies/mL (HR 2.4; 95% CI 1.27–4.59) at second‐line switch were predictors of VF. One‐fourth of children had VF while on second‐line ART. However, <10% developed major mutations to protease inhibitors, which may have been related to poor adherence or duration of VF. Greater advocacy is needed to create access to third‐line antiretrovirals in resource‐limited settings. 10.7448/IAS.18.5.20332 © 2015 Prasitsuebsai W et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: annette.sohn@amfar.org Rilpivirine 25 mg qd exposure was similar in adults and adolescents (Week 4 PAINT pharmacokinetic analysis). Week 48 safety and efficacy results are reported here. PAINT (NCT00799864) is a Phase II, ongoing, open‐label, single‐arm trial of rilpivirine plus two investigator‐selected N[t]RTIs in treatment‐naïve HIV‐1‐infected adolescents (≥12 to <18 years, from sites in India, Thailand, Uganda, South Africa, USA). After the adult approved indication, only patients with viral load (VL)≤100,000 copies/mL were enrolled. Virologic response was defined as VL<50 copies/mL (time‐to‐loss‐of‐virologic‐response (TLOVR) algorithm). Of 36 patients, 20 (56%) were female, 18 (50%) aged 12 to 100,000 copies/mL achieved virologic response. Of the 10 non‐responders (28%), eight were virologic failures (VFs), one was dosed although a protocol violator (screening NNRTI RAM) and withdrawn and one withdrew due to an AE (pulmonary tuberculosis). CD4+ count increased by median (range) 250.5 (−135 to 740) cells/mm3. For 2/8 VFs, overall adherence (pill count) was 100,000 copies/mL). Five of eight VFs developed rilpivirine RAMs, mostly E138K (n=4), K101E (n=2) and M230L (n=2); 4/5 developed N[t]RTI RAMs, mostly M184V (n=3). Mean (standard deviation) rilpivirine AUC24h and C0h were 2391 (991) ng.h/mL and 84 (39) ng/mL, respectively (population pharmacokinetic analysis). Most AEs were grade 1 or 2. Seven patients (19%) had grade 3 or 4 AEs regardless of causality, mainly malaria and depression (each n=2 and not related to rilpivirine). AEs considered at least possibly related to rilpivirine occurred in 13 (36%) patients, mainly (excluding investigations) somnolence (n=5, 14%) and nausea (n=2, 6%). This 48‐week analysis supports use of rilpivirine 25 mg qd combined with other antiretrovirals in treatment‐naïve HIV‐1‐infected adolescents (≥12 to <18 years) with VL≤100,000 copies/mL. Rilpivirine safety, virological and pharmacokinetic results were similar to those observed in adults. 10.7448/IAS.18.5.20333 © 2015 Lombaard J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: kboven@its.jnj.com Despite widespread use of tenofovir (TDF) in pregnant and breast‐feeding women, few data have been published on foetal bone development or child growth after in utero TDF exposure. We evaluated foetal long bone measurements in HIV‐infected pregnant woman/foetus dyads in Cape Town, South Africa. Measurements were conducted by a trained research sonographer using high‐resolution ultrasound. Foetal femur (FLZ) and humerus (HLZ) length z‐scores were compared by duration of in utero TDF exposure in three categories: 1) TDF‐exposed since conception (TDF‐C) versus 2) TDF‐exposed for ≥4 weeks and initiated after first trimester (TDF‐E), versus 3) TDF‐exposed for <4 weeks or TDF‐unexposed (TDF‐U). Ultrasounds performed at 4 weeks and initiated after first trimester (n=232) TDF‐exposed for <4 weeks or TDF‐unexposed (n=572) p Age of mother, years 31 (27–34) 27 (23–32) 28 (25–32) <0.001 GA, weeks 20 (14–28) 21 (14–28) 21 (16–27) 0.805 Maternal BMI at enrolment, kg/m2 29.14 (25.81–33.91) 28.50 (25.00–33.75) 28.63 (25.15–34.24) 0.790 CD4 cell count, cells/mm3 399 (273–523) 360 (239–478) 340 (232–507) 0.015 Log HIV RNA level at enrolment 1.59 (1.59–1.59) 4.13 (3.52–4.57) 3.99 (3.37–4.65) 2 ultrasound scans 147 (64.8) 126 (54.3) 479 (83.6) 0.001 Characteristics of ultrasound scans (n=408) (n=581) (n=968) p value Femur length z score 0.32 (−0.03, 0.70) 0.30 (−0.03, 0.63) 0.33 (−0.07, 0.79) 0.570 Humerus length z score 0.13 (−0.29, 0.59) 0.32 (−0.04, 0.59) 0.05 (−0.33, 0.46) 0.832 10.7448/IAS.18.5.20480 © 2015 Jao J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jennifer.jao@mssm.edu Isoniazid preventive therapy (IPT) has been demonstrated to reduce the risk of active tuberculosis (TB) in HIV‐infected adults, but the effectiveness of shorter IPT regimens (6–9 months) rapidly wanes in high TB burden settings. We examined the long‐term durability of six months of IPT among HIV‐infected adults in South Africa. We analyzed the experience of a prospective clinical cohort of HIV‐infected adults at one urban and one rural hospital in South Africa. The exposures of interest were receipt of IPT and antiretroviral therapy (ART), and the primary outcome was incident TB. We used multivariate Poisson regression to examine the association of IPT and ART with risk of TB. From 2003 to 2010, 3465 HIV‐infected adults were followed for 9908 person‐years (PY) during which 372 incident TB cases were diagnosed (incidence rate (IR): 3.8/100PY; 95% CI: 3.4–4.2). A total of 776 participants received IPT (median treatment length: 5 months (IQR: 2–6)). During 1886 PY of follow‐up after initiating IPT, 54 incident cases of TB were diagnosed (IR: 2.9/100 PY; 95% CI: 2.2–3.7), while during 8022 PY of follow‐up without IPT exposure, 318 incident TB cases were diagnosed (IR: 4.0/100 PY; 95% CI: 3.6–4.4). After adjusting for age, sex, study site, ART use and CD4 count, IPT was associated with a 23% reduction in TB incidence over seven years of follow‐up (adjusted IRR: 0.77; 95% CI: 0.7–1.0; p=0.070). IPT appeared to be protective only for the first year following initial IPT exposure (aIRR: 0.46; 95% CI: 0.36–0.98; p=0.042), after which the risk of TB was not significantly reduced. In this prospective cohort of HIV‐infected adults in South Africa, receipt of six months of IPT resulted in a marked (40%) reduction in risk for TB during the first year following IPT initiation, independent of ART status. No reduction in TB risk was observed beyond one year, confirming similar findings in settings of high TB burden. We demonstrate that IPT remains an important intervention for HIV‐infected individuals, and that even a short regimen can provide crucial protection from TB of up to one year for those not yet initiated on highly active antiretroviral therapy. Abstract MOAB0201–Table 1. Incidence of TB by time following IPT exposure IPT unexposed (n=2689) IPT exposed (n=776) Incidence rate ratio (95% CI) Time interval Cases/PY Rate/100 PY Cases/PY Rate/100 PY Unadjusted p Adjusted p Overall 318/8022 4.0 (3.6–4.4) 54/1886 2.9 (2.2–3.7) 0.72 (0.53–0.99) 0.042 0.77 (0.57–1.0) 0.070 0–1 year 151/2672 5.7 (4.8–6.6) 16/615 1.6 (1.6–4.2) 0.46 (0.26–0.80) 0.006 0.60 (0.36–0.98) 0.042 ≥1–2 years 75/2138 3.5 (2.8–4.4) 20/519 3.9 (2.5–6.0) 1.1 (0.63–1.9) 0.740 1.1 (0.67–1.8) 0.733 ≥2–3 years 47/1362 3.5 (2.6–4.6) 10/301 3.3 (1.8–6.2) 0.96 (0.50–1.9) 0.880 0.95 (0.51–1.8) 0.880 ≥3 years 45/1851 2.4 (18–3.3) 8/451 1.8 (0.89–3.7) 0.73 (0.30–1.6) 0.413 0.73 (0.34–1.6) 0.394 Abstract MOAB0201–Figure 1. Time to incident TB by IPT and HAART exposure. Abstract MOAB0201–Figure 1. Time to incident TB by IPT and HAART exposure. 10.7448/IAS.18.5.20334 © 2015 Hanrahan C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: chanrah1@jhmi.edu South Africa reports the third highest number of drug‐resistant TB (DR‐TB) cases and the largest population living with HIV in the world. We describe treatment outcomes of patients from the South African Electronic Drug Resistant Tuberculosis Register (EDRweb), the national database of all DR‐TB cases, after January 2009. Retrospective, de‐identified descriptive analysis of all patients with multidrug resistant (MDR) TB who initiated DR‐TB treatment in South Africa between 01/01/09 and 30/09/11. During this period, guidelines specified all MDR‐TB patients were admitted to specialized referral hospitals for the six‐month intensive phase of treatment or until culture conversion, then followed as outpatients for 12–18 months. Treatment outcomes included success (cured and treatment completed), failed, lost to follow‐up and died. Person‐time accrued from treatment initiation until the earliest of outcome date recorded or 24 months on treatment. Cox hazard models were used to evaluate the relationship between HIV status and all‐cause mortality. Models were adjusted for age, gender and previous history of TB treatment. In total, 13,692 confirmed MDR‐TB patients initiated treatment (median age 35.4 years; 53% male; 99% pulmonary TB). Eighty‐one percent (11,028/13,692) had HIV status recorded; of these 66% (7289/11,028) were co‐infected with HIV. Among those with an outcome reported (8465/13,692; 62%), overall mortality and success rates were 24.6% (95% CI 23.7–25.6) and 42.4% (41.3–43.4), respectively. Success was similar between HIV negative patients (42.9% (41.0–44.8); 18.1/100 person‐years (pys)) and those co‐infected with HIV (42.5% (41.0–43.9); 15.5/100 pys). Mortality was substantially higher in the HIV positive (27.3% (26.0–28.6); 10.1/100 pys) than the HIV negative (17.3% (15.9–18.7); 8.0/100 pys) group (adjusted hazard ratio 1.45 (1.30–1.62)). Fewer HIV positive patients were lost to follow‐up or failed treatment compared to HIV negatives (21.6 and 8.6% vs. 29.0 and 10.8%). In this analysis of the outcomes of MDR‐TB treatment in the South African national database, the reported rate of treatment success was low (42%) and did not vary by HIV status. Mortality was high in both groups but almost 1.5 times more in HIV co‐infected patients. New guidelines allowing decentralized (outpatient) treatment of some MDR‐TB patients and newly available drug regimens may improve treatment results. Abstract MOAB0202–Table 1. Summary of treatment outcomes of MDR‐TB patients in South Africa (n=13,692) Treatment success Total Cured Completed treatment Died Failed treatment Lost to follow‐up Not evaluated HIV status HIV −ve 3739 (27.3%) 803 (21.5%) 341 (9.1%) 460 (12.3%) 289 (7.7%) 773 (20.7%) 1073 (28.7%) HIV +ve 7289 (53.2%) 1356 (18.6%) 576 (7.9%) 1243 (17.1%) 390 (5.4%) 985 (13.5%) 2739 (37.5%) Unknown 2664 (19.5%) 328 (12.3%) 184 (6.9%) 383 (14.4%) 118 (4.4%) 236 (8.9%) 1415 (53.1%) TB treatment history New 3250 (23.7%) 653 (20.1%) 291 (9.0%) 439 (13.5%) 164 (5.0%) 476 (14.6%) 1227 (37.8%) Relapse 2351 (17.2%) 436 (18.5%) 177 (7.5%) 328 (14.0%) 139 (5.9%) 331 (14.1%) 940 (40.0%) LTFa 1232 (9.0%) 132 (10.7%) 80 (6.5%) 274 (22.2%) 99 (8.1%) 286 (23.2%) 361 (29.3%) Failed 1st 3959 (28.9%) 735 (18.6%) 333 (8.4%) 567 (14.3%) 186 (4.7%) 485 (12.3%) 1653 (41.7%) Failed 2nd 2516 (18.4%) 495 (19.7%) 197 (7.8%) 415 (16.5%) 180 (7.2%) 352 (14.0%) 877 (34.8%) Other 384 (2.8%) 36 (9.3%) 23 (6.0%) 63 (16.4%) 29 (7.6%) 64 (16.7%) 169 (44.0%) aLTF lost to follow‐up; 1st first‐line; 2nd second‐line. LTF lost to follow‐up; 1st first‐line; 2nd second‐line. 10.7448/IAS.18.5.20335 © 2015 Evans D H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: ebudgell@heroza.org Management of TB in HIV patients in Eastern Europe (EE) is challenged by high MDR‐TB prevalence, low rates of drug susceptibility testing (DST) and poor access to ART. We report 1‐year mortality estimates from a multi‐regional (EE, Western Europe (WE) and Latin America (LA)) cohort study. Deaths within 12 months of starting TB therapy (baseline) among consecutive HIV patients with TB in 2011–2013 were classified as being TB‐related or not. Risk factors for all‐cause and TB‐related death were assessed using standard survival analysis methods. Among 1410 patients starting TB therapy (EE=835, WE=319, LA=256), 257 (18%) died within 12 months of baseline; 170 (66%) of these were TB‐related. The cumulative probability of all‐cause and TB‐related death at 12 months was 29, 5 and 11% (p<0.001) and 22, 1 and 4% (p<0.001) in EE, WE and LA respectively. In EE, fewer patients were on cART at 12 months (68% vs. 90% and 85%, p<0.001), and many were treated without access to baseline DST (66% vs. 37% and 69%, p<0.001). Among those with DST, the empiric treatment regimen (composed when DST results were not yet known) included <3 active TB‐drugs in 36, 7 and 9% (EE, WE, LA, p<0.001); of those 81, 46 and 86% had MDR‐TB. Patients who started <3 active drugs were at excess risk of dying from TB compared to patients starting ≥3 active drugs (aHR=3.20, 95% CI=1.82–5.66). Patients without DST results (and thus no option for targeting subsequent therapy) also had a greater risk of death (aHR=2.33, 1.40–3.87). This appeared driven by deaths in EE (Figure, aHR=2.37, 1.66–3.40, analyses restricted to EE), although a formal test for interaction with region was not significant (p=0.44), potentially due to few deaths outside EE. There is an elevated risk of death from TB in HIV patients managed in EE compared to WE and LA. This is partly explained by modifiable risk factors including low rates of DST, hampering the optimized choice of TB drugs in a setting of high MDR‐TB prevalence. Our data call for urgent action to improve the care of HIV/TB patients in EE. Abstract MOAB0203–Figure 1. TB‐related death among HIV‐positive patients according to the number of active drugs used as part of empiric TB therapy. Abstract MOAB0203–Figure 1. TB‐related death among HIV‐positive patients according to the number of active drugs used as part of empiric TB therapy. 10.7448/IAS.18.5.20336 © 2015 Schultze A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: a.schultze@ucl.ac.uk Despite being preventable and curable, tuberculosis (TB) remains the leading cause of morbidity and mortality of people living with HIV (PLHIV). The past decade has seen considerable scale‐up of collaborative TB/HIV activities, however, implementation remains suboptimal. Closer inspection at each stage of the cascade of TB/HIV care is warranted to assess the gaps and to identify opportunities for strengthened service delivery in order to eliminate HIV‐associated TB mortality. Data were downloaded from the Global TB Programme Database on 22/01/2015 on the latest available TB treatment outcomes (2012 cohort), disaggregated by HIV status, from reporting high TB/HIV burden countries in the WHO African Region, along with related data on the implementation of collaborative TB/HIV activities. Data were analysed and missed opportunities identified. Fourteen countries reported the required outcome data, accounting for some 570,000 HIV‐positive incident TB cases, (Table 1), or 63% of the African burden and 49% of the global burden in 2012. More than 50,000 reported HIV‐positive TB cases died or were lost to follow‐up, representing 18% of evaluated cases, compared with 11% of evaluated HIV‐negative TB cases, (Figure 1). Of the estimated HIV‐positive TB cases almost 260,000 (46%) went unreported, (Table 1). Among registered TB patients, 11% (around 80,000) did not have an HIV test in the TB register. In eight countries that reported, there was a gap of over 1,700,000 reported as not having received a TB screen, (53% of the 3,300,000 people in HIV care). Among notified HIV‐positive TB cases, 42% (nearly 130,000) were not reported as receiving ART. Only five of the 14 countries reported providing Isoniazid Preventive Therapy (IPT) to people newly registered in HIV care. In the four countries that reported a denominator, 69% (some 900,000) people newly enrolled in HIV care did not receive IPT. This analysis highlights some considerable gaps in the care cascade, resulting from suboptimal implementation and/or recording and reporting. In order to prevent disproportionate TB mortality among PLHIV, countries are encouraged to scrutinize weaknesses in the care cascade at every level to enhance early detection of HIV‐associated TB, timely ART initiation and scaled‐up TB prevention. Abstract MOAB0204–Figure 1. Comparison of TB treatment outcomes according to HIV status in 14 African Countries 2012 cohort. Abstract MOAB0204–Figure 1. Comparison of TB treatment outcomes according to HIV status in 14 African Countries 2012 cohort. Abstract MOAB0204–Table 1. Analysis of the cascade of TB/HIV care in 14 high TB/HIV burden African Countries, 2012 cohort Est. HIV‐pos incident TB cases % of est. HIV‐pos TB cases unreported Notified TB cases % of TB cases with unreported HIV status Notified TB cases with HIV‐pos status % of HIV‐pos TB cases not on ART 14 high burden TB/HIV African countries 570,000 46 695,580 11 306,398 42 10.7448/IAS.18.5.20337 © 2015 Baddeley A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: baddeleya@who.int Strategies for reducing the high early mortality seen among patients initiating antiretroviral therapy ART in resource‐limited settings (RLS) are urgently needed. We hypothesized that given the high burden of tuberculosis (TB) in these settings, empiric TB treatment among patients at high risk for death would reduce early mortality. REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens) is a multicountry randomized clinical trial comparing two management strategies: ART+empiric 4 drug TB therapy (Empiric) vs. ART+isoniazid preventive therapy (IPT) in HIV‐infected individuals with CD4 count <50 cells/mm3. Participants were screened for TB prior to entry using symptom screen, locally available diagnostics per standard of care, and GeneXpert when available. The study was stratified according to CD4 count (<25 vs. ≥25 cells/mm3) and poor prognostic factors (body mass index <18.5, haemoglobin <8 g/dl, recent hospitalization). The primary endpoint was survival (death or unknown status) at 24 weeks postrandomization, and Kaplan–Meier estimates of the endpoint rates across arms were compared by the z‐test. Of 1368 participants screened, 850 (62%) were randomized; 53% were male, 90% were black and median (quartiles) age was 36 (30–42) years. The median (quartiles) CD4 count at study entry was 18 cells/mm3 (9, 32). At week 24, both arms had the same primary endpoint rate of 5.2% (95% CI: 3.5–7.8% for Empiric and 3.4–7.8% for IPT) with an absolute risk difference of −0.06% (95% CI: −3.05 to 2.94%). Primary endpoint rates were similar across arms for the stratification factors and for other secondary outcomes: viral load <400 copies/mL was achieved in 84% Empiric and 85% IPT; Grade 3 or 4 symptoms occurred in 12% Empiric and 11% IPT; Grade 3 or 4 laboratory abnormalities in 23% both arms; and new clinical events in 49% Empiric and 51% IPT. Among highly TB screened participants with advanced HIV in RLS, empiric TB therapy did not reduce mortality at 24 weeks compared to IPT. The low mortality seen in both arms supports enhanced screening for TB prior to ART initiation and the routine use of IPT. Abstract MOAB0205LB–Figure 1. KM graph for 5274 Abstract MOAB0205LB–Figure 1. KM graph for 5274 10.7448/IAS.18.5.20481 © 2015 Hosseinipour M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mina_hosseinipour@med.unc.edu The HPTN 052 trial was designed to evaluate whether antiretroviral therapy reduces sexual transmission of HIV. The trial started in April 2005 and ended in May 2015. HPTN 052 enrolled 1763 HIV serodiscordant couples in Malawi, Zimbabwe, South Africa, Botswana, Kenya, Thailand, India, Brazil and the U.S. (97% heterosexual). HIV‐infected index participants had CD4 cell counts between 350 and 550 cells/mm3 at enrolment. Index participants were randomized to receive ART at enrolment (early arm) or when their CD4 cell count fell to ≤250 cells/mm3 or they developed an AIDS‐defining illness (delayed arm). The primary analysis was based on genetically linked viral transmission events. When interim analysis in May 2011 demonstrated the benefits of early ART, ART was offered to all index participants in the delayed arm (N Engl J Med 2011;365:493–505); the study then continued otherwise unchanged. At the end of the trial, 1171 (66%) of 1763 couples remained in follow‐up (603/886 early arm; 568/877 delayed arm). Index participants were followed for 9822 person‐years (py). ART was initiated by all 886 index participants in the early arm and 785 (90%) of 877 index participants in the delayed arm. Before ART was offered to all index participants, there was 1 linked infection in the early ART arm (4 total infections/1776 py) and 35 linked infections in the delayed arm (42 total infections/1757 py). After ART was offered to index participants in both study arms, there were two linked infections in the early arm (15 total infections/2537 py) and six linked infections in the delayed arm (17 total infections/2412 py). Only seven linked infections were diagnosed while the index participant was receiving ART: four infections were diagnosed shortly after the index participant started ART and three were diagnosed after ART failure. These findings demonstrate that HIV transmission is very unlikely when viral replication is suppressed. The previously reported efficacy of early ART for HIV prevention was sustained for the duration of the HPTN 052 study. ART, combined with counselling and provision of condoms provides durable, highly effective protection from HIV transmission in serodiscordant couples. 10.7448/IAS.18.5.20482 © 2015 Cohen M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mscohen@med.unc.edu For antiretroviral treatment (ART) programs to have a preventive impact, the proportion of HIV‐infected people being treated should be high. In 2012, seven years after the beginning of ART programs in the South‐African township of Orange Farm, we measured the proportion of HIV+ who were virally suppressed, especially among age groups highly exposed to HIV (women 18–29 years and men 25–34 years). A community‐based cross‐sectional representative survey conducted in 2012 among 3293 men and 3473 women. Study procedures included a face‐to‐face questionnaire and collection of blood samples that were tested for HIV, 10 antiretroviral drugs (ARVs) and HIV‐viral load (VL). HIV prevalence was 17.0% (95% Confidence Interval: 15.7–18.3%) among men and 30.1% (28.5–31.6%) among women. Overall, 59.1% (57.4–60.8%) of men and 79.5% (78.2–80.9%) of women reported having ever been tested for HIV. When controlling for age, circumcised men were more likely to ever have been tested (66.1% vs. 53.6%; p<0.001). Among HIV+ individuals, 21.0% (17.7–24.6%) of men and 30.5% (27.7–33.3%) of women tested positive for any ARV. The ratio of ARV+ people over those HIV− was 0.084. Using basic calculations, we found that if ART programs were actually treating all eligible patients since 2005, this ratio should have been 0.21–0.28, indicating an effectiveness of ART programs around 47–63%. Among ARV+ participants, 91.9% (88.7–94.3%) had viral suppression (VL<400 cp/mL). The proportion of viral suppression among HIV+ was 27.0% (24.3–29.9%) among women and 17.5% (14.4–20.9%) among men. These proportions were lower among the highly‐exposed age groups: 15.6% (12.1–19.7%) among women and 8.4% (5.0–13.1%) among men. In Orange Farm, in the 2005–2012 period, ART programs were sub‐optimal and, among HIV+, proportion of viral suppression was low, especially among the highly‐exposed age groups. This suggests that, up to 2012, ART programs may not have substantially impacted HIV incidence. However, our study showed at community level that, when effectively taken, ARVs present a high effectiveness in suppressing VL. 10.7448/IAS.18.5.20338 © 2015 Jean K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: bertran.auvert@uvsq.fr Panama adopted Treatment as Prevention (TasP) in February 2014 and is now seeking efficient and effective ways to expand antiretroviral therapy (ART) coverage in key populations. We developed a mathematical model to determine the ART coverage and associated costs required to meet HIV incidence reduction targets for the female sex worker (FSW) population, which has a 1.6% HIV prevalence. The Government of Panama, British Columbia Centre for Excellence in HIV/AIDS and Simon Fraser University are collaborating to develop mathematical models for informing Panama's TasP strategy. Quantitative and qualitative information was collected from national reports, key informant interviews and focus groups with civil society to inform a compartmental HIV transmission model incorporating disease progression and treatment. The model was calibrated and validated for 2013. Estimated FSW population size is 17,000 and according to the Global AIDS Response Progress report, current ART coverage for both FSW and the hard‐to‐reach client population is about 47%. Annual ART cost/individual is US$625. Simulation scenarios for meeting 50, 70 or 90% reduction in HIV incidence in FSW in 15 years assumed ART expansion either for FSW and their clients (Scenario 1) or for FSW only (Scenario 2). ART expansion for FSW costs slightly more in Scenario 1 than 2. However, overall for both populations of FSW and clients, more infections are averted and treatment programme costs are lower for the strategy targeting FSW only (see Table 1). Furthermore, initial aggressive expansion of ART coverage leads to overall cost savings and a more effective means of averting new infections (see Figure 1). The result of no action compared to the 90% Scenario 2 strategy would be 170% more HIV infections and 50% more treatment costs over 15 years. Rapid expansion of TasP for female sex workers in Panama would avert infections and treatment costs already within 15 years. Initial short‐term investment to increase ART coverage would be offset by long‐term savings. Since Panama adopted TasP, UNAIDS has announced the 90–90–90 targets for HIV diagnosis, treatment and suppression, which call for an even more rapid reduction in incidence. Ongoing analyses are evaluating costs and outcomes of reaching the new targets by 2020. Abstract MOAC0103–Figure 1. Treatment cost for FSW population. Abstract MOAC0103–Figure 1. Treatment cost for FSW population. Abstract MOAC0103–Table 1. Outcomes and costs of TasP expansion scenarios Population Target incidence reduction in FSW in 15 years (%) No ART expansion new cases in 15 years No ART expansion US$ costs in 15 years TasP Scenario 1 new cases in 15 years TasP Scenario 1 US$ costs in 15 years TasP Scenario 2 new cases in 15 years TasP Scenario 2 US$ costs in 15 years FSW 50 2816 $1,240,560 2003 $911,016 2000 $1,025,737 Clients 50 4096 $3,841,072 2878 $3,308,139 2847 $3,139,332 Both 50 6912 $5,061,632 4881 $4,219,155 4847 $4,165,069 FSW 70 2816 $1,240,560 1620 $863,324 1605 $1,093,578 Clients 70 4096 $3,841,072 2331 $3,030,029 2259 $2,782,224 Both 70 6912 $5,061,632 3951 $3,893,353 3864 $3,875,802 FSW 90 2816 $1,240,560 1118 $777,438 1074 $1,107,593 Clients 90 4096 $3,841,072 1615 $2,818,353 1480 $2,260,854 Both 90 6912 $5,061,632 2733 $3,595,791 2554 $3,368,447 10.7448/IAS.18.5.20339 © 2015 Jenkins L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jenkins.lorna@yahoo.com HIV treatment guidelines are recommending ART at increasingly higher CD4 counts for maximizing individual and population benefits. However, the expansion of ART use may be at the expense of optimal adherence. We report on adherence and virological suppression when initiating ART at different CD4 thresholds within the Treatment as Prevention (ANRS 12249) trial of universal home‐based testing and immediate ART initiation in rural KwaZulu‐Natal. Using data of a cluster‐randomized trial of immediate ART versus initiation according to current national guidelines (CD4≤350 cells/mm3), we compared adherence levels (≥95% vs. <95%) measured using a visual analogue scale (VAS) and pill count (PC) and virological suppression at six months (<400 c/mL) according to CD4 count at ART initiation through logistic regression models, adjusting for possible confounders (age, sex, marital status, education and employment). During March 2012–May 2014, 601 participants who were not on ART entered care in trial clinics; 382 initiated ART; 254 have completed ≥6 months on ART, 227 of whom had six months HIV RNA data and were included in analyses. One hundred sixty‐nine were women; median (IQR) age and CD4 at ART initiation were 35 years (28, 46) and 313 cells/mm3 (206, 513). Adherence ≥95% at six months was high (88 and 83% by PC and VAS, respectively) with no evidence that this was associated with CD4 at initiation (aOR=0.97 per 100 cells/mm3 higher, 95% CI: 0.83–1.12, p=0.65 for VAS; aOR 1.13 per 100 cells/mm3 higher, 0.98–1.31, p=0.09 for PC). Male sex was independently associated with <95% adherence (2.58, 1.24–5.35, p=0.01; ref. females). Eighty‐three percent (183/227) of those who started ART achieved HIV suppression by six months with no association with CD4 at initiation (1.13 per 100 cells/mm3 higher, 0.96–1.33, p=0.40). Compared to those with ≥95% adherence by VAS, individuals with <95% adherence were somewhat less likely to suppress (0.44, 0.19–1.03, p=0.06). We found no evidence that, among people newly entering HIV care, higher CD4 at ART initiation was associated with reduced adherence or poorer virological suppression, at least in the short‐term. In this rural South African setting, motivation to adhere to ART may be independent of the presence of symptomatic HIV disease. 10.7448/IAS.18.5.20340 © 2015 Iwuji C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: ciwuji@yahoo.com To have a population impact in generalized HIV epidemics in Africa, high coverage of combination HIV prevention strategies that reduce the susceptibility of uninfected persons and the infectiousness of infected persons is needed. Community‐based HIV testing and counselling, with linkage to care and prevention, is a potential delivery platform for combination HIV prevention. We conducted a multisite programme of community‐based HIV testing and counselling, linkage to HIV care, and demand creation for voluntary medical male circumcision (VMMC) in rural communities in KwaZulu‐Natal, South Africa and Sheema district, Uganda. HIV testing was done at home or through mobile units. HIV‐positive persons were randomly allocated to linkage to care strategies: clinic facilitation by lay‐counsellors at the initial clinic visit, lay‐counsellor follow‐up visits at home, or standard clinic referral. HIV‐negative uncircumcised men were randomized to VMMC demand creation strategies: lay counsellor follow‐up visits at home, SMS reminders, or standard VMMC promotion at the time of testing. Between June 2013 and February 2015, 15,332 persons received HIV testing and counselling. Among 1325 HIV‐positive persons randomized to linkage strategies, the overall clinic linkage was high (93%). Compared to standard linkage, lay counsellor clinic facilitation increased linkage to care (RR=1.09, 95% CI: 1.05–1.13), and home follow‐up visits increased antiretroviral therapy (ART) initiation (RR=1.23, 95% CI: 1.02–1.47). In all arms, ART initiation was limited by bottlenecks in service delivery at the clinics, although 67% of those eligible initiated ART by nine months. Overall, 82% of persons initiating ART achieved viral suppression without significant difference between study arms. Of 750 HIV‐negative uncircumcised men randomized to VMMC promotion strategies, the uptake of circumcision was 41% by month 3. Compared to standard messages, VMMC uptake was significantly higher in the SMS promotion (RR=1.72, 95% CI: 1.36–2.17) and lay counsellor follow‐up arms (and RR=1.67, 95% CI: 1.29–2.14). Community‐based HIV testing and linkage to care and prevention effectively deliver combination HIV prevention. Simple strategies, such as SMS reminders or lay‐counsellor visits, increase linkage for ART initiation and male circumcision. Community‐based strategies require integration with efficient clinical services, and additional strategies are needed to address clinic delays that are barriers to ART delivery. 10.7448/IAS.18.5.20483 © 2015 Barnabas R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rbarnaba@uw.edu In 2011, results from an interim analysis of the HPTN 052 trial demonstrated that early antiretroviral therapy (ART) was highly effective for the prevention of HIV transmission from HIV‐infected adults (index participants) to their HIV‐uninfected sexual partners. All index participants were offered ART after May 2011; the trial ended in May 2015. This report describes the analysis of partner infections in HPTN 052. HIV from index‐partner pairs was analyzed. Phylogenetic methods were used to compare HIV pol sequences from index‐partner pairs and controls. Linkage probability was further assessed by comparing the genetic distances between pol sequences (Bayesian analysis). Selected samples were also analyzed using next generation sequencing (envy region). Three infections that occurred close to the time of index ART initiation were analyzed by BEAST and serologic methods to determine the probable timing of HIV transmission. This abstract presents provisional findings based on data available as of May 2015. Seventy‐five partner infections were confirmed (64 in Africa, 6 in Asia, 5 in the Americas), including 39 described previously (JID 2011; 204:1918–1926). Linkage status was determined for 70 cases (five cases failed analysis). Of these 70 cases, 26 (37%) were classified as unlinked (the partner was most likely infected from someone other than the index participant), and 44 (63%) were classified as linked (the index was most likely the source of the partner′s HIV infection). In 7 of the 44 linked cases, the partner seroconverted while the index was receiving study ART. In four of these seven cases, the partner seroconverted shortly after the index started ART, likely before the index was virally suppressed. In the remaining three cases, the partner seroconverted when the index was not virally suppressed due to ART failure. Laboratory and statistical methods were used to identify and characterize linked partner infections in HPTN 052. Seven linked infections were observed in partners after index participants started study ART: four occurred shortly after ART initiation and three occurred in the setting of ART failure. The timing of the linked transmission events supports the model that HIV transmission is very unlikely in the setting of viral suppression. 10.7448/IAS.18.5.20484 © 2015 Eshleman S H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: seshlem@jhmi.edu Under the Option B+ PMTCT strategy, HIV‐infected pregnant and breastfeeding women initiate lifelong ART. Long‐term retention after weaning is unknown. We examine treatment outcomes for up to 30‐months after ART initiation. We examined cumulative incidence of mortality, no follow‐up after ART initiation, loss to follow‐up after the first follow‐up visit (LTF), treatment discontinuation and retention in the Malawian “Option B+ programme.” We analyzed 24‐months aggregated facility‐level data (65,749 patients, 654 facilities) and 30‐months individual‐level data (3225 patients; six large facilities) from Option B+ patients who initiated ART during 2011–2014. We excluded patients who transferred to another facility. In facility‐level data, 79.9% (52,525/65,749) and 75.0% (40,509/54,029) of all patients were still in care 6 and 12 months after ART initiation. After 24 months, 70.6% (17,257/24,245) were retained, 26.8% were LTF, 1.5% had died and 0.6% stopped ART. In six large facilities with individual‐level data, slightly more patients defaulted or discontinued treatment: 24 and 30 months after ART initiation retention was 67.2 and 62.6%. Most patients were lost early and many did not return after the first visit (Figure 1), but after 18 months, further LTF was low. Of those who started ART during pregnancy, 15.8% (95% confidence interval (CI): 14.4–17.4%) had no follow‐up, 18.0% (95% CI: 16.0–20.0%) were LTF, 6.6% (95% CI: 5.1–8.3%) stopped ART and 0.5% (95% CI: 0.3–1.0%) died during 30 months of follow‐up. Of those who initiated ART while breastfeeding, 8.5% (95% CI: 6.8–10.4%) had no follow‐up, 18.6% (95% CI: 15.7–21.7%) were LTF, 1.9% (95% CI: 1.0–3.5%) stopped ART and 0.6% died (95% CI: 0.2–1.3%) (Fig. 1). Patients who collected 95% of the prescribed drugs (aHR: 3.02; 95% CI: 1.99–4.59). Suboptimal long‐term retention in care (67–70% after two years) needs to be addressed. Attrition rates are higher in those starting ART during pregnancy versus breast‐feeding. Poor early drug adherence predicts later LTF. If women stay in care throughout breast‐feeding, retention after weaning is likely. Abstract MOAC0201–Figure 1. ART outcomes for Option B+ patients. Abstract MOAC0201–Figure 1. ART outcomes for Option B+ patients. 10.7448/IAS.18.5.20341 © 2015 Haas A D et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: andreas.haas@ispm.unibe.ch In Malawi's antenatal programme, HIV counselling and testing (HCT) for pregnant women is nearly universal, but couple HCT (cHCT) is uncommon, even though it is included in the Option B+ guidelines. cHCT is critical for HIV‐infected women: many have HIV‐infected partners in need of HIV diagnosis and treatment or HIV‐uninfected partners in need of HIV prevention. cHCT may also increase Option B+ retention. Two partner recruitment strategies were assessed for cHCT uptake, male HIV status, female Option B+ retention and consistent condom use. Newly diagnosed HIV‐infected pregnant women≥16 years with male partners in Lilongwe were recruited from Bwaila District Hospital Antenatal Unit from March to October 2014 to participate in a randomized controlled trial. Women in the “invitation only” arm received an invitation inviting male partners to antenatal care; women in the “invitation plus tracing” arm received the same invitation but male partners were traced by phone and/or home visit if they failed to present within one week. Women were assessed one month later. Analyses were conducted using Chi‐squared tests. Of 220 eligible women, 200 (90%) consented and enrolled. cHCT uptake was 52% in the invitation only arm and 74% in the invitation plus tracing arm (p=0.001). Among the 126 men who presented for cHCT, 25% already knew they were HIV‐infected, 47% learned they were HIV‐infected for the first time and 25% were HIV‐uninfected with no difference by arm (p=0.8). There was a trend towards greater one‐month retention among women in the invitation plus tracing arm (91%) compared to the invitation only arm (83%) (p=0.09). Among HIV‐discordant couples, unprotected sex declined from 94 to 23% (p<0.001) following cHCT. Participation did not lead to intimate partner violence in either arm. The invitation plus tracing strategy was extremely effective for recruiting male partners for cHCT and substantially more effective than the invitation only strategy. Both strategies identified many HIV‐infected men and HIV‐discordant couples. cHCT resulted in higher ART retention, declines in unprotected sex in HIV‐discordant couples and no intimate partner violence. Scaling up an invitation plus tracing strategy within the Option B+ programme would have substantial public health benefits. 10.7448/IAS.18.5.20342 © 2015 Rosenberg N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: nora_rosenberg@unc.edu We evaluated the impact of Option A, rolled out in August–December 2011, on HIV‐free infant survival and mother‐to‐child transmission (MTCT) in Zimbabwe. In 2012 and 2014, we conducted cross‐sectional community‐based serosurveys of mother‐infants pairs residing in the catchment areas of 157 health facilities randomly selected from 5 of 10 provinces in Zimbabwe. Eligible infants (alive or deceased) were born 9–18 months before each survey to mothers ≥16 years old. We randomly selected mother‐infant pairs and conducted questionnaires and verbal autopsies and collected blood samples. The impact analysis was limited to 113 catchment areas unexposed to Option A activities at baseline according to facility records; we estimated the HIV‐free infant survival and MTCT rate within each catchment area and compared the 2012 and 2014 estimates using a paired t‐test. We enrolled 8568 mother‐infant pairs with viable maternal specimens in 2012 and 9619 in 2014, of whom 1107 (12.9%) and 1176 (12.2%) mothers respectively were HIV‐infected. Among infants born to HIV‐infected mothers, 90.6% (95% confidence interval (CI): 88.8, 92.3) of infants were alive and HIV‐uninfected at 9–18 months in 2012, compared to 94.7% (95% CI: 93.4, 96.0) of infants in 2014 (p=0.001); MTCT was 9.0% (95% CI: 7.3, 10.7) in 2012 and 5.3% (95% CI: 4.0, 6.6) in 2014. In the 113 catchment areas where Option A was implemented after the infants surveyed in 2012 were born, there was a 6.5 percentage point (95% CI: 3.3, 9.7) mean increase in HIV‐free infant survival (89.8 to 96.3%, p<0.001), and 6.2 percentage point (95% CI: 3.0, 9.4) mean decrease in MTCT (9.9 to 3.7%, p<0.001). We found a substantial and statistically significant increase in HIV‐free infant survival and decrease in MTCT among infants aged 9–18 months following the implementation of Option A in Zimbabwe. Our estimates capture transmissions during pregnancy, delivery and the first 9–18 months of breastfeeding. Notably, 72% of HIV‐exposed infants were still breastfeeding at baseline and 78% at endline, so additional infections may occur. The 2014 survey also provides a baseline for evaluating Option B+, which has been recently rolled out in Zimbabwe and should further accelerate efforts to eliminate MTCT. 10.7448/IAS.18.5.20343 © 2015 Buzdugan R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: f.cowan@ucl.ac.uk Infants born to HIV‐infected pregnant women presenting late are at high risk of intrapartum infection. Mother/infant antiretroviral (ARV) intensification may substantially reduce this risk. In a multicentre, phase 3, adaptive single‐arm trial in Thailand, pregnant women with <8 weeks of standard ARVs (zidovudine (ZDV)+lamivudine (3TC)+lopinavir/ritonavir) and their infants received “ARV intensification” to prevent transmission at delivery: women took a single nevirapine (NVP) dose in labour and continued ARVs for four weeks; formula‐fed neonates received two weeks AZT+3TC+NVP followed by two weeks AZT+3TC, instead of standard one‐week ZDV. Infants were tested for HIV at birth, one, two, four, six months. A negative DNA PCR <48 hours, followed by a confirmed positive PCR defined intrapartum transmission. Data from 3965 mother/infant pairs (84 intrapartum transmissions) in three PHPT randomized perinatal HIV prevention trials (NCT00386230, NCT00398684 and NCT00409591) conducted in the same setting were used to define an historical control and build an intrapartum transmission model. Viral load (VL) during pregnancy was modelled as a function of ARVs exposure and intrapartum transmission was predicted through a logistic model with VL, maternal/infant ARVs, delivery mode and prematurity status as covariates. The Bayesian estimation of the risks of intrapartum transmission with/without intensification used all historical information and decision rules to stop for futility or superiority of ARV intensification over standard of care (risk ratio, RR<1) were determined for three interim analyses. Prior intrapartum transmission probabilities were subsequently updated using the results of the intensification trial to derive posterior probabilities (credibility interval, CrI) as well as probability distributions of RR<1 and RR<0.5. At first interim analysis, the DSMB recommended stopping enrolment and reporting intensification efficacy. Overall 88 mother/infant pairs received intensification with no intrapartum transmission. The posterior probability of intrapartum transmission was 0.4% (95% CrI: 0.1–1.4%) with intensification compared to 2.0% (0.3–5.2%) without. The probability of superiority of intensification over standard of care (RR<1) was 94.1%, and that of at least a two‐fold reduction of risk (RR20 years, and 4) sessions on wound healing and post‐circumcision abstinence targeting female partners. Analysis was based on cluster‐level summary measures. Overall, 6251 men were enrolled in 10 intervention sites (1809 Njombe and 4442 Tabora) and 3968 men in the 10 control sites (1035 Njombe and 2933 Tabora). The proportion of clients aged 20–34 was greater in intervention sites compared to control sites (17.7% vs. 13.0%; RR=1.4; 95% CI: 0.9–2.0; p=0.11) and was associated with a greater number of clients in both regions (overall mean difference=227; 95% CI: 33–420; p=0.03). The effect of the intervention varied by region: in Njombe, there was little difference in attendance between control and intervention sites (11.3% vs. 14.7%; RR=0.77, 95% CI: 0.4–1.6; p=0.43), while in Tabora, there was over a twofold difference (27.5% vs. 11.5%; RR=2.39, 95% CI: 1.7–3.4; p=0.03). Similarly, the mean number of clients aged 20–34 was greater in intervention facilities in Tabora (mean difference=182; 95% CI: 5–359; p=0.05) and there was little difference in Njombe (mean difference=12; 95% CI: −13 to 36; p=0.31). The intervention was associated with a significant increase in the proportion of VMMC clients aged 20–34 years in Tabora but not in Njombe. The lack of intervention effect in Njombe may be due to saturation, as VMMC has been available for longer. The results suggest that the intervention may be more likely to be effective in areas newly targeted for VMMC. 10.7448/IAS.18.5.20486 © 2015 Wambura M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: wmwita@yahoo.com Identifying interventions to increase men's uptake of HIV testing in sub‐Saharan Africa is essential for the success of combination prevention strategies, including treatment as prevention. HIV self‐testing is an emerging approach with high acceptability, but limited evidence exists on optimal strategies for distributing self‐tests and reaching men in particular. This study explored a novel approach of providing multiple self‐tests to women with high HIV incidence to promote HIV testing among their sexual partners. HIV‐uninfected women aged 18–39 years were recruited at two sites in Kisumu, Kenya between January and March 2015: a drop‐in centre for female sex workers (FSWs) and a health facility with antenatal and postpartum clinics. Following informed consent and instructions on using the OraQuick Rapid HIV 1/2 Test, index participants (IPs) enrolled at the health facility and drop‐in centre received three and five self‐tests, respectively. Structured interviews were conducted with IPs at enrolment and multiple times over three months to determine how self‐tests were used. Key outcomes included the proportion of IPs reporting their primary sexual partner used a self‐test. A total of 278 IPs were enrolled (101 FSWs, 61 antenatal, 116 postpartum). Follow‐up interviews were completed with 262 IPs (94.2%) by May 9, 2015. Most self‐tests provided at enrolment were either used by the IP or given to other persons (mean 2.7 (90%) for antenatal and postpartum IPs, 4.7 (94%) for FSWs). All but two IPs gave ≥1 self‐tests to other persons, and a large majority gave a self‐test to their primary sexual partner (77% FSWs, 91.8% antenatal and 86% postpartum). Ninety‐eight percent of self‐tests given to other persons were reported to be used. Among 367 persons who received self‐tests from FSWs and used them, commercial sex clients were the largest group (211, 57%). In total, 10.6% (72/681) of those who received self‐tests from IPs and used them were reported to obtain an HIV‐positive result; 55% of them sought confirmatory testing. Provision of multiple HIV self‐tests to sub‐populations of women with high HIV incidence was successful in promoting HIV testing among their sexual partners. This novel strategy warrants further consideration as countries develop self‐testing policies. 10.7448/IAS.18.5.20487 © 2015 Thirumurthy H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: hthirumu@email.unc.edu On 23 January 2015, the Indiana State Department of Health began investigating an outbreak of HIV infection after disease intervention specialists (DIS) reported 11 confirmed HIV cases traced to a rural community in southeastern Indiana that had reported five HIV cases between 2004 and 2013. From 2009 to 2013, the community (population 4200) had substantial unemployment (8.9%), many adults without high school diplomas (21.3%), a substantial proportion living in poverty (19%) and a limited healthcare access. A public health emergency was declared on March 26 by executive order. We report on efforts to diagnose HIV infection in this community. For individuals newly diagnosed with HIV infection, partner services’ interviews elicited information about needle‐sharing and sex partners and social contacts (who could benefit from an HIV test) within the past 12 months. HIV testing was offered to all contacts who could be located. DIS identified 491 unique individuals during contact tracing, and as of May 13, 390/491 (79%) persons were located, assessed for risk and tested for HIV. Overall, 153/390 (39%) persons were diagnosed with HIV infection. There was no difference in age and sex between HIV‐positive and HIV‐negative tested persons (Table 1). Compared with HIV‐negative contacts (n=239), the 153 HIV‐infected individuals were more likely to be named as needle‐sharing partners (81% vs. 52%; p<0.0001) and less likely to be named as sexual partners only (1% vs. 15%; p97% nucleotide identity) and statistical evidence supporting relatedness was high (Shimodaira–Hasegawa probabilities >0.99). Recency of HIV infection was determined by avidity testing using a modified Bio‐Rad HIV 1/2 plus O assay (BRAI). HCV NS5B gene sequences were phylogenetically analyzed to determine the number of clusters of independent HCV strains within this population. The pol gene was sequenced for 57 HIV‐1‐infected persons. Two clusters of HIV‐1 subtype B infection were identified (Cluster 1, n=55; Cluster 2, n=2; Figure, panel a). Among 49 specimens available for BRAI testing, 45 (91.8%) were recent infections. Of 36 HIV‐infected specimens with HCV antibody results, 34 (94%) were HCV co‐infected. The NS5B gene was sequenced for 119 HCV‐infected persons. Genotype 1a (n=82) was most common, followed by genotype 3a (n=29), 2b (n=5) and 1b (n=3). Three unique clusters of HCV strains were identified (Cluster 1, n=45; Cluster 2, n=9; Cluster 3, n= 7; Figure, panel b). Of 118 HCV‐infected specimens with HIV antibody results, 38 (32.2%) were HIV co‐infected. In this prescription opioid injection‐associated outbreak, a single strain of HIV‐1 was introduced into a population infected with multiple HCV strains. In contrast to the homogeneity of HIV strains observed in this cohort, the heterogeneity of HCV strains (clustering and non‐clustering) suggests earlier introduction of HCV compared with HIV. These data demonstrate the outbreak potential with the introduction of HIV‐1 into a community where HCV prevalence is high among persons who inject prescription opioids. Abstract MOAC0304LB–Figure 1. Maximum likelihood phylogenetic tree of (a) HIV‐1 pol sequences and (b) HCV NS 5b sequences. Abstract MOAC0304LB–Figure 1. Maximum likelihood phylogenetic tree of (a) HIV‐1 pol sequences and (b) HCV NS 5b sequences. 10.7448/IAS.18.5.20489 © 2015 Galang R R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: ydh0@cdc.gov Daily oral FTC/TDF (Truvada) is US FDA‐approved for HIV pre‐exposure prophylaxis (PrEP). HPTN 067/ADAPT, a phase II randomized, open‐label PrEP trial, assessed the feasibility of intermittent FTC/TDF‐based PrEP for HIV prevention among men who have sex with men (MSM) and transgender women (TGW) in New York City (NYC). MSM and TGW were eligible if: male at birth, and reported anal intercourse and ≥1 other HIV risk factor in the past six months. Exclusion criteria included HIV infection, hepatitis B infection, acute HIV symptoms and abnormal renal function. Following six weeks of once/week directly observed dosing, participants were randomly assigned 1:1:1 to 24 weeks of PrEP dosed: daily (D), twice weekly plus one post‐sex dose (time‐driven (T)), or one pre‐ and one post‐sex dose (event‐driven (E)). Regimens were compared for prophylactic coverage (PrEP within four days pre‐ and 24 hours post‐sex) of sex events, pills taken, side effects and plasma drug levels. Adherence and coverage were assessed using electronic monitoring adjusted by self‐reported sex and pill taking behaviour collected in detailed weekly interviews. A total of 179 participants were randomized: 176 MSM, 3 TGW; median age 30 years; 70% black, 13% white and 25% Hispanic. D arm participants had significantly higher complete coverage of sex acts (66% D, 47% T, 52% E; p=0.03; Table 1) and highest adherence to regimen (65% D, 46% T, 41% E; p<0.001). Significantly fewer pills were used with intermittent (T and E) PrEP (p<0.001). Side effects were similar across arms, with gastrointestinal and neurologic symptoms most common. Participants reporting recent sex in all PrEP dosing arms achieved similar rates of detectable plasma tenofovir levels and of concentrations associated with effective PrEP dose frequency. While this cohort of mostly black MSM in NYC reported higher prophylactic coverage of sex acts and higher adherence to daily PrEP, non‐daily PrEP users who reported recent sex achieved comparable rates of effective tenofovir plasma concentrations. Intermittent PrEP required substantially fewer pills, although side effects were similar. This study demonstrates the feasibility of intermittent PrEP, a potentially more cost‐effective alternative to daily PrEP, among U.S. black MSM. Abstract MOAC0305LB–Table 1 Characteristic Study regimen daily (D), n=59 Study regimen time (T), n=60 Study regimen event (E), n=60 p Number of sex events during study, excluding oral sex 1083 1311 1502 0.20 % total sex events with complete coverage (or for sex events with partial coverage % pre‐sex only, % post‐sex only) 66 (24, 2) 47 (30, 8) 52 (29, 6) 0.03 Total number of required pills taken 5370 1708 1063 <0.001 Total % PrEP adherence 65 46 41 0.31 ng/mL) in plasma when reporting sex in last 7 days at 10 weeks, at 30 weeks 74, 61 76, 56 64, 50 0.58 Median plasma TFV concentration (ng/mL) in plasma when reporting sex in last 7 days at 10 weeks, at 30 weeks 83, 31 24, 11 15, 1 0.49 % achieving effective plasma TFV concentration (>5 ng/mL) when reporting sex in last 7 days at 10 weeks, at 30 weeks 63, 56 72, 50 61, 39 0.65 10.7448/IAS.18.5.20538 © 2015 Mannheimer S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: sbm20@columbia.edu Oral FTC/TDF PrEP is effective for preventing sexual HIV acquisition when used daily. An alternate dosing (non‐daily) regimen was effective in the IPERGAY trial. Daily and non‐daily regimens have not been compared directly with respect to prophylactic coverage for sexual exposure. We enrolled men who have sex with men (MSM) into a phase 2, randomized, open‐label trial of oral FTC/TDF PrEP in Bangkok, Thailand. We randomly assigned participants to one of three self‐administered dosing regimens for 24 weeks: daily (D); time‐driven twice weekly with a post‐sex dose (T) or event‐driven before and after sex (E). We contacted participants weekly to collect dates/times of PrEP use (monitored electronically by Wisepill™) and sex events. We defined adherence as the proportion of tablets taken as recommended, and coverage as taking ≥1 tablet in the four days before sex and ≥1 tablet within 24 hours after sex. We randomized 178 MSM (median age 31 years). PrEP coverages were similar in arms D and T (85% vs. 84%, p=0.79) and both were greater than in arm E (74%; p<0.05). Adherence was greater in D (85%) compared with T (79%) or E (65%; p<0.001). Compared with D, the number of doses required for full adherence was reduced by 57% in T and by 80% in E (p<0.001). Among MSM reporting sex in the past week, PBMC tenofovir diphosphate was detectable (≥9.1 fmol/million cells) among 31/31 (100%) in D, 28/29 (96.6%) in T and 28/30 (93.3%) in E at week 10 on study, and in 21/23 (91.3%), 18/19 (94.7%) and 12/14 (85.7%) at week 30, respectively (p=0.54). Median PBMC drug concentrations at week 30 were highest among men in D (102.0 vs. 46.8 vs. 32.9 fmol/million cells for D, T and E, respectively, p<0.001). No HIV infections occurred after randomization. Compared with the daily regimen, the time‐driven dosing regimens offered comparably high PrEP coverage for sex acts for Thai MSM, despite slightly less adherence, while requiring fewer tablets. However, since non‐daily dosing results in significantly lower PBMC drug concentrations, stricter adherence is required under these regimens to maintain prophylactic drug concentrations. Abstract MOAC0306LB–Table 1. Results from Bangkok HPTN 067/ADAPT study (n=178) Characteristic Daily (D) Time‐driven (T) Event‐driven (E) Total p value N 60 59 59 178 – Median age 31 28 31 31 – Number of sex events over full study, not including oral sex 1485 1337 1018 – 0.16 % total events fully covered 85 84 74 – See text Total required tablets actually taken 8047 3272 1255 – <0.001 Total tablets required 9420 4121 1928 – <0.001 Total % adherence 85 79 65 – 9.1 fmol/million) in PBMCs when reporting sex in last 7 days (at 10 weeks of follow up; at 30 weeks of follow up) 100; 91.3 96.6; 94.7 93.3; 85.7 96.7; 91.1 0.54 Median drug concentration in PBMCs (fmol/million cells) when reporting sex in last 7 days (at 10 weeks of follow up; at 30 weeks of follow up) 81.1; 102.0 35.3; 46.8 26.4; 32.9 45.5; 60.7 100 countries from 2013 to 2014. Through triangulation of baseline surveys, e‐surveys with the country MoH HIV focal point and data compiled from the 2014 Global AIDS Response Progress Reporting, we have documented the adoption of priority HIV treatment policies within the 58 WHO focal countries. Data are presented through end 2014. Within 18 months of the launch of the 2013 consolidated antiretroviral drugs (ARVs) guidelines, 44 of 58 (76%) of focus countries adopted at least one of the major recommendations; globally another 25 countries were in the process of adopting. Sixty percent of focus countries adopted a CD4 count initiation of ≤500 cells/mm3, while Brazil, Thailand and Yemen offer treatment to all adults regardless of CD4 cell count. Seventy‐one percent adopted a policy to treat all children with HIV <5 years; Ethiopia treats all children 50% undetectable HIV‐RNA, three Eastern European countries achieved under <20%. USA achieved undetectable HIV‐RNA for 30% overall, the lowest amongst high‐income countries, comparable to sub‐Saharan Africa (29%). The largest fall between stages in the treatment cascades was between prevalence and diagnosis for Switzerland, UK, The Netherlands, Sub‐Saharan Africa and Russia; from diagnosis to receiving ART for Australia, Brazil, USA, Georgia and Estonia, and between treatment and achieving undetectable HIV RNA for France and Canada. Only one of the 12 countries analyzed achieved the UNAIDS 90–90–90 coverage target of 73% of HIV positive people with undetectable HIV RNA. There were disparities between countries. A standardized reporting method should be implemented to facilitate comparisons between countries to better identify gaps and inform policy. Abstract MOAD0102–Table 1. Country level cascades versus 90–90–90 target Country % Diagnosed % On ART % Undetectable HIV‐RNA Country % Diagnosed % On ART % Undetectable HIV‐RNA UNAIDS 90–90–90 targets for 2020 90 82 73 Brazil (2013) 80 48 40 Switzerland (2012) 84 76 73 Canada (BC) (2011) 71 51 35 Australia (2013) 86 66 62 USA (2013) 82 40 30 United Kingdom (2013) 76 68 61 Sub‐Saharan Africa (2013) 45 39 29 Denmark (2010) 85 62 59 Georgia (2012) 52 26 20 The Netherlands (2013) 73 59 53 Estonia (2013) 87 29 19 France (2010) 81 60 52 Russia (2013) 49 11 9 10.7448/IAS.18.5.20346 © 2015 Levi J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jacob.levi11@imperial.ac.uk Expanded access to HAART in Latin America began slowly in the late 1990s and faster in early 2000s; many antiretrovirals used then, are now outdated and most patients presented with advanced disease stages. Characterizing these patients’ major outcomes (death, loss to follow‐up (LTFU), viral suppression, CD4+ cell (CD4) count evolution and regimen changes) after a decade of HAART – not well defined at present – may provide insights into their present and future situation and provide information relevant for the management of patients who initiated HAART more recently. The study included adults from six CCASAnet sites: Argentina, Brazil, Chile, Haiti, Honduras and Mexico who initiated HAART before 2004, without exclusion of non‐ART‐naïve. Status (active, LTFU or dead) for each patient was registered at six‐month intervals for up to 10 years, as well as CD4 and viral load (VL) in active patients. The proportions of patients in first, second, third or further HAART regimen or not on HAART were also measured. In total, 4975 patients (66% male) met inclusion criteria. At HAART initiation, the median age was 35 years, 23% had AIDS and 45% were not ART‐naïve. At 1, 3, 5, 7 and 10 years, overall rates of mortality were 4.2, 6.8, 9.0, 10.8 and 13.6% respectively. LTFU rates for the same periods were 2.4, 6.8, 10.9, 14.8 and 24.2% respectively; 62% remained in active care at 10 years (Figure 1). At the end of follow up, 85% of active patients had VL<400 copies/mL (Haiti excluded because VL not regularly measured) and median CD4 increased from 153 to 517 cells/mm3 . After 10 years, only 11% of patients remained active and on their first HAART regimen, 13% were on their second, 12% were on their third and 23% were on their fourth or more regimen. Heterogeneity in outcomes between sites was substantial. Despite advanced disease and use of mostly old antiretrovirals, a large proportion of first HAART initiators in these Latin American cohorts were alive, in active control, with substantial immune recovery and virologic suppression after 10 years. Early death was a problem as well as persistent LTFU and frequent change of therapy. Abstract MOAD0103–Figure 1. Major outcomes of early HAART programs at CCASAnet. Abstract MOAD0103–Figure 1. Major outcomes of early HAART programs at CCASAnet. 10.7448/IAS.18.5.20347 © 2015 Wolff M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: marcewolff@yahoo.com The integration of HIV‐care into primary health care (PHC) clinics is a strategy to expand access to antiretroviral therapy (ART). However, integration may compromise PHC service delivery within weak health systems. We designed a study to examine changes in PHC service provision (pre and post‐integration) in public‐sector PHC clinics in Free State, South Africa. We analyzed administrative data on 15 PHC indicators. The data were collected monthly over a critical four year period as integration was implemented into 131 PHC clinics representing a catchment population of 1.5 million. We defined integration as the month and year the PHC clinic provided comprehensive HIV‐care, from testing to treatment to follow‐up. We utilized interrupted time series analysis at ±18 and ±30 months from HIV integration in each clinic to identify changes in PHC services post‐integration. We conducted sensitivity analyses with linear mixed effect models to study the relationship between HIV service indicators and the PHC indicators. The number of patients receiving ART in the 131 PHC clinics studied increased from 121 (April 2009) to 57,958 (March 2013). We did not observe any changes in service indicators for 11 of the 15 PHC indicators we examined, However, we did observe decreases in population‐level immunization coverage after integration by 0.98% (SE=0.25, p<0.001) at ±18 months and by 1.31% (SE=0.16, p<0.001) at ±30 months. Clinic level immunization coverage also decreased by 33 infants per 100,000 patients (SE=8, p<0.001) at ±30 months. None of these changes were associated with the number of HIV patients at the clinics. We also observed decreases in total clinic visits per year for adults and children under five years old. Despite an extraordinary increase in patients accessing ART in PHC clinics during our study period, the vast majority of PHC indicators remained unchanged. Our findings suggest that the integration of HIV‐care into public‐sector PHC clinics is a viable strategy through which to expand access to ART. However, further research is needed to understand how immunization coverage is affected. 10.7448/IAS.18.5.20348 © 2015 Rawat A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: angelirawat@gmail.com The Adherence Club (AC) model of care was piloted by Médecins Sans Frontières starting in 2007. ACs are groups of approximately 30 stable antiretroviral therapy (ART) patients who met every eight weeks for group support, brief symptom screen and collection of pre‐packed ART facilitated by a lay‐healthcare worker. Following good pilot outcomes, from 2011 the Cape Metro health district in turn piloted, using a collaborative quality improvement approach and then adopted the model of care. Few data on large‐scale implementation of novel models of care exist. We describe the implementation scale‐up across the district highlighting key efficiencies and context‐specific adaptations to the model. We describe the scale‐up from January 2011 to December 2014. Data from routine electronic monitoring of the ART programme provide the total number of ART patients retained in care (RIC) while monitoring of AC participation is reported monthly by each AC. AC implementation expanded over the four‐year period with the number of patients retained in AC care increasing annually from 5675 in December 2011 to 30,790 in December 2014 (Figure 1). By December 2014, ACs were offered at 76.1% of ART facilities (51/76) with only 7.5% of ART patients in care at a facility where ACs were not operating. The proportion of patients receiving ART within an AC grew from 7.3% in 2011 to 25.0% by the end of 2014 (Figure 1). Over a four‐year period, the AC model of care was widely accepted and expanded to support a quarter of all patients receiving ART in the district. Adaptations to the model of care supported implementation within the various facility contexts. Some facilities offered ACs at the facility while others decentralized the model to outreach community and home venues. Most used various lay cadres of staff, while some used nurses to facilitate the groups. The model offered efficiencies both to patients and the health system. For ACs to expand to provide quality care to a greater proportion of ART patients, appropriate resources are required. Further research is needed to evaluate the outcomes of AC patients. Abstract MOAD0105LB–Figure 1. Number of patients receiving care within an Adherence Club and the proportion of all ART patients in the Cape Metro health district receiving care within an Adherence Club, January 2011–December 2014. Abstract MOAD0105LB–Figure 1. Number of patients receiving care within an Adherence Club and the proportion of all ART patients in the Cape Metro health district receiving care within an Adherence Club, January 2011–December 2014. 10.7448/IAS.18.5.20540 © 2015 Wilkinson L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: msfocb‐khayelitsha‐coord@brussels.msf.org Treatment of HIV infection with antiretrovirals reduces individuals’ plasma viral loads to undetectable levels and in turn decreases the risk of transmission. Despite epidemiological evidence supporting the efficacy of “Treatment as Prevention,” quantifying this success remains a significant challenge. Phylogenetic analysis of viral sequence data can yield crucial insights into epidemic processes, including transmission dynamics. We sought to evaluate the impact of treatment on HIV transmission rates in British Columbia (BC), Canada, using phylogenetic methods. We recovered 27,296 anonymized HIV protease and RT sequences from 7747 HIV patients in BC from the BC Centre for Excellence in HIV/AIDS database. Sequences were annotated with: sample collection date, treatment status at sample collection, date of first antiretroviral treatment and risk factor (intravenous drug use (IDU), men having sex with men (MSM) and heterosexual (HET)). Codons associated with known drug resistance were censored from the alignment prior to tree inference. We inferred a set of 1000 maximum likelihood phylogenetic trees. We calculated a lineage level phylogenetic branching rate for each HIV lineage in the trees, which provides an approximate measure of transmission rates. We stratified branching rates by treatment experience and risk factor. To assess the impact of treatment on onward transmission of HIV, we compared the mean HIV branching rate between treatment‐experienced and treatment‐naive lineages across the BC epidemic as a whole and among risk factors. Phylogenetic branching rates were significantly lower among treatment‐experienced HIV lineages relative to treatment‐naive lineages (p<0.001), implying reduced rates of HIV transmission in the former. Importantly, treatment experienced lineages had significantly lower HIV branching rates irrespective of HIV transmission risk factor (p<0.001 for IDU, MSM and HET) or exposure to different antiretroviral drug classes (p<0.001 NRTI, NNRTI, PI), suggesting these results are not driven by penetrance of health care into particular risk groups or therapeutic regimens. Our results provide independent evidence that antiretroviral HIV treatment has limited the onward transmission of HIV to new hosts. These results are based on a lineage level measure, are measured phylogenetically rather than epidemiologically and are replicated both across different risk exposure categories and different treatment regimens. 10.7448/IAS.18.5.20349 © 2015 Joy J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jjoy@cfenet.ubc.ca Sexual HIV‐1 infection requires penetration of the virus across the mucosal barrier and the establishment of infection in target cells. It is widely accepted that only one or a small number of HIV‐1 clones is successfully transmitted from the donor to the recipient. However, little is known about the phenotypic properties of the transmitted virus and the influence the phenotype plays in the genetic bottleneck selection process. Here we evaluated possible phenotypic differences between acute and chronic HIV‐1 that may effect transmission fitness. We compared the genetic diversity of HIV‐1 isolates from the female genital tract with isolates from the blood of the same donor by 454 pyrosequencing of the env region. Furthermore, we generated chimeric viruses from acute and chronic envelope genes using a yeast‐based cloning strategy. The chimeric clones were then evaluated for host cell entry and receptor efficiency, sensitivity to entry inhibitors and for replication fitness in PBMCs, T cells and macrophages. Additionally we evaluated the transmission fitness across mucosal tissues by multi‐virus competitions. Both acute and chronic HIV‐1 clones showed similar cell entry and receptor efficiency, sensitivity to inhibitors and replication fitness. Sequence analysis revealed that primary infection in the cervix resulted in a highly genetically diverse HIV‐1 population, while only one or a few HIV‐1 clones are in matched blood. Analysis of mixed competitions of acute and chronic HIV‐1 env‐clones in ex vivo tissue models revealed higher transmission fitness of acute isolates than chronic. We observed that higher transmission fitness was related to a reduced number of conserved N‐linked glycans on the envelope of acute viruses. Chronic HIV‐1 isolates appear to stay and replicate in the mucosal tissue, while acute isolates are preferentially bound by tissue residing dendritic cells/langerhans cells (DCs/LCs) and are subsequently transmitted to T cells. High levels of mannose binding proteins in tissue and lectins on epithelial cells may be responsible for a passive selection process of HIV‐1 with fewer glycans for transmission due to reduced lectin binding. 10.7448/IAS.18.5.20350 © 2015 Klein K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: kklein5@uwo.ca HLA‐driven HIV‐1 immune escape mutations that persist following transmission could gradually spread in the viral population, compromising host antiviral immunity over time. We investigate the extent and correlates of escape mutation accumulation in HIV‐1 Polymerase (Pol) sequences in North America from 1979 to present. HIV‐1 RNA Pol and HLA class I genotyping was performed on 338 Historic (1979–1989) and 278 Modern (2001–2011) specimens from Boston, New York, San Francisco and Vancouver. HLA‐associated polymorphisms were defined according to published lists. Historic and modern datasets were also investigated for the presence for novel HLA‐associated mutations using phylogenetically‐ informed methods. Ancestral reconstruction of the HIV‐1 epidemic founder sequence was performed using bayesian evolutionary analysis by sampling trees (BEAST) and Hypothesis testing using Phylogenies (HyPhy). The estimated HIV‐1 epidemic founder sequence dated to ~1969 and was near‐identical to the modern subtype B consensus, suggesting no historic selective sweeps have occurred to shift the population consensus. No HLA‐associated polymorphisms unique to the historic dataset were identified. Nevertheless, pairwise sequence diversity of modern HIV‐1 sequences was approximately two‐fold greater than historic sequences, with diversification predominating at HLA‐associated sites (p<0.0002). N=20 published HLA‐associated polymorphisms were investigated for spread over time. Overall, their median “background” frequencies (in individuals lacking the restricting HLA) were 6.6% vs. 16.8% in historic and modern eras respectively (p=0.0004); polymorphism frequencies in reconstructed pre‐1979 ancestral sequences were also consistent with gradual spread (p<0.01). No correlation was observed between HLA allele frequency and relative spread of its associated polymorphisms (r=−0.13, p=0.8); rather, polymorphisms restricted by protective HLA alleles exhibited greater relative spread than those restricted by non‐protective alleles (r=0.83, p=0.0047). Despite these overall increases, the frequency of many polymorphisms (e.g. B*51‐associated RT‐I135T) remained consistent throughout the eras. Moreover, at the whole‐sequence level, the median extent of adaptation of the typical circulating modern HIV‐1 Pol sequence to the average North American host remains 0%, indicating a low overall risk of acquiring HIV‐1 harbouring adaptations to one's HLA profile. Immune escape mutations in HIV‐1 Pol have spread significantly in the population since the genesis of the North American epidemic; however, these changes are unlikely to herald immediate consequences for host antiviral immunity on this continent. 10.7448/IAS.18.5.20351 © 2015 Kinloch N N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: nkinloch@sfu.ca Dolutegravir is an integrase inhibitor that has shown a high genetic barrier against the emergence of resistant strains. No resistance substitution has been observed in treatment‐naïve individuals treated with this drug. In tissue culture experiments, we have identified the R263K resistance substitution as a signature substitution for HIV resistance against dolutegravir, an observation that was later confirmed in highly treatment‐experienced individuals. Given the importance of DNA integration in the establishment of HIV persistence, we tested the ability of dolutegravir‐resistant HIV strains to integrate within human DNA. We used an Alu‐mediated quantitative PCR to measure levels of integration of dolutegravir‐resistant variants in primary human PBMCs. Levels of integration were normalized using the b‐actin gene. These experiments were performed using subtype B and C viruses. Our results show that dolutegravir‐resistant variants are impaired in their ability to integrate within human DNA. The integration levels of subtype B and C R263K variants were decreased by 30% and 40% compared to WT viruses, respectively. More important, the addition of several secondary substitutions failed to restore integration to a level comparable to WT and, in some cases, further lowered integration to only 20% of WT. The relative inability of dolutegravir‐resistant variants to integrate within human DNA may contribute to a progressive decrease in the viral reservoir of individuals who develop these substitutions. 10.7448/IAS.18.5.20352 © 2015 Mesplède T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: tibo_mes@hotmail.com Distinct integration patterns of different retroviruses, including HIV‐1, have puzzled virologists for over 20 years. A tetramer of the viral integrase (IN) assembles on the two viral cDNA ends, docks onto the target DNA (tDNA) to form the target capture complex (TCC) and catalyzes viral genome insertion into the host chromatin. We combined structural information on the Prototype Foamy Virus TCC with conservation in retroviral IN protein alignments to determine aa‐tDNA base contacts. We generated HIV‐1 variants based on the observed variability at these positions, assessed replication capacities and performed integration site sequencing to reveal their integration preferences. Finally, we examined their effect on disease progression in a chronic HIV‐1 subtype C infection cohort. We identified retroviral IN amino acids affecting molecular recognition in the TCC and resulting in distinct local tDNA nucleotide biases. These residues also determine the propensity of the virus to integrate into flexible tDNA sequences. Remarkably, natural polymorphisms INS119G and INR231G retarget viral integration away from gene dense regions. Precisely these variants were associated with rapid disease progression in a chronic HIV‐1 subtype C infection cohort. Our findings reveal how polymorphisms at positions corresponding to HIV IN119 and IN231 affect both local and global integration site targeting. Intriguingly, these findings link integration site selection to virulence and viral evolution but also to the host immune response and antiretroviral therapy, since HIV‐1 IN119 is under selection by HLA alleles and integrase inhibitors. 10.7448/IAS.18.5.20353 © 2015 Demeulemeester J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rik.gijsbers@med.kuleuven.be The RV144 trial had a vaccine efficacy of 31%, and IgG antibodies to HIV‐1 Envelope (Env) amino acid positions 120–204 were identified as a predictor of decreased risk of infection. The IgG responses were binding to scaffolded Env antigen comprising the variable loops 1 and 2, flanked by partial regions of the first and second conserved domains. Since HLA class II molecules are expressed on antigen‐presenting cells and modulate CD4 T‐cell stimulation of antibody production by B cells, we tested whether HLA allotypes influenced vaccine response and efficacy. HLA‐DRB1, DQB1 and DPB1 were genotyped in 760 individuals. Direct associations of 31 HLA class II alleles on Env (120–204)‐specific IgG were compared using linear regression models. Interaction of HLA with IgG response to Env (120–204) was tested for an effect on acquisition by logistic regression. Higher levels of Env (120–204) IgG antibody directly correlated with the presence of DPB1*13 (p=0.002, q=0.05). Env (120–204)‐specific IgG antibody levels also associated with decreased risk of HIV‐1 infection only with the presence of DPB1*13 (OR=0.29 per 1‐SD increase, p=0.006). Both of these findings were replicated with Env antigens across multiple viral subtypes. Vaccine efficacy increased to 71% among individuals that were DPB1*13+ and had higher levels of Env (120–204)‐specific IgG levels relative to the placebos. To delineate the anti‐Env antibody responses in DPB1*13+ individuals, we screened overlapping peptides to Env (120–204). Frequency and magnitude of IgG response specifically to Env peptide positions 119–133, which are involved in Env binding to CD4, associated with both presence of DPB1*13 and protection from HIV‐1 acquisition among individuals with a DPB1*13 allele. Further evidence that immune responses induced by vaccination in individuals carrying DPB1*13 are different from those without DPB1*13 was apparent in significant viral sequence differences specifically in infected vaccine recipients with DPB1*13. DPB1*13‐associated immune responses to vaccination is associated with decreased risk of HIV‐1 acquisition. The specific differences in vaccine‐induced responses elicited by individuals with HLA‐DPB1*13 should be examined to determine the mechanism of protection of the vaccine. Understanding this HLA class II restricted mechanism will enable improved HIV vaccine design. 10.7448/IAS.18.5.20541 © 2015 Prentice H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rthomas@hivresearch.org Nuclease‐mediated gene editing in hematopoietic stem cells (HSCs) holds great promise in the cure of HIV infection, but little information is available regarding the feasibility of this approach in large animal models. To better evaluate the function of HSCs following gene editing, we have engineered cells with disrupted CCR5 alleles and assessed engraftment following autologous transplant in the pigtailed macaque, M. nemestrina. Disrupted CCR5 alleles in this model should directly protect against infection with simian/human immunodeficiency virus (SHIV). We are evaluating the extent to which CCR5‐disrupted cell progeny engraft in macaques and testing whether these cells impede infection by SHIV. Zinc finger nucleases (ZFNs) are used to target the CCR5 locus in macaque HSCs. Engraftment and persistence of these autologous stem cells and stem cell‐derived lymphoid and myeloid cells are measured ex vivo and in vivo. Animals are challenged with SHIV virus containing an HIV envelope; to approximate the status of an HIV+ patient, three‐drug combination antiretroviral therapy (cART) is initiated following viral set point. Animals reach undetectable levels of plasma viremia prior to autologous transplant with gene‐edited cells. CCR5 targeting experiments yield up to 60% gene disruption in CD34+ cells ex vivo, translating to approximately 5% steady state bulk disruption in vivo. Gene‐disrupted cells demonstrate long‐term, multilineage engraftment in macaques, including comparable levels of disruption in CD3+, CD20+, CD14+ and granulocyte subsets. We also observe biallelic disruption of CCR5 in colony forming assays. Importantly, this approach is equally feasible in SHIV‐naïve and in SHIV‐infected, cART‐suppressed animals. During robust SHIV replication, our preliminary data suggest that CCR5‐deleted cells undergo positive selection in vivo. This is the first demonstration of successful long‐term multilineage engraftment of ZFN‐edited, CCR5‐deleted HSCs in a non‐human primate (NHP) transplantation model. Our strategy results in robust levels of target gene disruption in vivo, yet does not impair HSC engraftment or differentiation. CCR5‐deleted cells can undergo positive selection following challenge with SHIV. Our model enables the evaluation of novel therapeutic approaches not only in the context of acute HIV exposure, but also in the clinically relevant setting of pre‐existing latent HIV infection. 10.7448/IAS.18.5.20354 © 2015 Peterson C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: cwpeters@fhcrc.org A sterilizing cure for HIV‐1/AIDS requires a strategy that eliminates all or at least some critical regions of the HIV‐1 genome including the promoter positioned within the 5’ LTR of the viral genome from cells serving as a stable reservoir for HIV‐1, that is, resting CD4+ T‐lymphocytes, macrophages and brain microglia, with no adverse impact on the host cells. We have tailored CRISPR/Cas9 gene editing by bioinformatic screening, surveyor assay, and whole genome sequencing and have successfully developed a series of guide RNAs (gRNAs) that, in complex with Cas9 nuclease, effectively and safely eliminate integrated copies of HIV‐1 proviral DNA in several human cell culture models. We assessed the impact of our gene editing strategy on viral transcription and replication by measuring the level of a GFP reporter and viral p24, upon reactivation of virus from the latent stage by treatment with phorbol myristate acetate (PMA) and trichostatin A (TSA). We demonstrated inactivation of HIV‐1 gene expression and replication in latently infected T‐lymphocytes and promonocytic human cell lines as well as microglial cells upon excising the proviral DNA fragment corresponding to the entire coding sequence of HIV‐1 spanning the 5’ to 3’ LTRs from the host chromosome by the CRISPR/Cas9 approach. Further, we demonstrate that the presence of LTR‐specific multiplex of guide RNAs in cells expressing Cas9 acts as an efficient inhibitor blocking new HIV‐1 infection. Our findings suggest that the strategy involving the newly developed CRISPR/Cas9 serves as a promising platform that can be advanced for eradication of HIV‐1 and a cure for AIDS. Abstract TUAA0203–Figure 1. Eradication of HIV‐1 DNA in latently infected cells. A. Treatment of latently infected T‐lymphocytes with PMA and TSA activates viral gene expression and expression of GFP reporter in more than 93% of the cells. The presence of gRNAs (LTR A/B) and Cas9 dramatically prevented viral replication. B. Examination of DNA by PCR and direct sequencing verifies removal of integrated proviral DNA from chromosome 16. Abstract TUAA0203–Figure 1. Eradication of HIV‐1 DNA in latently infected cells. A. Treatment of latently infected T‐lymphocytes with PMA and TSA activates viral gene expression and expression of GFP reporter in more than 93% of the cells. The presence of gRNAs (LTR A/B) and Cas9 dramatically prevented viral replication. B. Examination of DNA by PCR and direct sequencing verifies removal of integrated proviral DNA from chromosome 16. 10.7448/IAS.18.5.20355 © 2015 Kaminski R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: kkhalili@temple.edu HIV infection induces a series of phenotypic and functional changes to T cells that eventually results in a state of T‐cell exhaustion and failure to control viral replication. T‐cell‐Ig‐and‐ITIM‐domain (TIGIT) is a recently described negative checkpoint receptor expanded on CD8+ T cells during LCMV infection in mice and inhibits anti‐viral effector CD8+ T‐cell activity. We hypothesized that during progressive HIV infection, TIGIT surface expression will mark an expanded population of dysfunctional T cells, and that novel monoclonal antibodies (mAb) targeting TIGIT would restore anti‐HIV‐specific T‐cell responses. Surface expression of TIGIT and PD‐1 on T cells was measured by flow cytometry from 103 HIV‐infected participants (non‐controllers (n=20), elite controllers (n=20), antiretroviral (ART) suppressed (n=39), acutely infected (n=24)) and 20 age‐ and gender‐matched HIV‐uninfected controls. Quantified cell associated HIV (CA‐HIV) DNA and RNA from purified CD4+ T cells. Functional characterization of TIGIT+ T cells was performed, and ex vivo HIV‐specific cytokine and proliferative responses were assessed in the presence of mAb targeting TIGIT and/or PD‐1 pathways (anti‐TIGIT mAb and anti‐PD‐L1 mAb). In controls, a median of 28.05% of CD8+ T cells was TIGIT+ (IQR 24.43, 39.15). In comparison, we found a significant expansion of TIGIT+CD8+ T cells during chronic (median 57.1%, IQR 42.6, 63.45; p50% HIV‐specific CD8+ T cells; however, TIGIT+ T cells failed to produce cytokines in response to HIV antigens. Single blockade of TIGIT led to a significant increase of interferon gamma response to HIV Gag compared to no blockade (p=0.027). Co‐blockade of TIGIT and PD‐L1 led to greater restoration of HIV‐specific CD8+ T‐cell proliferative responses (4.10%, IQR 1.46, 22.28) than single blockade of TIGIT (3.47%, IQR 1.11, 10.08; p=0.0078) or PD‐L1 (3.945%, IQR 1.15, 17.53; p=0.039). These findings identify TIGIT as a novel marker of dysfunctional HIV‐specific T cells and suggest TIGIT along with other checkpoint receptors may be novel curative HIV targets. 10.7448/IAS.18.5.20542 © 2015 Chew G et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: glenchew@hawaii.edu Unbiased shRNA library screens have been used to identify novel genes and pathways that are required to maintain HIV latency and/or play an essential role in HIV transcription. One of the most prominent and robust “hits” was the oestrogen receptor type 1 (ESR‐1). The activities of ESR‐1 agonists, antagonists and oestrogen on proviral reactivation were studied in transformed and primary cell models of latency and in patient cells. Specific antagonists of ESR‐1, such as Tamoxifen and Fulvestrant, are weak proviral activators but sensitize latently infected cells to very low doses of the proviral activators TNF‐α (NF‐κB inducer) and SAHA (HDAC inhibitor). By contrast, a selective ESR‐1 agonist propylpyrazoletriol and the broader spectrum ESR‐1 agonist diethylstilbestrol strongly suppress both TNF‐α and SAHA reactivation. In contrast to the ESR‐1 antagonists, ESR‐2 antagonists were not effective inducers of HIV expression in cell models. Co‐activator 3 (SRC‐3) is an upstream modulator of ESR‐1, which was also identified as a hit in the shRNA screen. Blocking of SRC‐3 by its inhibitor Gossypol also induces latent proviruses. Consistent with these results, specific knock‐down of ESR‐1 in Jurkat 2D10 cells with shRNA constitutively re‐activates the latent provirus. In the HAART‐treated patient samples, there was a modest increase of spliced HIV env mRNA when resting memory cells were treated with the ESR antagonists Fulvestrant or Tamoxifen alone. Proviral reactivation by ESR antagonists was synergistically increased by SAHA. By contrast, β‐estradiol at concentrations in the physiological range led to dramatic reductions in proviral reactivation efficiencies. This is consistent with earlier observations that high levels of β‐estradiol can block HIV replication. ESR‐1 is a pharmacologically attractive target that can be exploited in the design of therapeutic strategies aimed at eradication of the latent reservoir. Our results show that drugs targeting ESR‐1 can be used to either promote the re‐activation of latent proviruses (antagonists) or limit their responses (agonists). The profound effects of β‐estradiol on HIV reservoir reactivation suggest that there may be gender‐specific differences in HIV reservoirs and highlight the need to tailor latency reactivation strategies for both men and women. 10.7448/IAS.18.5.20543 © 2015 Karn J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jonathan.karn@case.edu Asian HIV‐infected patients generally experience higher systemic exposure to HIV protease inhibitors (PIs). We compared the efficacy and safety of switching to lower versus standard dose of atazanavir/ritonavir (ATV/r) in virologically suppressed second‐line patients. Patients with plasma HIV‐RNA (pVL) <50 copies/mL, ALT 200 copies/mL. Patients in ATV200 with VF resumed standard dose PI‐based regimens. Treatment groups were regarded as non‐inferior if the lower limit of the 95% confidence interval (95% CI) for the difference in VF was above −10% in an intention‐to‐treat (ITT) analysis at 48 weeks. A total of 559 patients were randomized (ATV200; N=279 vs. ATV300; N=280). At baseline, 85% used lopinavir/ritonavir, mean age was 42 years, body weight was 59 kg, CD4 was 539 cells/mm3 and total bilirubin was 0.85 mg/dL. At week 48, by ITT, the proportion of patients in ATV200 vs. ATV300 with pVL <200 copies/mL (difference, 95% CI) was 97.1% vs. 96.4% (0.68, −2.29 to 3.65), the proportions with pVL <50 copies/mL were 93.4% vs. 91.7% (1.71, −2.67 to 6.09). In per‐protocol analyses, the proportions with pVL 0.1). Comparing ATV200 vs. ATV300, the number (%) of patients with total bilirubin >3.2 mg/dL was 27 (10%) vs. 46 (17%) respectively (p=0.017). A lower dose of ATV/r‐based regimens in Thais is non‐inferior compared to standard dose ATV/r. Higher dose ATV was associated with higher rates of treatment discontinuation. ATV/r 200/100 mg can be recommended as part of routine care for Asian adults who have well‐controlled HIV infection on a PI‐based regimen. 10.7448/IAS.18.5.20356 © 2015 Bunupuradah T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: torsak.b@hivnat.org Despite a favourable efficacy and safety profile, TDF‐based regimens may be associated with renal toxicity and reduced bone mineral density (BMD). TAF is a novel tenofovir prodrug in which TFV plasma levels are 90% lower than seen with TDF, thereby reducing off‐target side effects. Week 48 data in patients switching to a once‐daily fixed dose combination regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF) are described. Virologically suppressed adults (HIV‐1 RNA <50 copies/mL) with normal renal function taking one of four different TDF‐based regimens for at least 48 weeks were randomized 2:1 to receive E/C/F/TAF or to retain their prior TDF‐based regimen. Following randomization, all treatments were open‐label. Of 1196 patients completing at least 48 weeks of treatment, 799 received E/C/F/TAF and 397 received their prior TDF regimen: E/C/F/TDF, 31.9%; EFV/FTC/TDF, 26.1%; ATV/RTV + FTC/TDF, 26.8%; ATV/COBI + FTC/TDF, 15.0%. Virologic success <50 copies/mL occurred in 95.6% on E/C/F/TAF and 92.9% on FTC/TDF + 3rd Agent (weighted difference: 2.7%; 95% CI: −0.3% to +5.6%), with virologic failure in 1.1% and 1.3% of patients, respectively. General safety was similar between the arms. The mean percent change (SD) in hip BMD: +1.95% (3.0) for E/C/F/TAF and −0.14% (3.0) for FTC/TDF+3rd Agent (p<0.001); the mean percent change (SD) in spine BMD: +1.86% (3.1) for E/C/F/TAF and −0.11% (3.7) for FTC/TDF+3rd Agent (p<0.001). There were no cases of Fanconi Syndrome on E/C/F/TAF and one case on FTC/TDF+3rd Agent. For patients on either a COBI or RTV boosted regimen prior to randomization, the estimated GFR increased 1.8 mL/min for E/C/F/TAF and decreased 3.7 mL/min for FTC/TDF+3rd Agent (p<0.001). As shown in the table, multiple measures of quantitative proteinuria, including tubular proteinuria, had statistically significant improvements for patients switching to E/C/F/TAF as compared with those retaining their prior TDF‐based regimen. These 48 week data demonstrate that patients who switch from a TDF‐based regimen to E/C/F/TAF maintain high efficacy, have statistically significant increases in BMD and have statistically significant improvements in multiple tests of renal function, as compared with patients remaining on their prior TDF‐based regimen. Abstract TUAB0102–Table 1. Changes in proteinuria and tubular proteinuria Median % change baseline to Week 48 E/C/F/TAF FTC/TDF+3rd agent Significance Urine protein: creatinine (UPCR) −18.5% +9.4% p<0.001 Urine albumin: creatinine (UACR) −18.4% +5.3% p<0.001 Retinol binding protein: creatinine (RBP: CR) −32.9% +15.7% p<0.001 Beta‐2‐microglobulin: creatinine (B2MG: CR) −49.2% +14.4% p<0.001 10.7448/IAS.18.5.20357 © 2015 Mills T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: tmills@tonymillsmd.com Tenofovir (TFV) is renally eliminated, and the prodrug, tenofovir disoproxil fumarate (TDF), has been associated with renal toxicity and reduced bone mineral density (BMD). Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that results in 90% lower plasma TFV levels as compared to TDF. The safety and efficacy of a once‐daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and TAF (E/C/F/TAF) was assessed in HIV‐1 infected patients with mild to moderate renal impairment. Virologically suppressed adults with stable renal impairment (eGFRCG 30–69 mL/min) had their treatment switched from both TDF‐ and non‐TDF‐containing regimens to open‐label E/C/F/TAF. Week 48 safety data by pre‐switch TDF use are presented. Of 242 subjects switched to E/C/F/TAF (mean age 58 years (range: 24–82), 18% Black, 39% HTN and 14% DM) 158 subjects (65%) were taking TDF‐containing regimens prior to switch. At Week 48, the median (Q1, Q3) change from baseline for eGFRC‐G was +0.2 (−5.8, 6.3) mL/min (p=0.81) and for eGFR‐cystatin C was +2.7 (−6.2, 14.1) mL/min/1.73 m2 (p=0.003). The following measures of renal tubular function improved significantly (p200 mg/g) and albuminuria (UACR ≥30 mg/g) decreased from 48 to 13% and from 56 to 22%, respectively. Significant increases in mean% change in hip (+1.29%) and spine (+2.60%) BMD were observed at 48 weeks (p100,000 copies/mL. Primary endpoints were the proportion of patients with HIV RNA 100,000 c/mL Endpoint DOR† (N=108) EFV† (N=108) Difference [DOR‐EFV] (95% CI) HIV RNA100K§ (n=38, 38) 60.5% 65.8% −5.3 (−26.4, 16.4) HIV RNA100K§ (n=38, 38) 92.1% 94.7% −2.6 (16.5, 10.7) Mean change in CD4 count§ 154/mm3 146/mm3 8 (−37, 52) †with TDF/FTC. ††Non‐completer=Failure (NC=F) approach to missing data. §Observed Failure (OF) approach to missing data. Abstract TUAB0104–Table 2. Week 24 Clinical Adverse Event (AE) Summary & Primary Safety Analysis (CNS AEs) Proportion of patients with: DOR† (N=108) EFV† (N=108) Difference [DOR‐EFV] (95% CI) One or more AEs 75.9% 84.3% −83 (−19.1, 2.4) Drug‐related AEs 27.8% 55.6% −27.8 (−39.9, 14.8) Serious AE 0.9% 4.6% −3.7 (−9.6, 0.9) Serious drug‐related AEs 0% 0.9% −0.9 (−5.1, 2.5) Discontinued due to AEs 0.9% 5.6% −4.6 (−10.8, 0.1) One or more CNS AEs 26.9% 46.3% −19.4 (−31.7, 6.6)* †with TDF/FTC. *Pre‐specified safety hypothesis, p<0.001. with TDF/FTC. Non‐completer=Failure (NC=F) approach to missing data. Observed Failure (OF) approach to missing data. with TDF/FTC. Pre‐specified safety hypothesis, p<0.001. 10.7448/IAS.18.5.20359 © 2015 Gatell J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: gatell@fundsoriano.es Raltegravir (RAL), though currently category C in pregnancy and not recommended for use in newborns, has been used in exceptional cases for prevention of mother‐to‐child‐transmission (PMTCT). We report on the outcomes of 14 infants exposed in utero to RAL and the first newborn to be treated with RAL for six weeks for PMTCT. Infants born to mothers treated with RAL during pregnancy from the Centre Maternel et Infantile sur le Sida (CMIS) mother‐child cohort between 2010 and 2014 were included in the study. RAL levels were tested on the first available stored plasma sample after birth, and in the treated newborn, therapeutic drug monitoring was done at weekly intervals. In RAL‐exposed infants, RAL was given to mothers at standard dosing of 400 mg BID, started at a mean GA of 30 weeks (range pre‐conception‐37.5 weeks). Indications for RAL included drug resistance and/or detectable viral load in the third trimester. Mean GA was 38.5 weeks (±1.76), and mean birthweight was 3200 g (±540). There were no clinical adverse events noted among RAL‐exposed infants (mean follow‐up time 119 weeks, range 48–144), and all were confirmed HIV negative. RAL levels tested in two exposed newborns at 16 and 30 hours of life were detectable at 0.9345 mg/L and 0.0381 mg/L, respectively, and undetectable in six other infants tested at days 4–14. RAL granules for suspension (Merck, special access) were obtained for prophylaxis of a term newborn (39 weeks GA) from a mother with multidrug‐resistant virus and started at 1.5 mg/kg BID, along with zidovudine and lamivudine at standard doses. RAL levels were consistently above the targeted trough for treatment (0.02 mg/L) (Table 1) for the duration of therapy. RAL was well tolerated and at follow‐up, the infant was confirmed HIV negative. RAL in late pregnancy had no adverse effects on infants exposed in utero. RAL treatment in the newborn at doses of 1.3–1.6 mg/kg BID was well tolerated and resulted in therapeutic drug levels. Given detectable levels of RAL in the first 30 hours of life in exposed infants, the timing and role of RAL in PMTCT should further be considered. Abstract TUAB0105–Table 1. Raltegravir levels in a treated newborn Day of life Weight (kg) Dose mg/kg/dose Trough (hours) Trough level Peak (hours) Peak level Adjusted 6 3.115 5 mg BID 1.61 11.67 0.36 1.97 0.87 No 9 3.220 5 mg BID 1.55 11.25 0.75 1.25 0.15 No 20 3.565 5 mg BID 1.40 12 0.07 1.17 0.33 No 27 3.835 5 mg BID 1.30 11 0.06 1.15 0.02 Increased to 6 mg BID 40 4.275 6 mg BID 1.40 N/A N/A N/A N/A Stopped 10.7448/IAS.18.5.20360 © 2015 Trahan M‐J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: fatima.kakkar@umontreal.ca BMS‐955176 is a second‐generation HIV‐1 maturation inhibitor that targets the HIV‐1 Gag polyprotein, inhibiting the last protease cleavage event between capsid protein p24 and spacer peptide 1, resulting in the release of immature, non‐infectious virions. Ten days of BMS‐955176 monotherapy resulted in maximum median declines in HIV‐1 RNA that plateaued at ~1.64 log10 c/mL at doses between 40 mg and 120 mg once daily (QD). Two drug combination studies in vitro demonstrated that BMS‐955176+atazanavir (ATV) had an additive effect. Due to the proximity of their sites of inhibition in the virus life cycle and the potential for synergy, we assessed the antiviral activity and safety of BMS‐955176 with ATV±ritonavir (RTV) for 28 days in HIV‐1‐infected subjects. In addition, this combination is being further evaluated to potentially serve as part of a booster‐sparing and nucleot(s)ide‐sparing strategy. AI468002 (NCT01803074) was a Phase 2a, randomized, multipart trial. In Part B, 28 HIV‐1 subtype B‐infected subjects (HIV‐1 RNA≥5000 c/mL, CD4+ T‐cell counts≥200 cells/µL) were randomized 2:2:2:1 to four treatment groups (all QD): BMS‐955176 40 mg+ATV 400 mg; BMS‐955176 40 mg+ATV 300 mg+RTV 100 mg; BMS‐955176 80 mg+ATV 400 mg; and a standard‐of‐care (SOC) control of tenofovir disoproxil fumarate 300 mg+emtricitabine 200 mg (fixed‐dose combination)+ATV 300 mg+RTV 100 mg. Median change in HIV‐1 RNA at Day 29 was −1.66, −1.99, −2.18 and −2.22 log10 c/mL, and maximum median change in HIV‐1 RNA from baseline to end of study/discharge (Day 42) was −1.86, −2.20, −2.23 and −2.39 log10 c/mL, for BMS‐955176 40 mg+ATV 400 mg, BMS‐955176 40 mg+ATV 300 mg+RTV 100 mg, BMS‐955176 80 mg+ATV 400 mg, and the SOC control, respectively (Table 1 and Figure 1). There were no deaths, serious adverse events (SAEs), or AEs leading to discontinuation. Furthermore, the median bilirubin level was below the upper limit of normal for subjects receiving unboosted ATV with BMS‐955176, in contrast to the level observed for subjects receiving BMS‐955176 40 mg+ATV+RTV or SOC. In this study, BMS‐955176 80 mg+ATV and 40 mg+ATV+RTV had similar maximum median declines in HIV‐1 RNA compared with the SOC control. BMS‐955176 with ATV±RTV was generally well tolerated. A Phase 2b study investigating BMS‐955176 in a booster‐sparing and nucleot(s)ide‐sparing regimen in treatment‐experienced patients will begin in Q2 2015. Abstract TUAB0106LB–Table 1. Changes in HIV‐1 RNA from baseline BMS‐955176 (40 mg QD)+ATV (400 mg QD) BMS‐955176 (40 mg QD)+ATV (300 mg QD)+RTV (100 mg QD) BMS‐955176 (80 mg QD)+ATV (400 mg QD) Tenofovir disoproxil fumarate (300 mg QD)+emtricitabine (200 mg QD) (fixed‐dose combination)+ATV (300 mg QD)+RTV (100 mg QD) N 8 8 8 4 Maximum decline in HIV‐1 RNA (log10 c/mL); median (min, max) −1.86 (−1.49, −2.37) −2.20 (−1.24, −3.52) −2.23 (−1.87, −2.68) −2.39 (−1.83, −3.04) Median decline in HIV‐1 RNA (log10 c/mL) on Day 29 (min, max) −1.66 (−1.19, −2.04) −1.99 (−1.04, −3.32) −2.18 (−1.53, −2.68) −2.22 (−1.83, −2.84) Abstract TUAB0106LB–Figure 1. Median change in HIV‐1 RNA (log10 c/mL) over time. Abstract TUAB0106LB–Figure 1. Median change in HIV‐1 RNA (log10 c/mL) over time. 10.7448/IAS.18.5.20544 © 2015 Hwang C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: carey.hwang@bms.com Both protease inhibitors (PI) and non‐nucleoside reverse transcriptase inhibitors (NNRTI) have been associated with acute hepatotoxicity, but their long‐term effect on liver fibrosis remains uncertain. We explored rates of change in liver fibrosis as measured by the aspartate‐to‐platelet ratio index (APRI) among HIV‐hepatitis C (HCV) co‐infected users of modern PI‐ or NNRTI‐based regimens. Data from a Canadian prospective multicentre cohort were analyzed for 397 HCV PCR+ persons who initiated antiretroviral therapy in or after 2000, with regimens at cohort entry comprised of a backbone of either Tenofovir/Emtricitabine or Abacavir/Lamivudine with a PI or NNRTI as the anchor agent. The natural logarithm of the APRI score was the outcome of interest. Three multivariate linear regression analyses with generalized estimating equations were performed. Analysis 1 (intention‐to‐treat) used baseline exposure to PI or NNRTI; analysis 2 (per protocol) was restricted to persons with a viral load under 1000 copies/mL and censored participants when the class of anchor agent was changed; analysis 3 (as treated) allowed for changes in the class of anchor agent during follow‐up. At cohort entry, 74% of participants were male, the median age was 44 years and 56% had used alcohol in the past six months. Therapy was started a median of 1.9 years before cohort entry (IQR: 0.3, 5.0), 70% used a PI and 69% were on a backbone of Tenofovir/Emtricitabine. PI use was associated with a median increase in APRI per 5 years of 16% (95% CI: 3%, 30%) in Analysis 1, 16% (95% CI: 0%, 32%) in Analysis 2 and 13% (95% CI: −1%, 27%) in Analysis 3. NNRTI use was not significantly associated with change in APRI in any of the three analyses, as shown in the Table. PI use seems to be associated with a faster progression of liver fibrosis, as measured by the median change in APRI score over five years. The consistency of estimates across the three analyses suggests that this is not the result of the type of patients using PI‐based regimens, although we could not account for all patient characteristics influencing the choice of an anchor agent. Abstract TUAB0201–Table 1. Multiplicative median change in APRI per 5 years Analysis APRI score at cohort entry, median (IQR) PI users (APRI units/5 years), Exp(β) (95% CI)a NNRTI users (APRI unit/5 years), Exp(β) (95% CI)a 1. Intention‐to‐treat 0.63 (0.39–1.30) 1.16 (1.03, 1.30) 1.05 (0.90, 1.20) 2. Per protocol 0.60 (0.39–1.22) 1.16 (1.00, 1.32) 1.07 (0.89, 1.24) 3. As treated 0.63 (0.39–1.30) 1.13 (0.99, 1.27) 1.09 (0.93, 1.25) aAdjusted for baseline age, sex and time since HCV infection and updated alcohol use, CD4 cell count, viral load or virologic failure and number or type of previous regimens. Adjusted for baseline age, sex and time since HCV infection and updated alcohol use, CD4 cell count, viral load or virologic failure and number or type of previous regimens. 10.7448/IAS.18.5.20361 © 2015 Brunet L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: laurence.brunet@mail.mcgill.ca Historically HIV co‐infection was considered a negative predictor of HCV response to treatment with interferon/ribavirin (IFN/RBV). For sofosbuvir‐based regimens, HIV/HCV patients have achieved similar sustained virologic response (SVR) rates as HCV mono‐infected patients. We evaluated the safety and efficacy of the IFN‐free, RBV‐free, single tablet regimen of ledipasvir/sofosbuvir (LDV/SOF) in HCV genotype 1 or 4 patients co‐infected with HIV‐1 in the Phase 3 ION‐4 study. HCV treatment naïve and experienced HIV co‐infected patients on stable, approved antiretroviral (ARV) regimens were enrolled and received LDV/SOF (90 mg/400 mg) once daily for 12 weeks. Patients with compensated cirrhosis were eligible. Permitted concomitant ARVs included tenofovir and emtricitabine (TDF+FTC) with raltegravir (RAL), efavirenz (EFV) or rilpivirine (RPV). Safety evaluations included adverse event (AE) and standard laboratory parameter monitoring in addition to enhanced renal toxicity monitoring, CD4 count and HIV‐1 RNA levels. The primary efficacy endpoint was SVR12. A total of 335 patients with GT1a (75%), GT1b (23%) and GT4 (2%) were enrolled; 82% were male, 61% were white, mean age was 52 (range 26–72), mean baseline HCV RNA was 6.7 log10 IU/mL (range 4.1–7.8), median baseline CD4 count was 662 cells/µL (Q1, Q3=469, 823), 20% had cirrhosis, 24% were IL28B CC genotype and 55% had not responded to prior HCV treatment. Patients were taking EFV (48%) or RAL (44%) or RPV (9%). The table shows SVR12 by ARV regimen. Overall, the SVR12 rate was 96% (320/335); two patients had on‐treatment virologic failure likely due to non‐compliance and 10 had virologic relapse after discontinuing treatment. SVR12 was similar among non‐cirrhotic (96%) and cirrhotic (94%) patients and also among treatment naïve (94%) and treatment experienced (97%) patients. No patient had confirmed HIV virologic rebound (HIV‐1 RNA≥400 copies/mL). No patients discontinued study drug due to an AE. AEs occurring in ≥10% of patients were headache (25%), fatigue (21%) and diarrhoea (11%). No significant lab abnormalities were observed. The IFN‐free, RBV‐free, single tablet regimen of LDV/SOF administered once daily for 12 weeks is highly effective and well tolerated in treatment‐naïve and experienced, genotype 1 or 4 HCV‐infected patients with HIV‐1 co‐infection, including those with cirrhosis. Abstract TUAB0202–Table 1. SVR12 by HIV regimen and overall Virologic response TDF+FTC+EFV (N=160) TDF+FTC+RAL (N=146) TDF+FTC+RPV (N=29) Overall (N=335) SVR12, n (%) 151 (94) 141 (97) 28 (97) 320 (96) On‐Treatment Failure, n (%) 1 (<1) 0 1 (3) 2 (<1) Relapse, n (%) 8 (5) 2 (1) 0 10 (3) Other, n (%) 0 3 (2) 0 3 (<1) 10.7448/IAS.18.5.20362 © 2015 Naggie S et al; licensee International AIDS Society Published 22 July 2015 The 3 direct‐acting antiviral (3D) regimen of ombitasvir (OBV), paritaprevir (identified by AbbVie and Enanta; co‐dosed with ritonavir; PTV/r) and dasabuvir (DSV) with ribavirin (RBV) is approved to treat HCV genotype 1 infection in patients with HIV‐1 co‐infection. In the TURQUOISE‐I trial, response rates were 94 and 91% in this population when treated for 12 and 24 weeks, respectively. We report the week 12 post‐treatment sustained virologic response rates (SVR12) by baseline characteristics. Patients were randomized to receive OBV/PTV/r + DSV + RBV for 12 (N=31) or 24 weeks (N=32). Eligible patients in this open‐label study were treatment‐naïve or pegIFN/RBV‐experienced with or without cirrhosis, had CD4+ count ≥200 cells/mm3 or CD4+% ≥14%, and plasma HIV‐1 RNA suppressed while receiving a stable atazanavir‐ or raltegravir‐inclusive antiretroviral (ART) regimen. Sixty‐three patients were enrolled, of whom 92% were male, 24% black race, 19% with compensated cirrhosis and 16% with a prior null response to pegIFN/RBV treatment. Two patients in the 12‐week treatment group (1 withdrawn consent, 1 HCV relapse), and three in the 24‐week treatment group (1 on‐treatment virologic breakthrough, 2 post‐treatment HCV re‐infections) did not achieve SVR12. The patients with on‐treatment breakthrough and relapse were both genotype 1a‐infected with prior null response to pegIFN/RBV and had F4 fibrosis (cirrhosis). High SVR12 rates were achieved in patients with historically difficult‐to‐cure characteristics including those with IL28B non‐CC genotype, high viral load, prior treatment failure and advanced liver disease (Table 1). Lower baseline CD4+ T‐cell counts did not negatively affect SVR12 rates. The regimen was well tolerated with no discontinuation due to adverse event or serious adverse event. In HCV genotype 1 patients co‐infected with HIV‐1, OBV/PTV/r + DSV + RBV achieved high rates of SVR12 regardless of baseline host, viral and disease characteristics whether treated with 12 or 24 weeks of therapy. Abstract TUAB0203–Table 1. SVR12 rates by baseline characteristic, n/N (%) Characteristic 12‐week OBV/PTV/r + DSV + RBV 24‐week OBV/PTV/r + DSV + RBV Overall 29/31 (94) 29/32 (91) Black race Hispanic or Latino ethnicity 7/7 (100) 7/8 (88) 7/8 (88) 7/8 (88) Age, ≥55 years 7/8 (88) 12/12 (100) BMI ≥30 3/3 (100) 7/7 (100) IL28B genotype CT TT 16/16 (100) 8/10 (80) 19/20 (95) 4/5 (80) Prior pegIFN/RBV treatment experience Naïve Relapser Partial response Null response 19/20 (95) 1/1 (100) 5/5 (100) 4/5 (80) 20/22 (91) 3/3 (100) 2/2 (100) 4/5 (80) Baseline HCV RNA ≥800,000 IU/mL Baseline CD4+ T‐cell cells/mm3 <350 350 – <500 25/27 (93) 2/2 (100) 8/8 (100) 26/28 (93) 5/5 (100) 7/8 (88) Baseline CD4+ T‐cells/mm3 <350 350 – <500 Baseline fibrosis stage F2 F3 F4 2/2 (100) 8/8 (100) 5/5 (100) 3/4 (75) 5/6 (83) 5/5 (100) 7/8 (88) 5/5 (100) 1/1 (100) 5/6 (83) SVR12, sustained virologic response at post‐treatment week 12; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; DSV, dasabuvir; RBV, ribavirin. SVR12, sustained virologic response at post‐treatment week 12; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; DSV, dasabuvir; RBV, ribavirin. 10.7448/IAS.18.5.20363 © 2015 Wyles D et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: dwyles@ucsd.edu There are few data about the clinical outcome of hepatitis C (HCV)/HIV co‐infected patients with liver cirrhosis after therapy, considering the possibility of fibrosis regression (FR). We compared the incidence rate (IR), and the time to develop a liver complication and death, in 139 cirrhotic patients according to sustained virological response (SVR) or/and FR, as established by a confirmed 1‐point decrease in Metavir score by transient elastography (TE). Overall, 42 patients reached SVR, and 23 of them (55%) had FR, in comparison with only 14 of the 91 (15%) without SVR. During a median follow up of 6.8 years (916.8 person‐years), the IR of death, liver‐related death, liver‐related complications and hospital admissions were significantly lower in patients with SVR/FR (Table). SVR patients without FR had a worse IR of death (5.36) and liver‐related death (2.68) than non‐SVR patients with FR (1.3 and 0.65, respectively; p<0.01). In Cox multivariate analysis, only FR was associated with a lower risk of death (adjusted hazard ratio, HR, 0.36; 95% CI 0.15–0.86), and liver‐related death (HR 0.15; 95% CI 0.03–0.65), whereas both FR (HR 0.09; 95% CI 0.03–0.3, p<0.01) and SVR (HR 0.24; 95% CI 0.07–0.87) decreased the risk of liver‐related complications. FR is frequent after anti‐HCV therapy in HIV/HCV co‐infected patients with compensated cirrhosis who achieve SVR, and it is associated with the highest reduction of death of any cause, liver‐related mortality, liver‐related complications and hospital admissions. Abstract TUAB0204–Table 1 SVR (42) No SVR (91) FR (23, 55%) No FR (19, 45%) p FR (14, 15%) No FR (77, 85%) p TE (Kpa) 7.1 (6.3–8.8) 17.5 (13.8–26.3) <0.01 11.6 (6.3–11.2) 21.3 (17.2–45.4) <0.01 Death (n, %) IR 4 (17%) 2.45 6 (32%) 5.36 0.01 2 (14%) 1.3 37 (48%) 7.6 <0.01 Liver‐related death (n, %), IR 1 (4%) 0.61 3 (16%) 2.68 0.01 1 (7%) 3.65 29 (38%) 5.9 <0.01 Liver‐related complications (n, %) IR 1 (4%) 1.22 2 (11%) 1.78 0.2 0.15 5 (36%) 3.25 33 (43%) 6.81 0.0150 copies/mL 175 (25) 225 (25) HbA1c>10% (used HOMA IR>2 as surrogate) 171 (24) 217 (24) APRIb of <1 or ≥2 129 (18) 171 (19) CD4 T‐cell count <200 cells/mm3 106 (15) 136 (15) Decompensated liver disease 23 (3) 27 (3) aSOF trial: emtricitabine/tenofovir plus atazanavir/ritonavir; or darunavir/ritonavir; efavirenz; raltegravir; rilpivirine. SIM trial: excluded all boosted PIs and allowed only raltegravir, sustiva and ripilvirine; baspartate aminotransferase/platelet ratio index (APRI) <1 defined as non‐cirrhotic or ≥2 defined as cirrhotic based on SOF trial. SOF trial: emtricitabine/tenofovir plus atazanavir/ritonavir; or darunavir/ritonavir; efavirenz; raltegravir; rilpivirine. SIM trial: excluded all boosted PIs and allowed only raltegravir, sustiva and ripilvirine; aspartate aminotransferase/platelet ratio index (APRI) 200 cells/mm3 and an HIV RNA 500 cells/mm3 and VL 5× resistance to EBR in vitro (L31M, Y93S). Adverse events (AEs) were reported in 157/218 (72%) patients; serious AEs occurred in 2/218 (0.9%) patients. Adherence was >90% in the total population, including virologic failures. There was no difference in PK parameters in patients who achieved SVR12 versus patients who did not achieve SVR12. A 12‐week regimen of GZR/EBR FDC was highly effective among HIV/HCV co‐infected patients with GT1, 4 or 6 infection, with a favourable safety profile. SVR was high across all patient subgroups including African‐Americans and those with cirrhosis. Abstract TUAB0206LB–Table 1. SVR12 by genotype All patients GT1a GT1b GT4 (N=218a) (N=144) (N=44) (N=28) SVR12b n/N 207/218 136/144 42/44 27/28 % 95.0% 94.4% 95.5% 96.4% 95% CI 91.2, 97.5 89.3, 97.6 84.5, 99.4 81.7. 99.9 LTFU or unrelated to VFc 4 3 1 0 Relapsed 5 4 0 1 Reinfection 2 1 1 0 aFAS (Full Analysis Set): all patients who received at least one dose of GZR/EBR. bHCV RNA assessed via COBAS TaqMan v2.0 [lower limit of quantitation <15 IU/mL]. N=Number of subjects included in the analysis. n (%)=Number of subjects who achieved SVR12 and the percentage calculated as (n/N)*100. cTwo subjects were lost to follow‐up; one patient was discontinued for taking a prohibited concomitant medication, and one subject's FW12 visit was outside the analysis window. dAt baseline in the NSSA gene, one of the relapses had L31M/L RAV and one of the relapses had the Y93S RAV. The other three relapses had the WT NSSA gene at baseline. FAS (Full Analysis Set): all patients who received at least one dose of GZR/EBR. HCV RNA assessed via COBAS TaqMan v2.0 [lower limit of quantitation <15 IU/mL]. N=Number of subjects included in the analysis. n (%)=Number of subjects who achieved SVR12 and the percentage calculated as (n/N)*100. Two subjects were lost to follow‐up; one patient was discontinued for taking a prohibited concomitant medication, and one subject's FW12 visit was outside the analysis window. At baseline in the NSSA gene, one of the relapses had L31M/L RAV and one of the relapses had the Y93S RAV. The other three relapses had the WT NSSA gene at baseline. 10.7448/IAS.18.5.20545 © 2015 Rockstroh J K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: juergen.rockstroh@ukb.uni‐bonn.de All‐oral regimen with daclatasvir (DCV; NS5A replication complex inhibitor)+sofosbuvir (SOF; NS5B polymerase inhibitor)±weight‐based ribavirin (RBV) has demonstrated high sustained virologic response (SVR) rates in HCV mono‐infected patients. This analysis reports SVR4 and SVR12 results from an ongoing multicentre compassionate use programme (ATU) in France. HIV‐HCV co‐infected patients with advanced liver disease from 221 centres have been included since March 2014. All patients received DCV+SOF QD for 12 or 24 weeks, with RBV added at the physician's discretion. Baseline characteristics, virological response rates and adverse events were collected through a standardized form. We report interim SVR rates at 4 and 12 weeks after the end of treatment for patients who have completed treatment to date. Of 562 patients enrolled, 73.8% were males, median age was 52.3 years (30–74), 395 (71.0%) were cirrhotic and 460 (82.6%) were treatment‐experienced. Child Pugh was A=85.4%, B=12.9%, C=1.7%. Genotype distribution was as follows: 387 GT1 (69.7%), 2 GT2 (0.4%), 72 GT3 (13.0%), 93 GT4 (16.8%) and 1 GT6 (0.1%), 7 missing data. Median HCV‐RNA was 6.10 logUI/mL (1.08–7.97). Combined antiretroviral therapy included: NRTI in 88%, PI in 36.4%, NNRTI in 23% and INI in 63.7% of the patients. Baseline median CD4 count was 551/mm3 (0–1922). HIV‐RNA was undetectable in 505 patients (98.4%). RBV was added to DCV+SOF in 67 patients (12.0%). Treatment duration was 24 weeks in 478 (85.1%) and 12 weeks in 84 (14.9%) patients. Overall, SVR4 was obtained in 90.2% (148/164) and SVR12 in 95.9% (94/98) of the cases Among patients treated with DCV+SOF for 12 or 24 weeks, 96.0% (24/25) and 95.1% (58/61) achieved an SVR12, respectively, compared to 100% (6/6) and 100% (6/6) for patients receiving DCV+SOF+RBV. Neither duration of treatment nor cirrhosis status and genotype influenced the rate of SVR12 (Table 1). Treatment discontinuations occurred in 17 patients (3%) and were related to an adverse event (n=5), death (n=4, not related to treatment), patient decision (n=3), contraindication (n=3), unknown reason (n=1) and patient lost to follow‐up (n=1). DCV+SOF±RBV regimen was well tolerated and demonstrated high SVR12 rate in HIV‐HCV co‐infected patients with advanced liver disease. Abstract TUAB0207LB–Table 1. Efficacy of DCV+SOF±RBV regimens in HIV/HCV co‐infection Treatment duration Genotype status 12 weeks 24 weeks GT1 (all) GT1 cirrhotic GT3 (all) GT3 cirrhotic GT4 (all) GT4 cirrhotic SVR4, N=164 41/49 (83.7%) 107/115 (93.0%) 104/116 (89.7%) 80/87 (92.0%) 13/15 (86.7%) 12/13 (92.3%) 26/28 (92.9%) 16/17 (94.1%) SVR12, N=98 30/31 (96.8%) 64/67 (95.5%) 66/68 (97.1%) 52/53 (98.1%) 11/11 (100%) 11/11 (100%) 14/15 (93.3%) 10/11 (90.9%) 10.7448/IAS.18.5.20546 © 2015 Lacombe K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: dominique.salmon@aphp.fr Young women in southern Africa have high rates of sexually transmitted infections, including herpes simplex virus type‐2 (HSV‐2) and HIV. We investigated whether conditional cash incentives (CCIs) reduced the incidence of HSV‐2 and HIV in rural high school students in South Africa. An open‐label, matched‐pair, cluster randomized controlled trial (CAPRISA 007) was undertaken in 3217 consenting male (n=1517) and female (n=1700) grade 9 and 10 students. A locally developed HIV prevention programme, My Life! My Future!, was actively implemented in all 14 schools. Seven schools (n=1592 students) were randomly assigned to receive; in addition, cash incentives (maximum of $175 over two years) for fulfilling any combination of four conditions; annual HIV testing, performance in school tests, participation in My Life! My Future!, and a written report on their community involvement project. HSV‐2 and HIV serology was undertaken at baseline, 12 months and 24 months. In the intent‐to‐treat analysis, incidence rate ratios (IRRs) and p‐values were adjusted for the matched‐pair cluster design. HSV‐2 prevalence at baseline was 9.0% in CCI schools and 7.3% in control schools. During follow‐up, there were 319 new HSV‐2 infections, with an incidence rate of 6.2 per 100 person‐years in CCI schools compared to 8.7 per 100 person‐years in control schools (IRR=0.70, 95% CI: 0.57–0.86; p=0.007). HSV‐2 incidence was 7.1 per 100 person‐years in the 760 students who received $95 (Trend test, p=0.12). The lower‐than‐anticipated overall HIV incidence rate of 1.6 per 100 person‐years was similar in both groups of schools (IRR=1.26, 95% CI: 0.66–2.39; p=0.419). A fourfold larger study would be required for 80% power to observe a 30% HIV incidence reduction. CCI schools had 30% lower HSV‐2 incidence. Students who received larger cash incentives had lower HSV‐2 incidence rates. The impact of CCI on HIV could not be adequately assessed as incidence was lower than expected, likely due to HIV lowering effects of both study‐initiated and background community HIV interventions. 10.7448/IAS.18.5.20547 © 2015 Karim Q A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: quarraisha.abdoolkarim@caprisa.org Low uptake of male circumcision has been a major challenge to scaling‐up and maximizing the HIV prevention impact of voluntary medical male circumcision (VMMC) services in eastern and southern Africa. There is limited evidence on effective demand creation strategies for VMMC that address reported barriers to male circumcision. Building on insights from behavioural economics, we assessed whether providing compensation for opportunity costs of time or lottery‐based rewards can increase VMMC uptake among men in Nyanza Province, Kenya. Uncircumcised men aged 21–39 years were provided information on VMMC services and randomized in 1:1:1 ratio to two intervention groups or a control group. One intervention group was offered compensation of US$12.50 conditional on VMMC uptake. Compensation was provided in the form of food vouchers valid at shops in the study region. A second intervention group was offered the opportunity to participate in a lottery with high‐value prizes upon undergoing circumcision. The primary outcome was VMMC uptake within three months. Among 903 participants enrolled, those randomized to receive compensation of US$12.50 had the highest VMMC uptake (8.4%, 26/308), followed by those receiving lottery‐based rewards (3.3%, 10/302) and those in the control group (1.3%, 4/299). Logistic regression analysis showed that compared to the control group, the US$12.50 group had significantly higher VMMC uptake (Adjusted odds ratio (AOR) 7.1; 95% CI 2.4–20.8). Participants in the lottery‐based rewards group were not significantly more likely to become circumcised than participants in the control group (AOR 2.5; 95% CI 0.8–8.1). The effect of providing compensation of US$12.50 was largest among participants who were contemplating circumcision at the time of enrolment. Providing conditional economic compensation was effective in increasing circumcision uptake among men in a short time period. The results are consistent with studies showing that small incentives can modify health behaviours by addressing barriers such as opportunity costs of time and present‐biased decision‐making. Contrary to findings from studies in high‐income countries, lottery‐based rewards did not significantly increase circumcision uptake. Testing economic interventions in other settings and applying them to different HIV behaviours can be useful for assessing the generalizability of the findings. 10.7448/IAS.18.5.20366 © 2015 Thirumurthy H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: hthirumu@email.unc.edu Homelessness has been identified as an important structural barrier to effective antiretroviral therapy (ART) utilization among HIV‐infected people who use drugs (PWUD). However, the potential effect of reducing homelessness on viral suppression rates at the community level is unknown. We used an imputation‐based marginal modelling approach to estimate change in the prevalence of viral suppression among HIV‐infected PWUD, if homelessness were eliminated from the population. We used data from a cohort study of community‐recruited PWUD in Vancouver, Canada. Of note, HIV/AIDS treatment and care is provided free of charge in this setting. Persons were eligible to participate if they were HIV‐infected and used an illicit drug in the month prior to enrolment. We assessed self‐reported baseline housing status in the past six months. Viral suppression was defined as HIV RNA viral load <50 copies per mm3 at first study visit. We estimated the effect of homelessness on viral suppression using modified‐Poisson regression, adjusting for demographics, socioeconomic characteristics, trauma history, depression, addiction treatment and other confounders. Then, a marginal modelling approach was applied. First, we imputed the outcome probability for each individual while manipulating the exposure (homelessness) to never exposed, and then averaged these probabilities across the population. Bootstrapping was conducted to calculate 95% confidence limits. Of 718 eligible individuals enrolled between January 2005 and December 2013, the majority was male (66%), white race/ethnicity (55%) and had a history of injection drug use (94%). At baseline, 230 (32%) reported homelessness. The prevalence of viral suppression was 35% (95% CI: 31–38%). Adjusted marginal models estimated a 14% relative increase (95% CI: 10–24%) in viral suppression prevalence in the entire sample – to 40% (95% CI: 36–45%) – if all homeless individuals were housed. Among those homeless at baseline, adjusted marginal models estimated that eliminating this exposure would increase viral suppression from 19% (95% CI: 14–24%) to 37% (95% CI: 33–42%). Reducing homelessness among HIV‐infected PWUD could have significant population‐level benefits on outcomes in the HIV care continuum. Low threshold shelter and housing support programs should be considered as key components in comprehensive strategies to increase population‐level viral suppression for PWUD. 10.7448/IAS.18.5.20367 © 2015 Marshall B D L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: brandon_marshall@brown.edu Behavioural economic theory suggests that understanding motivations and future preferences of people living with HIV infection (PLHIV) can inform the development of interventions supporting adherence to treatment and care. For example, PLHIV with high levels of intrinsic motivation to adhere to ART may require less external motivation, such as cash incentives. In addition, PLHIV who disproportionally value the present and heavily discount the future may be less likely to adhere to ART, a behaviour with future benefits and present costs. We measured these constructs among antiretroviral therapy (ART) initiates at four HIV care and treatment clinics in Shinyanga Region, Tanzania. We analyzed data collected from in‐person interviews between December 2013 and December 2014 with food‐insecure, HIV‐infected adults who initiated ART in the past 90 days. Temporal discount rate, the rate at which individuals discount future costs and benefits, was measured using a bidding process to assess the acceptable percent increase of a hypothetical monetary offer they would receive in three months compared to a smaller amount received today. Future health expectations were assessed for one year from now, and intrinsic motivation for ART adherence was measured as the mean score (range: 0–3) on a Likert‐scale using questions in the Treatment Self‐Regulation Questionnaire. Overall, 511 food‐insecure recent ART initiates were interviewed (mean age: 37, 64% female). Nearly all (99%) expected their health to be somewhat (55%) or much better (44%) one year from now. Excluding those who initiated treatment on the same day of the interview, mean internal motivation was 2.75 (standard deviation 0.36; n=423). Temporal discount rates (n=489) fell into four ranges: 200% (2%). These data indicate high levels of both intrinsic motivation for ART adherence and optimism towards future health among food‐insecure ART initiates in Tanzania, suggesting that interventions designed to strengthen and sustain intrinsic motivation may be appropriate. The high discount rates indicate a greater focus on the present; thus, interventions aiming to overcome the short‐term cost barriers to adherence and care (e.g. time, transport and competing needs) in order to achieve future gains may be highly effective among this population. 10.7448/IAS.18.5.20368 © 2015 Czaicki N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: nczaicki@berkeley.edu The South African disability grant (DG) has been theorized to incentivize poor recovery by tying grant receipt to AIDS sickness. Prior to 2008, many official guidelines defined qualifying AIDS disability as a CD4 count below 200 mmHg, and this recommendation persists unofficially. We make two predictions: 1) The population distribution of CD4 counts will have an observable discontinuity with excess mass just below the CD4 qualification threshold of 200 mmHg, and 2) individuals receiving the grant will recover more slowly around this threshold than those who do not, due to threat of grant loss. The analysis utilizes a two‐stage panel regression methodology to absorb individual trends and identify differential recovery rates around the CD4 threshold of 200 mmHg. The dataset for this analysis utilizes the Africa Centre Demographic Information System (ACDIS), an open cohort health and demographic monitoring programme consisting mainly of annual surveys, individually matched with an HIV‐focused clinical informatics system in rural KwaZulu‐Natal, South Africa. Data are restricted to HIV+ individuals from 2004 to 2011, who have at least four observed CD4 counts, with at least one observed CD4 count above and below 200 mmHg. The cohort for this analysis consists of 11,160 observations from 1450 individuals. The distribution of CD4 counts shows clear excess mass just below a CD4 count of 200 mmHg, with more pronounced for CD4 counts occurring in 2008 or earlier. Among observations around the threshold, the rate of recovery of those receiving DGs is 0.23 mmHg/year lower (p=0.020) than that of those not receiving DGs, controlling for individual recovery trends, age, education, time, household assets and employment. Stratifying on gender, the effect is seen much stronger among women with a differential recovery rate of 58 mmHg/year (p=0.018). The effect is significantly larger for observations in 2008 or earlier. This study finds that the South African DG system resulted in a modest but significant manipulation of CD4 counts in order to qualify for the grant. While policy changes have likely reduced the severity of the effect, policy makers should ensure that incentives from grants are aligned with health incentives to reduce poor outcomes, infectivity and drug resistance. 10.7448/IAS.18.5.20369 © 2015 Haber N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: nhaber@mail.harvard.edu Young women in South Africa face a particularly high risk of HIV infection. Structural factors such as schooling, socio‐economic status (SES) and financial dependence on partners contribute to this risk. Cash transfers have shown promise in reducing HIV risk in young women by addressing these factors. HPTN 068 is the first randomized trial to examine the impact of conditional cash transfers on HIV incidence among young women. HPTN 068 is a phase III individually randomized trial to assess the impact of a conditional cash transfer on the acquisition of HIV among South Africa young women. Young women and their parent/guardian in the intervention arm received a monthly cash transfer conditional on 80% school attendance, which was verified using school attendance rosters. The intervention ran from April 2011 to March 2015. Participants enrolled in the study were aged 13–20, in high school, not married or pregnant and resident in the Agincourt Health and Demographic Surveillance System (AHDSS) site in rural Mpumalanga Province. Participants were seen at baseline, then annually for up to three follow‐up visits, where HIV and HSV‐2 testing was conducted and an interview was completed using Audio Computer‐Assisted Self Interviewing (ACASI). The interview assessed sexual behaviour including partner‐specific details, schooling, mental health, SES and gender power dynamics. Participants were tested for HIV infection using two HIV rapid tests with Western blot confirmation. Stored samples from all participants at all visits were also tested at the HPTN Laboratory Center using assays that included an HIV antigen/antibody test and a qualitative HIV RNA test. To compare treatment arms, time to first HIV detection was analysed using a Cox proportional hazards model. We will present the impact of the conditional cash transfer on HIV incidence, unprotected sex, pregnancy, age difference with partners, number of sex partners, transactional sex, age of sexual debut and school attendance. Cash transfers are increasingly being included as part of the package of prevention services that should be offered to young women to reduce HIV risk in sub‐Saharan Africa. The evidence from this RCT will have important implications for HIV prevention policy and practice. 10.7448/IAS.18.5.20548 © 2015 Pettifor A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: apettif@email.unc.edu Pre‐exposure prophylaxis (PrEP) with daily oral FTC/TDF prevents HIV infection and is safe, but concern has been raised that PrEP could cause hepatitis B virus (HBV)‐associated flares when discontinued by people with HBV infection, particularly among individuals with cirrhosis. The safety and feasibility of providing HIV PrEP in the setting of HBV infection was evaluated in the iPrEx study. The iPrEx study randomized 2499 HIV‐negative men and transgender women who have sex with men to once‐daily oral FTC/TDF versus placebo. Hepatitis serologies and transaminases were obtained at screening and at PrEP discontinuation. Participants with a reactive hepatitis B surface antigen were enrolled if there was no clinical evidence of cirrhosis and transaminases were <2.5‐fold the ULN. HBV DNA was assessed by PCR and drug resistance was assessed by population sequencing (Abbott labs) at least once for individuals with evidence of HBV DNA. Vaccination was offered to individuals susceptible to HBV. Among 2499 enrolled participants, 12 (0.5%; including six randomized to FTC/TDF) had chronic HBV infection. After stopping study drug, five of six in the active arm had LFTs performed at follow‐up. LFTs remained within normal limits at post‐stop visits except for a Grade 1 elevation in one participant at post‐stop week 12 (ALT=90, AST=61). There was no evidence of flares. PCR of stored samples showed that four had evidence of acute HBV infection at enrolment (two in the active arm). Both had evidence of grade 4 transaminase elevations by week 4 with subsequent resolution. Overall, there was no evidence of TDF or FTC resistance among tested genotypes. Of 1633 eligible for vaccination, 1587 (97.2%) received at least one vaccine and 1383 (84.7%) received the complete series. Anti‐HBs detection was 44.4% after one, 74.5% after two and 86.9% after three doses. PrEP can be safely offered to persons with HBV infection if there is no evidence of cirrhosis or substantial transaminase elevation. As information is limited and treatment for HBV is complex, referral to a specialist is appropriate when available. HBV vaccination rates at screening were low globally, yet uptake and efficacy were high when offered. 10.7448/IAS.18.5.20370 © 2015 Solomon M M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: robert.grant@ucsf.edu Pre‐exposure prophylaxis (PrEP) has demonstrated efficacy in reducing HIV acquisition in men who have sex with men (MSM) and transgender women (TGW). Little is known about adherence, sexual behaviour and HIV/STI incidence among those who elect to take PrEP in real‐world settings. The Demo Project is the first US multi‐site open‐label study assessing PrEP delivery in municipal STD (San Francisco, Miami) and community‐health (Washington, DC) clinics. HIV‐uninfected MSM/TGW were offered 48 weeks of PrEP. Tenofovir‐diphosphate levels were measured in dried blood spots (DBS) in a random sample of participants (pts). Correlates of adherence were assessed using multivariable logistic regression. Sexual behaviours, PrEP discontinuations and HIV/STI incidence are described. From 9/2012 to 1/2014, 557 pts enrolled, with 83% retained for the final visit (468.8 person‐years (py)). Longitudinal drug levels, sexual behaviour and STI incidence are shown (Figure). Among 147 pts with DBS testing, 65% had drug levels consistent with taking ≥4 doses/week at all visits, 3% always had DBS levels <2 doses/week, and 32% had an inconsistent pattern. Black pts, being self‐referred to the PrEP programme and having a greater number of condomless anal sex (AS) partners were independently associated with DBS ≥4 doses/week (all p<0.05). Median AS partners in the past three months declined from baseline to week 48 (5 to 4, p<0.0008). Two‐thirds reported condomless receptive AS (CRAS) at baseline, which remained stable during follow‐up (p=0.96). Twenty pts chose to stop PrEP due to low self‐perceived HIV risk, however 65% of these pts reported CRAS in the prior three to six months. Three participants were acutely infected at enrolment, and one seroconverted during follow‐up (HIV incidence 0.21/100 py). This subject had DBS 25 ng/mL) was 94%. At months 1, 3, 6, 9 and 12, the proportion with detectable mean tenofovir levels were 93, 93, 100, 93 and 90%, respectively. After starting drug, no HIV infections were observed during the study. In this open‐label study of TDF/FTC for oral PrEP, we observed high self‐reported three‐day medication adherence, high percentage of detectable DBS tenofovir levels and no HIV infections. These findings lend support to efforts to expand availability of PrEP in the context of generalized epidemics in resource‐limited settings. Further work is needed to define longer‐term adherence for such populations. 10.7448/IAS.18.5.20372 © 2015 Henderson F et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: inh3@cdc.gov Young men who have sex with men (YMSM), particularly racial/ethnic minority YMSM, are a key population for implementation of domestic pre‐exposure prophylaxis (PrEP) interventions. This open‐label PrEP study examined uptake and adherence to PrEP and assessed sexual risk behaviour among a diverse sample of YMSM in 12 U.S. cities. ATN110 combined PrEP with evidence‐based behavioural risk reduction interventions along with frequent sexual health and adherence promotion counselling. Eligible participants were 18‐ to 22‐year‐old HIV‐uninfected MSM who reported HIV transmission risk behaviour in the past six months. Participants were recruited and screened for preliminary eligibility through venue‐based outreach, community presentations and online advertising. Laboratory screening determined final eligibility. Study visits occurred at baseline, monthly through week 12, then quarterly through week 48. Dried blood spots were serially collected for the quantification of tenofovir diphosphate (TFV‐DP) blood levels. Between March and September 2013, 2186 individuals were approached, 277 (13%) were preliminarily eligible and 200 were enrolled (mean age=20.2; 54.5% Black, 26.5% Latino). Eleven (4%) had undiagnosed HIV infection at screening and two acute HIV infections were diagnosed at baseline. Diagnosis of STIs at baseline was high (22%) and remained high across visits. Most participants (98%) chose to take PrEP. Figure 1 shows TFV‐DP levels. At week 4, 56% of participants had TFV‐DP levels consistent with ≥4 pills/week. By week 48, 34% of participants had TFV‐DP levels consistent with ≥4 pills/week, with a noticeable drop‐off occurring at Week 24. Four HIV seroconversions occurred on study (3.29/100 person‐years); all had TFV‐DP BLQ at diagnosis. Condomless sex was reported by >80% of participants throughout the study and condomless anal sex with last partner was associated with higher TFV‐DP levels. ATN110 enrolled a diverse sample of YMSM vulnerable to HIV. PrEP uptake was high with the majority achieving protective drug levels during initial monthly visits. As visits decreased in frequency, so did adherence, while reported sexual risk behaviour remained constant. Given the frequency of STI diagnoses, HIV infections may have been higher without PrEP. YMSM in the U.S. may need access to PrEP in youth‐friendly settings with tailored adherence support and potentially augmented visit schedules. Abstract TUAC0204LB–Figure 1. Tenofovir diphosphate levels (fmol/punch) and PrEP dosing estimates as measured by dried blood spot assay. Abstract TUAC0204LB–Figure 1. Tenofovir diphosphate levels (fmol/punch) and PrEP dosing estimates as measured by dried blood spot assay. 10.7448/IAS.18.5.20549 © 2015 Hosek S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: shosek@cookcountyhhs.org In Brazil, men who have sex with men (MSM) and transgender women (TGW) are the populations most heavily affected by the AIDS epidemic. Although the WHO recommends pre‐exposure prophylaxis (PrEP) for these populations, the feasibility and interest in this prevention strategy in real‐world settings in low‐ and middle‐income countries are unknown. This study aims to describe PrEP uptake and associated factors in Brazil. PrEP Brasil is a demonstration project to assess the feasibility of implementing PrEP provided at no cost to high risk MSM and TGW within the Brazilian public health system. The project was advertised through social and other media. Participants were assessed for PrEP eligibility at FIOCRUZ‐RJ, CRT‐SP and USP‐SP. At USP, 100% participants were self‐referred, while at FIOCRUZ and CRT, they were either self‐referred or assessed for participation during HIV‐testing or post‐exposure prophylaxis provision. Predictors of PrEP uptake were assessed using a Poisson regression model. Of 986 MSM/TGW approached between April/2014 and April/2015, 798 were potentially eligible and 409 were enrolled. PrEP uptake was 51.25%. Median age at enrolment was 29 years (IQR 25–35); 93.5% had≥12 years of education; 83.9%, 8.8% and 5.9% identified themselves as homosexual, bisexual or TGW, respectively (Table); syphilis prevalence, rectal Chlamydia and Gonorrhoea detection were 21.3%, 8.2% and 4.7%, respectively. In multivariate analysis, factors associated with PrEP uptake were: recruitment at CRT‐SP (aRR 1.27; 95% CI 0.99–1.62) or USP‐SP (aRR 1.72; 95% CI 1.33–2.24) versus FIOCRUZ; having a steady partner (aRR 1.45, 95% CI 1.18–1.78); having an HIV‐test within the last 12 months (aRR 1.33, 95% CI 1.01–1.74); prior PrEP awareness (aRR 1.27, 95% CI 1.0–1.59) and having≥2 male condomless anal sex partners within the last 12 months (aRR 1.65, 95% CI 1.32–2.05). This is the first PrEP demonstration project for MSM and TGW in a middle‐income country. Overall, PrEP uptake was high. The higher uptake among those at higher risk and with an existing awareness of PrEP emphasizes the importance of establishing strategies to improve HIV risk perception and PrEP awareness in the MSM and TGW communities in Brazil. Abstract TUAC0205LB–Table 1. Study population characteristics and PrEP uptake Approached (1) N (%) Potentially Eligible (2) N (%) Included (3) N (%) Declined (4) N (%) Percent of PrEP uptake* p‐value** Overall 986 798 409 365 51.25 Site location (5) 45 56 (5.68) 50 (6.27) 31 (7.58) 15 (4.11) 62 Sexual Identity 0.04 Homosexual 823 (83.55) 658 (82.56) 343 (83.86) 293 (80.49) 52.13 Bisexual 99 (10.05) 87 (10.92) 36 (8.8) 47 (12.91) 41.38 Tranagender woman 44 (4.47) 36 (4.52) 24 (5.87) 14 (3.85) 66.67 Other 19 (1.93) 16 (2.01) 6 (1.47) 10 (2.75) 37.5 Color/Race 0.05 White 455 (46.15) 399 (50) 219 (53.55) 161 (44.11) 54.89 Non‐white 531 (53.85) 399 (50) 190 (46.45) 204 (55.89) 47.62 Schoolong years 0.06 12 897 (90.97) 732 (91.73) 383 (93.64) 323 (88.49) 52.32 Steady partner <0.001 Yes 472 (47.87) 385 (48.25) 223 (54.52) 149 (40.82) 57.92 No 514 (52.13) 413 (51.75) 186 (45.48) 216 (59.18) 45.04 Perceived likelihood of getting HIV in the next year <0.001 0–25% 569 (57.71) 437 (54.76) 189 (46.21) 237 (64.93) 43.25 50–100% 417 (42.29) 361 (45.24) 220 (53.79) 128 (35.07) 60.94 Previous HIV test (last 12 months) <0.001 Yes 657 (66.63) 575 (72.06) 334 (81.66) 219 (60) 58.09 No 329 (33.37) 223 (27.94) 75 (18.34) 146 (40) 33.63 Prior PrEP awareness <0.001 Yes 594 (60.43) 498 (62.64) 296 (72.55) 183 (50.41) 59.44 No 389 (39.57) 297 (37.36) 112 (27.45) 180 (49.59) 37.71 # Male condomless anal sex partners (last 12 months) <0.001 <2 512 (51.93) 370 (46.37) 143 (34.96) 222 (60.82) 38.65 2 or more 474 (48.07) 428 (53.63) 266 (65.04) 143 (39.18) 62.15 Anal sex with HIV‐positive partners (12 months) <0.001 Yes 346 (35.09) 324 (40.6) 208 (50.86) 104 (28.49) 64.2 No 211 (21.4) 87 (10.9) 41 (10.02) 44 (12.05) 47.13 I do not know 429 (43.51) 387 (48.5) 160 (39.12) 217 (59.45) 41.34 STD diagnosis (12 months) 0.01 Yes 138 (14) 128 (16.04) 79 (19.32) 39 (10.68) 61.72 No 848 (86) 670 (83.96) 330 (80.68) 326 (89.32) 49.25 (1)All individuals approached for pre‐screening who were age 18 or older, male at birth, lived in the State, self‐reported HIV negative status and reported having at least one male sexual partner in last 12 months. (2)Includes all individuals approached at pre‐screening (1) who: a) reported 2 or more male condomless anal sex partners OR anal sex with HIV positive partner OR STD diagnosis in last 12 months; and b) had a negative HIV test results. (3)Individuals who enrolled the study. (4)Decline represents the sum of refusals in all steps. Indivuduals who agreed to participate but did not show up at the screen or enrollment visit were considered as declining. (5)FIOCRUZ‐RJ: Fundação Oswaldo Cruz, located in Rio de Janelro; CRT‐SP: Centro de Referencla e Treinamento em DST e AIDS, located in São Paulo; USP‐SP: Universidade de São Paulo. *% uptake‐ # Included/# Potentially elligible at pre‐screening. **chi‐square for bivariate analyses. All individuals approached for pre‐screening who were age 18 or older, male at birth, lived in the State, self‐reported HIV negative status and reported having at least one male sexual partner in last 12 months. Includes all individuals approached at pre‐screening (1) who: a) reported 2 or more male condomless anal sex partners OR anal sex with HIV positive partner OR STD diagnosis in last 12 months; and b) had a negative HIV test results. Individuals who enrolled the study. Decline represents the sum of refusals in all steps. Indivuduals who agreed to participate but did not show up at the screen or enrollment visit were considered as declining. FIOCRUZ‐RJ: Fundação Oswaldo Cruz, located in Rio de Janelro; CRT‐SP: Centro de Referencla e Treinamento em DST e AIDS, located in São Paulo; USP‐SP: Universidade de São Paulo. % uptake‐ # Included/# Potentially elligible at pre‐screening. chi‐square for bivariate analyses. 10.7448/IAS.18.5.20550 © 2015 Hoagland B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: beatriz.grinsztejn@gmail.com Tenofovir (TFV) gel, when used consistently as a vaginal microbicide, prevents HIV infection. As unprotected anal intercourse is prevalent amongst heterosexual women, data on TFV concentrations and anti‐HIV activity in the rectal compartment following vaginal application, and vice versa, are needed. MTN‐014 is a phase 1 cross‐over, randomized trial comparing the pharmacokinetics of TFV reduced‐glycerin (RG) 1% gel following 14 days each of daily rectal versus vaginal directly observed dosing (DOD), with a six‐week washout period in between each phase. Vaginal and rectal tissue and fluid and blood samples were collected 24 hours after the end of each phase and analyzed for TFV and TFV‐diphosphate (TFV‐DP) concentrations. Vaginal and rectal fluids were tested for HIV inhibition using a TZM‐bl assay. Fourteen HIV‐uninfected women, mean age 34 years, were enrolled at the Bronx Prevention Center in New York City and 13 completed all study procedures. Of the 392 expected doses, 91% were DOD, two (0.5%) were missed and the remaining doses were reported as used. Mean plasma TFV concentrations were similar after 14 days of either dosing route (Table). Rectal concentrations of TFV and TFV‐DP were detectable after vaginal dosing in only 1 of 13 and 2 of 13 tissue samples, respectively, while vaginal concentrations of TFV and TFV‐DP were detectable after rectal dosing in 6 of 14 and 3 of 14 samples, respectively. Rectal and vaginal dosing phases each resulted in markedly lower levels of tissue TFV and TFV‐DP concentrations in the opposite compartment, with at least 1.7 log 10 differences between mean concentrations in the two compartments. After vaginal dosing, inhibition of HIV increased by 42% in vaginal fluid, but no change was found in rectal fluid. No change in HIV inhibition in vaginal or rectal fluid was noted after rectal dosing. Cross‐compartmental concentrations of TFV and TFV‐DP were low in this study comparing rectal and vaginal DOD TFV RG 1% gel, and pharmacodynamics activity was noted only in the vaginal fluid compartment. Whether these low tissue concentrations are protective remains to be determined. Abstract TUAC0206LB–Table 1. Compartmental pharmacokinetics of tenofovir gel Vaginal use phase Rectal use phase Compartment Mean (standard deviation) number of samples with detectable drug Median, IOR Mean (standard deviation) number of samples with detectable drug Median, IQR Plasma TFV (ng/mL) 0.99 (1.27) 10/14 (71%) 0.58 (0, 1.31) 1.19 (1.74) 10/14 (71%) 0.82 (0, 1.22) Vaginal tissue TVF (ng/mg) 45.8 (72.6) 12/13 (92%) 8.5 (1.0, 44.8) 0.09 (0.12) 6/14 (43%) 0 (0, 0.16) TFV‐DP (fmol/mg) 1945 (4105) 12/13 (92%) 166 (37, 2377) 13 (30) 3/14 (21%) 0 (0, 0) Rectal tissue TFV (ng/mL) 0.02 (0.06) 1/13 (8%) 0 (0, 0) 12.2 (27.1) 12/14 (86%) 3.0 (0.7, 10.9) TFV‐DP (fmol/mg) 10.48 (25.81) 2/13 (15%) 0 (0,0) 710 (1306) 10/14 (71%) 196 (0, 550) 10.7448/IAS.18.5.20551 © 2015 Nair G et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jj2158@columbia.edu Recent upsurge of new HIV infections among men who have sex with men (MSM) is a major concern in China. Paucity of national‐level information regarding the burden and predictors of this progressive epidemic of new infections called for a multi‐centric, comprehensive investigation. Mixed methods were used to recruit MSM (engaged in sex with men (oral and/or anal) within the last one year, aged 18 years or older and agreed to provide written informed consent) from seven cities (Shanghai, Nanjing, Changsha, Zhengzhou, Ji'nan, Shenyang and Kunming) in different regions of China between 2012 and 2013. Early and established HIV infections were determined by Western Blot and BED HIV‐1 capture enzyme immunoassay. Syphilis and herpes simplex virus‐2 (HSV‐2) were also tested. The study process and content were approved (No. 2011(36)) by the Ethics Committee of The First Affiliated Hospital of China Medical University. A total of 4496 eligible MSM were recruited. The majority was aged ≤35 years (77.5%), migrants (60.3%), never married (69.8%) and played receptive role in anal sex (70.5%). The HIV prevalence was 9·9% and 41·9% were recently infected, with HIV incidence of 8·9/100 person‐years. The prevalence of HSV‐2 and syphilis were 12·5 and 8·5%, respectively. Early HIV infection was associated with having multiple male partners (aOR=1.4, 95% CI 1.1–1.9), recreational drug use (aOR=2.2, 95% CI 1.6–3.0), anal bleeding (aOR=2.1, 95% CI 1.4–3.0), circumcision experience (aOR=2.0, 95% CI.1·3–3.1), syphilis infection (aOR=2·8, 95% CI 1.9–4.3) and HSV‐2 infection (aOR=2.3, 95% CI 1.5–3.3). HIV epidemic among Chinese MSM was worsening with an alarming number of recently infected HIV patients along with high burden of STIs. High rate of early HIV infection is potentially resulting in progressive deterioration of the overall HIV epidemic among MSM in China. Interventions specifically targeting high‐risk MSM especially those having high‐risk behaviours (especially multiple partners and recreational drug use), syphilis or HSV‐2 infection and anal bleeding were urgently required for efficient control of HIV among MSM in China. 10.7448/IAS.18.5.20373 © 2015 Xu J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: xjjbeijing@gmail.com Current Thailand Ministry of Public Health (MOPH) recommendations state that men who have sex with men (MSM) should repeat HIV testing every 6–12 months. We investigated the proportion and trend of repeat HIV voluntary counselling and testing (VCT) within 12 months among Thai MSM attending Silom Community Clinic @TropMed. Silom Community Clinic @Trop Med has been located in downtown Bangkok since late 2005, with easy access and convenient operating hours for MSM. It provides free‐of‐charge, confidential and rapid HIV VCT by MSM‐friendly staff. We advertize the clinic via website, Facebook, outreach and friend referrals. For first‐time testers, we recommend that they repeat VCT every 6–12 months. For this analysis, we included men with an initial HIV test who had visited the clinic for ≥12 months and had a baseline HIV‐negative result; the first VCT visit occurred between 2006 and 2013 with follow‐up period through October 2014. On a yearly basis, we looked at the number and proportion of first‐time testers who had another VCT visit within the next 12 months. We used chi‐square test for trend to test changes in the proportion of repeat testing within 12 months by calendar year. Between 2006 and 2013, 9345 MSM were tested by our testing services and 4597 met the criteria above and were included in this analysis. Most (67.1%) were 25 years and older and most (87.9%) lived in Bangkok or nearby provinces at time of first test. Among these MSM, 2016 (43.9%) repeated VCT. The number of new testers increased annually from 340 men in 2006 to 880 in 2013. The proportion of MSM who repeated VCT within one year varied between 15.3 and 26.1% by calendar year (mean=22.2%) and there was a statistically significant increasing trend from 2006 to 2013 (p60% of new cases. Although recent data suggest HIV incidence is declining nationally, rates in MSM are stable, and the proportion of cases occurring in black MSM is increasing. Because sexual mixing is largely age‐assortative, using life tables to estimate risk within birth cohorts may be useful in assessing and anticipating trends in the population's risk. We constructed life tables for the period 1982–2012 to estimate the cumulative risk of HIV diagnosis among MSM born 1940–1994 in King County. We used U.S. Census data to define the size of the white and black male populations of King County, Washington, national and local survey data to estimate the proportion of men who are MSM, and local surveillance data to define the number of HIV diagnoses in MSM each year. We estimated that 6% of the local male population was MSM. Age‐specific risk of HIV diagnosis increased in birth cohorts from the 1940s until the mid‐1960s and thereafter declined, plateauing among cohorts born after the mid‐1970s (Figure 1). This trend occurred in both white and black MSM. In the peak risk cohort, among MSM born 1960–64, >40% of white and >60% of black MSM had been diagnosed with HIV by age 50. A dramatic decline in this risk was evident when comparing the percentage of MSM diagnosed with HIV in different birth cohorts. Among white and black MSM born 1960–1964, the cumulative risk of HIV diagnosis by age 35 was 29 and 42%, respectively, while among MSM born 1975–1979, this risk decreased to 9 and 15%, respectively. However, as absolute risk of HIV diagnosis decreased overall in younger cohorts, relative differences between white and black MSM appeared to increase. Throughout the period and across birth cohorts, cumulative HIV risk was 18 to 84% higher among black versus white MSM. Comparing birth cohorts, cumulative HIV risk among MSM in King County has declined approximately 65% in those born after the mid‐1960s, although racial disparities persist. Our findings highlight the importance of evaluating HIV risk within birth cohorts and demonstrate remarkable local progress in HIV prevention. Abstract TUAC0303–Figure 1. Cumulative risk of acquiring HIV among MSM. Abstract TUAC0303–Figure 1. Cumulative risk of acquiring HIV among MSM. 10.7448/IAS.18.5.20375 © 2015 Chan G et al; licensee International AIDS Society Published 22 July 2015 In many settings, laws or institutional review board policies require parental permission for youth <18 years to participate in research. Individual and social risk factors for HIV acquisition often occur before age 18. Youth may be unwilling to participate in HIV epidemiological research requiring parental consent due to the sensitive nature of risk factors such as sexual behaviours and experiences of violence. Young men who have sex with men (MSM) are at especially high risk for HIV acquisition and are often unwilling or unable to disclose their sexual orientation or practices to their parents. In sub‐Saharan Africa, where HIV prevalence among MSM is high and sex between men is criminalized or highly stigmatized in many countries, epidemiologic research on this vulnerable population of young MSM is particularly relevant and sparse. One strategy for assessing the potential size of the population of young (<18) MSM is to ask adult MSM retrospective questions about the age at which they first had anal sex with a man. MSM aged 18 or older were recruited using respondent‐driven sampling in Burkina Faso, Togo, Lesotho, Malawi and Swaziland. MSM aged 15 and above were recruited using snowball sampling in The Gambia. Participants completed a survey that included a question asking how old they were when they first had anal sex with another man. This variable was dichotomized and tabulated to assess the prevalence of anal sex under the age of 18. Across settings, 40.20% (1106/2751) of MSM had anal sex with a man before the age of 18. The highest percentage was in Lome, Togo (63.84%), while the smallest percentage was in Swaziland (14.46%). MSM under the age of 18 represented 12.14% of the study sample in The Gambia. A substantial proportion of MSM participants had anal sex with a man under the age of 18. Further research on this group, including a waiver of requirements for parental consent for participation, is warranted. Given the relatively small proportion of study participants under the age of 18 in a setting where this was feasible, additional outreach strategies such as web‐based recruitment may be necessary. Abstract TUAC0304–Table 1. Proportion of MSM sampled who had anal sex 3 months ago or the partner did not know when he last tested (48% vs. 40%, p=0.02). Of 222 men with HIV‐positive partners, 60 and 64% decided whether to have sex/use condoms based on their partners’ ART use or VL, respectively. CAI with an HIV‐positive partner was more common among men who reported ART/VL serosorting compared to those who did not (79% vs. 57%, p=0.03), but testing newly positive for HIV was less common among men who reported ART/VL serosorting compared to men who did not (1/120 (1%) vs. 2/23 (9%)). Among Seattle MSM, nuanced seroadapative behaviours such as ART/VL serosorting and using the recency of a partner's HIV test to inform sexual decision‐making are common. The high prevalence of these behaviours suggests they could impact HIV incidence rates, but the individual‐ and population‐level effects of these behaviours are uncertain. 10.7448/IAS.18.5.20377 © 2015 Khosropour C M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: ckhosro@uw.edu There are very limited data from homosexual male serodiscordant couples (HM‐SDC) on the impact of antiretroviral therapy (ART) and viral load (VL) on HIV transmission risk and on risk behaviours within such couples. To date, no studies have investigated the issue in middle income countries. Opposites Attract is an ongoing multisite cohort study of HM‐SDC in Australia, Brazil and Thailand. HIV‐positive partners (HPP) had VL tested; HIV‐negative partners (HNP) had HIV antibody tests and reported sexual behaviour and perception of the HPP's most recent VL test. Undetectable VL (UVL) was defined as <200 copies/mL. We compared couples from the three countries; baseline differences were examined with bivariate logistic regression. By January 2015, 242 couples were enrolled (Australia=137, Brazil=53, Thailand=52). The majority of HPP were taking ART (80.2%); this was lower in Thailand than in Australia and Brazil (p<0.001), accompanied by higher proportions with UVL in Australia (88.2%) and Brazil (85.0%) than in Thailand (69.2%, p=0.008). Overall, 61.2% of HNP perceived their HPP's last VL test result to be undetectable. Brazilian and Thai HNP were more likely not to know the result (17.0 and 38.5%) compared to Australians (5.1%, p<0.001). Australian HNP reported more sex with other partners than Brazilian (p=0.013) but not Thai HNP (p=0.183). Australian HNP reported more condomless anal intercourse (CLAI) with outside partners compared to both Brazilians (p=0.002) and Thais (p=0.012). 54.6% of HNP reported CLAI with study partner in the last three months. Compared to Australia (67.9%), this was lower in Brazil (45.3%, p=0.005) and Thailand (28.9%, p< 0.001). Overall, 63.5% of HNP who perceived the HPP's VL to be undetectable reported CLAI in the last three months, compared to only 40.4% of HNP in which the HPP's VL was perceived to be detectable/unknown (OR=0.39, 95% CI=0.23–0.66, p=0.001). While this was strongly associated amongst Australian couples (p=0.002), there was no such association in Brazil or Thailand. Australian HNP were more aware of their partner's VL results. Australian HM‐SDC with perceived UVL practiced more CLAI, suggesting they may be acting upon beliefs that treatment‐as‐prevention is effective. This pattern was not seen in Brazil and Thailand. Abstract TUAC0306–Table 1. Baseline characteristics of HIV‐positive and HIV‐negative Total (n=242) Australia (n=137) Brazil (n=53) Thailand (n=52) HPP: taking ART 194 (80.2) 124 (90.5) 45 (84.9) 25 (48.1) HPP: viral load 90% (of those taking ART) 170 (91.9) 107 (92.2) 40 (88.9) 23 (95.8) HNP: perceived VL of HPP Undetectable VL 148 (61.2) 107 (78.1) 34 (64.2) 7 (13.5) Detectable VL 58 (24.0) 23 (16.8) 10 (18.9) 25 (48.1) Don't know VL 36 (14.9) 7 (5.1) 9 (17.0) 20 (38.5) HNP: any CLAI with outside partners, last three months 45 (18.6) 38 (27.7) 2 (3.8) 5 (9.6) HNP: any CLAI with study partner, last three months 132 (54.6) 93 (67.9) 24 (45.3) 15 (28.9) 10.7448/IAS.18.5.20378 © 2015 Bavinton B R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: bbavinton@kirby.unsw.edu.au There are few[VR1] data on HIV prevalence and the number of people who inject drugs (PWID) in Mozambique. As part of the Integrated Biological and Behavioral Surveillance (IBBS) Survey implemented in 2014, we conducted the first population size estimation among PWID in two urban areas, Maputo (n=353) and Nampula (n=139). Given the lack of a gold standard, we synthesized four independent methods to estimate the number of PWID: unique object multiplier, wisdom of the crowd, sequential sampling and literature review. The unique object estimate is calculated as the number of objects distributed to PWID pre‐survey, divided by the proportion of survey participants who reported receiving the objects. The wisdom of the crowd method polls the participants on how many people they believe inject drugs in each city (responses equal to the personal network size were excluded). The sequential sampling method applies a Bayesian approach to the self‐reported PWID network size of each participant to infer the size of the hidden population. In the literature review, estimates were based on proportions of adults who are PWID from other African locations applied to the 2014 census projections for Maputo and Nampula. A consensus meeting among stakeholders agreed that the median of all four methods was the best estimate of population size of PWID in each city and also agreed to the lowest and highest estimates as “acceptable bounds.” HIV prevalence was 50.3% (95% confidence interval (CI): 40.7–58.9) and 36.8% (CI: 24.3–49.3) in Maputo and Nampula, respectively. The numbers of PWID were estimated at 1445 (0.19% of adults) (acceptable bounds: 1281 (0.17%) to 3524 (0.46%)) and 465 (0.14%) (acceptable bounds: 354 (0.10%) to 3921 (1.16%)). Using these population size estimates, there are 727 and 171 PWID infected with HIV and in need of care and/or treatment services in Maputo and Nampula, respectively. Our results highlight the feasibility of using the median of multiple methods to estimate the size of PWID in two urban areas in Mozambique. Given the limited population size and high rates of infection, harm‐reduction, prevention interventions and HIV care and treatment services should be practical and affordable in this population. Abstract TUAC0401–Figure 1. (a) Population size estimation using four independent methods, Maputio City. (b) Population size estimation using four independent methods, Nampula. Abstract TUAC0401–Figure 1. (a) Population size estimation using four independent methods, Maputio City. (b) Population size estimation using four independent methods, Nampula. 10.7448/IAS.18.5.20379 © 2015 Sathane I et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: isabels@itech‐mozambique.org HIV incidence among people who inject drugs (PWID) in Ukraine is among the highest in the world. We assessed the efficacy of two interventions, a network‐based peer intervention combined with HIV testing and counselling (T/C combined; experimental condition, N=614) versus HIV testing and counselling alone (T/C alone; control condition, N=592), in reducing HIV incidence among PWID. Between 2010 and 2014, 1205 HIV‐seronegative PWID were recruited from street settings in Odessa, Donetsk and Nikolayev. We used a clustered randomized design that consisted of 611 networks and included: peer‐leaders; first wave network members; and second wave network members. Participants were randomly assigned to interventions in groups of 16 and interviewed at baseline, 6 and 12 months. Interviewers and HIV tester/counsellors were not blinded to intervention. Cox regression was used to compare HIV incidence between groups, incorporating GEE to account for clustering. Preliminary results suggest that mean age and duration of injection was 31.8 and 11.7 years, respectively; 75% were male. In the past 30 days, 43% injected daily, 46% always injected with others, 78% had ≥1 sex partner. HIV incidence was 19.0 per 100 person‐years (py) in the experimental condition compared to 31.8 per 100 py in the control condition (p<0.001). PWID in the experimental condition had a 39% reduced hazard for HIV seroconversion versus the control group (p<0.001). With each year increase in age, the hazard increased by 5% (p<0.001), and with each injection episode in the past 30 days, the hazard increased by 0.6% (p=0.02). Those who were sexually active in the last 30 days had a 26% reduced hazard (p=0.03). The combined network‐based peer intervention and was more efficacious in reducing HIV incidence among PWID in Ukraine than T/C alone. 10.7448/IAS.18.5.20380 © 2015 Booth R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: robert.booth@ucdenver.edu Treatment‐as‐prevention‐based efforts to reduce HIV/AIDS‐associated morbidity, mortality and HIV viral transmission among people who use illicit drugs (PWUD) rely on prompt engagement in antiretroviral therapy (ART). However, the longitudinal factors that promote or block initiation of ART among PWUD are not well described. Thus, we sought to identify factors associated with time from seroconversion to ART initiation among PWUD. Using data from two observational prospective cohorts of illicit drug users linked to comprehensive ART dispensation records, we included HIV‐seronegative individuals at baseline who seroconverted during follow‐up. We fit multivariable Cox proportional hazards models adjusted for a time‐updated measure of clinical eligibility for ART to identify factors independently associated with time to treatment initiation following seroconversion. We included 133 individuals of whom 98 (73.7%) initiated ART during follow‐up at a rate of 17.6 per 100 person‐years. In a multivariable model adjusted for clinical eligibility, living in the HIV epicentre (adjusted hazard ratio (AHR)=1.62, 95% confidence interval (95% CI)=1.01–2.58), methadone maintenance therapy (MMT) (AHR=2.37, 95% CI=1.56–3.60) and a later year of interview (AHR=1.07, 95% CI=1.02–1.13) were associated with shorter time to ART initiation. Barriers to ART initiation were illicit income generation (AHR=0.51, 95% CI=0.32–0.79) and incarceration (AHR=0.52, 95% CI=0.28–0.97). In this sample of community‐recruited HIV‐positive PWUD with well‐defined dates of seroconversion, we found that illicit income generation and incarceration were barriers to ART initiation while MMT and living in the HIV epicentre promoted ART initiation independent of clinical eligibility. Current efforts to scale‐up HIV treatment among PWUD should consider these factors in order to reduce HIV/AIDS‐associated morbidity, mortality and HIV viral transmission. 10.7448/IAS.18.5.20381 © 2015 Joseph B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: bjoseph@ualberta.ca In Vietnam, injecting drug use is[VR1] the leading cause of HIV transmission. Multiple local transmission models suggest periodic HIV testing and counselling (HTC) and initiating antiretroviral therapy (ART) irrespective of CD4 count in people who inject drugs (PWID) can markedly reduce HIV‐related mortality and transmission. Programme experience with this approach in Vietnam is limited. Therefore, the acceptability and feasibility of this approach was assessed in two high‐burden provinces. We present preliminary ART outcomes. Village health workers, PWID peer educators, and health staff were educated on the new approach and the benefits and risks of immediate ART initiation. Since April 2014, HTC has been recommended to PWID every six months, and immediate ART, that is, initiation irrespective of CD4 count, has been offered to PWID living with HIV in Thai Nguyen and Thanh Hoa provinces. Following consent, PWID were followed for 12 months. HIV viral load (VL) was assessed before ART start (baseline) and at months 6 and 12. Of 232 identified HIV‐positive PWID, 218 (94%) agreed to participate and initiate immediate ART, among which 102 initiated ART before 30 June 2014. Of this cohort, 97.1% were males, median age was 36 years, 47.1% reported methadone use in the past three months, 38.2% had baseline CD4 counts greater than 350 cells/mm3 and median baseline VL was 4.1 (IQR 2.3–5.2) log10 copies/mL. Ninety‐one of the 102 participants (89.2%) were retained after six months (eight died and three lost‐to‐follow‐up). Retention was 84.1 and 97.4% among PWID with baseline CD4 counts below and above 350 cells/mm3, respectively (Figure 1). Excluding five patients who transferred to other care sites and seven patients whose samples were not available due to logistical issues, 67 of the 79 participants (84.8%) achieved viral suppression (i.e. VL<1000 copies/mL) at month six. Viral suppression was 84.4 and 85.3% among PWID with CD4 counts below and above 350 cells/mm3, respectively (Figure 1). The preliminary results suggest high uptake and adherence to ART irrespective of CD4 count among PWID; however, late presentation to care remains a critical problem. The results are informing the revision of the national guidelines to include immediate ART in key populations. Abstract TUAC0404–Figure 1. Retention on ART and viral suppression among PWID enrolled in the study disaggregated by CD4 at ART initiation. Abstract TUAC0404–Figure 1. Retention on ART and viral suppression among PWID enrolled in the study disaggregated by CD4 at ART initiation. 10.7448/IAS.18.5.20382 © 2015 Nguyen H H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: katom@wpro.who.int There is extensive documentation of the direct clinical benefits of antiretroviral therapy (ART) adherence leading to plasma HIV RNA‐1 viral load suppression. However, very little is known about the social, socio‐economic and ancillary clinical benefits of ART adherence, particularly among people who use illicit drugs (PWUD). We used longitudinal data from a prospective cohort of community‐recruited HIV‐positive PWUD in Vancouver, Canada, a setting of free and universal access to HIV care. Participant data were linked to comprehensive HIV clinical monitoring and ART dispensation records. We developed a series of generalized linear mixed effects models, adjusting for potential confounders. Models examine whether, among ART‐exposed individuals, becoming optimally adherent to ART medication (i.e. ≥95% using a validated measure of pharmacy dispensation) resulted in associated social, socio‐economic and ancillary clinical benefits, such as relationship initiation, transitioning out of homelessness, entering employment, ceasing involvement in illegal or prohibited income generation activity (e.g. street‐based income generation, sex work, drug dealing or other illegal activities) and enrolling in addiction treatment. Between December 2005 and November 2013, of the 724 eligible study participants, 241 (33.3%) self‐reported as women and 404 (55.8%) as Caucasian, with 463 (64.0%) individuals becoming ≥95% adherent to ART at least once during the study period. In final multivariate models, becoming adherent to ART was positively and significantly associated with ceasing prohibited or illegal income generation activities (adjusted odds ratio (AOR): 1.52; 95% confidence interval (CI): 1.20–1.94) and transitioning out of homelessness (AOR: 1.38; 95% CI: 1.12–1.71), while ART adherence was marginally associated with initiating a romantic relationship (AOR: 1.31, 95% CI: 0.96–1.81). These findings suggest that becoming adherent to ART results not only in virologic suppression among HIV infected PWUD, but also increases the likelihood of reducing key drivers of social and socio‐economic vulnerability. These secondary benefits of ART adherence hold the potential to reinforce ongoing engagement in HIV care and support significant improvements in quality of life and individual health among this marginalized population. Findings reinforce the clinical and non‐clinical importance of promoting access and adherence to ART among HIV‐positive individuals who use illicit drugs. 10.7448/IAS.18.5.20383 © 2015 Richardson L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: lrichardson@cfenet.ubc.ca Since 2010, HCV incidence among active (i.e. injection past six months) PWID in Montréal remains greater than 15 of 100 person‐years (p‐y). The arrival of new direct‐acting antivirals (DAA) with high sustained virological response rates and improved tolerability raises the question of whether treatment could be used to prevent HCV transmission. Our objective was to assess how improvements in the cascade of care can impact future HCV incidence, prevalence and complications among PWID in Montréal. We used a dynamic model to simulate HCV transmission and natural history among active PWID in Montréal from 2015. The reference scenario (scenario 1) was the current cascade of care including new DAA as standard treatment (see Table 10). HCV prevalence and incidence after 10 years and the number of liver complications avoided after 40 years were estimated under different conditions: decreased time from chronic infection to diagnosis (scenario 2), greater adherence to treatment (scenario 3), improved treatment rate (scenarios 4 and 5) and a combination of these interventions (scenario 6). Due to a lack of data on time to linkage to care (time between diagnosis and first consultation related to hepatitis C), simulations considered three such intervals: one, three and five years. A thousand simulations were performed per scenario. Scenarios 2 and 3 showed similar results for HCV prevalence (53.3–59.5%) and incidence (9.1–10.3/100 p‐y) after 10 years, and less than a 3.4% difference in the number of liver complications after 40 years relative to the reference scenario. Improving access to treatment (scenarios 4 and 5) demonstrated a great decrease in all outcomes. When combining all interventions (scenario 6), prevalence and incidence decreased until 26.9% and 4.9/100 p‐y, respectively, and the number of liver complications until 39.3%, depending on the time to linkage to care. Our results suggest that decreasing time to diagnosis or improving treatment adherence is not sufficient to impact HCV prevalence, incidence and complications among PWID in Montréal. The current level of treatment access in the cascade of care is limiting a massive decrease in disease burden and transmission. A substantial treatment scale‐up is necessary in this population. Abstract TUAC0406LB–Table 1 Scenario Average time before linkage to care (years) Prevalence after 10 years (%) mean (95% CI) Incidence after 10 years (/100 persons‐years) mean (95% CI) % of compilation avoided compared to Scenario 1 over 40 years mean (95% CI) Scenario 1 (Reference) New DAAs under the current cascade of care: 1 54.6 (54.4;54.8) 9.4 (9.1;9.6) / average time from chronic infection to diagnosis δ=2.0 years; 3 57.7 (57.5;57.8) 10.1 (9.8;10.4) / annual lost to follow‐up probability Ψ=14%; 5 59.5 (59.4;59.7) 10.3 (10;10.6) / initiation of treatment if linked to care α=5%/year; SVR rate with current adherence to treatment (SVR)=81.3% Scenario 2 1 53.5 (53.3;53.7) 9.1 (8.9;9.4) 0.9 (−0.2;2.0) Decrease time from chronic infection to diagnosis: 3 56.8 (56.7;57) 9.9 (9.6;10.1) 1.7 (0.8;2.6) δ=0.5 years 5 58.7 (58.5;58.9) 10.1 (9.9;10.4) 1.7 (0.7;2.7) Scenario 3 1 53.3 (53.1;53.5) 9.1 (8.8;9.4) 2.7 (1.6;3.8) Improve adherence to treatment: 3 56.6 (56.5;56.8) 9.6 (9.4;9.9) 3.2 (2.2;4.2) SVR rate likewise in clinical trials (SVR=90%) 5 58.5 (58.3;58.7) 9.8 (9.5;10.1) 3.4 (2.6;4.3) Scenario 4 1 45.6 (45.4;45.8) 7.8 (7 6;8.0) 15.5 (14.7;16.3) Improve treatment rate: 3 50.5 (50.3;50.7) 8.4 (8.2;8.7) 14.6 (13.7;15.4) α=10%/year 5 53.5 (53.4;53.7) 9.1 (8.9;9.4) 12.4 (11.5;13.2) Scenario 5 1 34.1 (33.9;34.3) 6.1 (5.9;6.3) 29.6 (28.9;30.2) Improve treatment rate: 3 41.4 (41.2;41.6) 7.3 (7.1;7.5) 27.2 (26.3;28.0) α=20%/year 5 45.7 (45.5;45.9) 7.8 (7.6;8.1) 24.3 (23.6;25.1) Scenario 6 1 26.9 (26.7;27.0) 4.9 (4.8;5.1) 39.3 (38.8;39.8) Combined scenario 3 35.7 (35.5;35.8) 6.4 (6.2;6.6) 34.8 (34.2;35.4) combine scenarios 2, 3 and 5 5 41.2 (41;41.4) 7.2 (7.1;7.4) 31.6 (30.8;32.4) CI: confidence interval SVR: Sustained virological response CI: confidence interval SVR: Sustained virological response 10.7448/IAS.18.5.20552 © 2015 Cousien A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: anthony.cousien@inserm.fr The HIV “cascade of care” provides a framework for identifying priority areas for improvement of HIV services. In sub‐Saharan Africa, the cascade has yet to be characterized nationally due to challenges such as distinguishing first initiation of care from re‐initiation absent unique patient identifiers. Lacking direct data characterizing the cascade, we hypothesize that national‐level temporal trends in care can be triangulated based on epidemiological, actuarial and programmatic information fed into a quantitative model. We simulated the HIV care cascade in South Africa using an epidemiological model calibrated to age‐ and gender‐specific HIV prevalence and mortality, national population dynamics and monitoring data from the public‐sector HIV treatment programme. Data were available up to 2012, beyond which we assumed continuation of current trends in scale‐up. HIV‐associated mortality in the model was classified into those dying without initiating care, having initiated late (CD4<200), lost to follow‐up (LTFU) after previous initiation or currently in care. Failure to initiate care constituted the largest but most rapidly declining category of HIV mortality, predicted to decline from 47% of HIV‐associated deaths in 2015 to 37% in 2020. Late initiation was the second‐largest and declined more slowly because increasing CD4 counts at initiation were partially offset by growing numbers of patients initiating care. LTFU was the third‐largest but the most rapidly‐growing category of HIV mortality. Programmatic data about re‐initiation of care is lacking, but under the assumption that half of patients LTFU will re‐initiate care, deaths LTFU were not expected to surpass deaths due to late initiation by 2020. Those receiving care constituted 3% of HIV‐associated deaths, mostly among those receiving treatment rather than in pre‐ART care. This proportion remained constant over time because the growing population on treatment was offset by improvements in treatment quality, such as expansion of virological monitoring and availability of second‐line regimens. More data are required to fully characterize the spatial heterogeneities and dynamics of the care cascade. Nevertheless, trends revealed by model‐based triangulation were consistent with findings in well‐studied populations such as demographic surveillance sites. Failure to access care remains the largest but most rapidly declining category of HIV mortality. Abstract TUAD0101–Figure 1. HIV mortality along the care cascade. Abstract TUAD0101–Figure 1. HIV mortality along the care cascade. 10.7448/IAS.18.5.20384 © 2015 Bershteyn A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: abershteyn@intven.com Estimates of adherence to antiretroviral therapy (ART) using pharmacy refill data have outperformed self‐report and can identify patients at risk for virologic failure, especially in settings where viral load testing is limited. Uncertainty exists about the best method to estimate adherence using pharmacy refill data and the optimal duration of data to predict virologic outcomes. We identified individuals over 18 on first and second line ART from a national private sector (Aid for AIDS) and regional public sector (Khayelitsha) programme. The area under (AUC) the receiver operating characteristic (ROC) curves for virologic suppression (VS) (viral load1000 copies/mL) in the private programme: 80 and 72% for first and second line therapy. respectively. Adherence measures that identify gaps in pharmacy data were superior and consistent across programs and regimen lines and could be used to identify people at risk of poor ART outcomes. Abstract TUAD0102–Figure 1. Area under ROC curve with 95% CI (private programme). Abstract TUAD0102–Figure 1. Area under ROC curve with 95% CI (private programme). 10.7448/IAS.18.5.20385 © 2015 Leisegang R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rory.leisegang@uct.ac.za Accurate estimates of antiretroviral therapy (ART) coverage are needed to track progress towards global targets from the Joint United Nations Programme on HIV/AIDS (UNAIDS) which aim for 90% of HIV+ persons on ART by 2020. ART coverage is reported annually to UNAIDS using mathematically‐modelled estimates of the number of HIV+ persons eligible for ART based on an assumed distribution of CD4 counts in the HIV+ population and the number of persons receiving ART in health facilities. We compared ART coverage reported to UNAIDS with coverage estimated from a nationally representative survey in Kenya using two independent methods. The 2012 Kenya AIDS Indicator Survey was a population‐based household survey of persons aged 18 months‐64 years conducted from 10/2012 to 2/2013. Interviews collected data on ART use for persons reporting HIV+ status. Blood samples were tested for HIV, and HIV+ samples tested for ART by High Performance Liquid Chromatography coupled to Tandem Mass Spectrometry. We estimated and compared ART coverage among HIV+ persons aged 15–64 years based on: 1) routine programme monitoring data; 2) self‐report; and 3) biological confirmation of ART. ART eligibility in the survey was defined as: CD4 count <350 cells/mm3 or having active tuberculosis. Estimates were weighted to adjust for survey design and non‐response. According to ART programme monitoring data, 549,000 adults were receiving ART in 2012, covering 39.6% (confidence interval (CI) 36.8–43.0) of HIV+ persons and 78.3% (CI 74.8–82.8) of those ART‐eligible. Of 11,626 survey respondents, 648 (5.6%) were HIV+ and 559 (86.3%) had samples available for ART testing. Among those, 42.5% (CI 0.4–47.7) tested positive for ART while 34.2% (CI 29.1–39.3) reported receiving ART. Based on biological confirmation of ART, coverage among ART‐eligible persons was 71.0% (CI 63.2–78.9) or 444,000 persons while coverage based on self‐report was 63.4% (CI 53.2–73.6) or 374,000 persons. Self‐report underestimated ART coverage by 70,000 persons while programme data may overestimate coverage by up to 105,000 persons. Until monitoring systems for the national ART programme are strengthened and mathematical models are updated to reflect actual need for ART, surveys that provide biological confirmation of ART may be required to accurately track national estimates of ART coverage. 10.7448/IAS.18.5.20386 © 2015 Kim A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: aakim@cdc.gov Improving first‐time HIV testing among key populations, especially young MSM and transgender (TG) individuals, is a global health priority. However, most HIV testing campaigns do not reach untested populations and have minimal input from key populations. Crowdsourcing, the process of taking a task performed by an individual and opening it to a large group in the form of a contest, may enhance HIV testing interventions. We organized a non‐inferiority, pragmatic randomized controlled trial to compare first‐time HIV testing rates among MSM and TG individuals who received either a crowdsourced HIV test promotion intervention or a health marketing intervention. Participants were recruited through three large MSM web portals in China. We randomly assigned 721 MSM and TG individuals (≥16 years old, never before tested for HIV) to one of two video interventions. The crowdsourced video was developed using an open contest and formal transparent judging while the evidence‐based health marketing video was designed by experts. We followed up four weeks post‐intervention via text message to assess HIV test uptake. Descriptive statistics and sensitivity analyses for missing data were carried out to assess test uptake. Cost‐minimization analysis was used to evaluate economic and financial costs of the two interventions. The trial was registered (NCT02248558). Overall, 624/721 (86.5%) MSM and TG individuals responded to the text message. HIV test uptake was similar between the crowdsourced arm (37.1%, 114/307) and the health marketing arm (35.0%, 111/317). Sensitivity analysis using imputation supported the similarity of the two approaches. Within the crowdsourced arm, individuals who previously viewed the video were more likely to receive HIV testing compared to first‐time viewers (52.4% vs. 26.5%, p<0.001). Among those tested, 30.7% (69/225) reported a new HIV diagnosis. The crowdsourced intervention cost substantially less than the health marketing intervention in eliciting first‐time testing ($131/person vs. $238) and detecting new HIV diagnoses ($415/person vs. $799). We provide proof of principle for using crowdsourcing as a tool to enhance community engagement and improve HIV testing services. Crowdsourcing may be a cost‐effective method to optimize HIV interventions, especially interventions targeting young key populations. Abstract TUAD0104–Table 1. Pre‐specified sub‐analyses among MSM in China Crowdsourced Health marketing Tested/total (%) RR 95% CI p Tested/total (%) RR 95% CI p Multi‐time video watching 66/126 (52.4%) 1.97 1.47–2.65 500 and CD4<350 at last report. Programme staff contacted patients to offer assistance relinking to HIV care and treatment. The primary study outcome was time to viral suppression (first VL 500 in the past year than persons with no labs in the past year. Data‐to‐Care programmes can relink some persons to HIV care, but the effect of these programmes may be limited by the large numbers of persons who have moved, died or cannot be reached, and the rate of relinkage to care in the absence of the intervention. Focusing on persons with recently reported unsuppressed VLs rather than a gap in lab reports may be more effective and efficient. Abstract TUAD0105LB–Figure 1. Flowchart of programme implementation. Abstract TUAD0105LB–Figure 1. Flowchart of programme implementation. Abstract TUAD0105LB–Table 1. Summary of intention‐to‐treat (ITT) and modified I Population, outcome % Achieved by end of observation period Hazard ratio (95% CI) of incidence rates in intervention versus control period Total population, viral suppression ITT analysis (N=1008) 30 1.27 (0.89–1.80) mITT analysis (N=824) 37 1.18 (0.83–1.68) No labs for 12 months, relinkage mITT analysis (N=276) 47 0.99 (0.74–1.34) No labs for 12 months, viral suppression mITT analysis (N=276) 28 0.79 (0.40–1.55) Last VL>500 in past year, viral suppression mITT analysis (N=548) 41 1.4 (0.96–2.19) 10.7448/IAS.18.5.20553 © 2015 Dombrowski J C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jdombrow@uw.edu Retaining HIV‐positive mothers and their babies in prevention of mother‐to‐child HIV transmission (PMTCT) care is critical for the elimination of mother‐to‐child‐transmission. mothers2mothers is a peer education and psychosocial support programme operating in six Option B+ countries in Africa. m2m Mentor Mothers are women living with HIV who have recently experienced PMTCT. They are trained and employed to support other mothers and their families through the same process. In 2014, the m2m Mentor Mother Model implemented under the STAR‐EC Programme in Uganda was evaluated externally in order to investigate whether maternal and infant PMTCT outcomes and maternal psychosocial well‐being outcomes were associated with exposure to m2m Mentor Mothers. A quasi‐experimental matched area comparison design was used. PMTCT outcomes were measured retrospectively among 2282 mother‐baby‐pairs who accessed PMTCT services between January 2011 and March 2014 in 31 intervention facilities (where m2m Mentor Mothers provided peer education and psychosocial support) and 31 matched control facilities (where no peer education and psychosocial support were provided). Furthermore, 796 pregnant women and new mothers accessing PMTCT between June 2012 and March 2014 across both study arms participated in facility based Psychosocial Wellbeing surveys. Bivariate and multivariate inferential statistical analysis was done using STATA 12. Propensity Score Matching was used to investigate the net effect attributable to the m2m standard‐of‐care. Comparison of the intervention and control sites indicated that clients in m2m‐supported health facilities showed improved uptake of PMTCT services (see Table 1). The m2m model was further associated with increased coping self‐efficacy (86.6% vs. 64.5%, p<0.001); coping behaviour (69.4% vs. 56.9%, p<0.001); HIV disclosure and safer sex self‐efficacy (71.7% vs. 50.7%, p<0.001); and reduction in the experience of depression (83.5% vs. 78.1%, p=0.028). m2m has developed and refined a simple, scalable, adaptable and sustainable model of peer education and psychosocial support that improves uptake of PMTCT services and addresses the challenges facing HIV‐positive pregnant women and mothers. The evidence shows that m2m's psychosocial peer support helps HIV‐positive pregnant women and new mothers and their families cope more effectively with HIV and enhances their psychosocial wellbeing. Integration of peer education and psychosocial support into clinical PMTCT standard‐of‐care is recommended. Abstract TUAD0201–Table 1. Comparison of PMTCT outcomes Outcome indicator Average effects among matched exposed subjects in m2m sites (%) Average effects among matched unexposed subjects in control sites (%) PSM net effect (percentage points) p Receipt of ARVs/ART for PMTCT among HIV‐positive pregnant women 91.8 95.1 −3.3 <0.001 ANC attendance at least four times during pregnancy among HIV‐positive women 49.30 39.70 9.6 <0.001 Delivery by skilled health personnel in past 12 months among HIV‐positive women 87.10 75.80 11.3 <0.001 Retention in care among HIV‐positive women 12 months after ART initiation 90.90 63.60 27.3 <0.001 Receipt of Nevirapine suspension at birth by HIV‐exposed babies (ART prophylaxis for PMTCT) 86.00 59.00 27 <0.001 Percentage of HIV‐exposed children who were given a PCR test at six weeks after birth 71.50 45.80 25.8 <0.001 Percentage of HIV‐exposed children who were given an HIV test six weeks after cessation of breast feeding 60.50 31.40 29.4 <0.001 Percentage of HIV‐exposed children who were given an HIV test 18 months after delivery 60.20 18.10 42.1 <0.001 Linkage of HIV‐positive babies to paediatric ART 60.90 27.80 33 <0.001 10.7448/IAS.18.5.20388 © 2015 Schmitz K et al; licensee International AIDS Society Published 22 July 2015 Novel strategies are needed to increase retention in, and adherence to prevention of mother‐to‐child HIV transmission (PMTCT) services, and ultimately enhance PMTCT implementation effectiveness in sub‐Saharan Africa. To determine whether small, increasing cash payments conditioned on attending scheduled clinic visits and receiving proposed services can increase the proportion of HIV‐infected pregnant women who attend PMTCT visits and adhere to available PMTCT services through six weeks postpartum. Newly diagnosed HIV‐infected women, ≤32 weeks pregnant, were recruited at antenatal care clinics in Kinshasa, Democratic Republic of Congo, and randomly assigned in a 1:1 ratio to an intervention group that received compensation on the condition they attend scheduled clinic visits and accept offered PMTCT services ($5 plus $1 increment at each subsequent visit) or to a control group that received usual care. Outcomes assessed included: retention in care measured by loss‐to‐follow‐up (LTFU), and adherence to PMTCT services (attend all scheduled clinic visits and accept proposed services) through six weeks postpartum. Analysis was by intention to treat. The study is registered with clinicaltrials.gov: NCT01838005. Between April 2013 and August 2014, 612 potential participants were identified, 545 were screened and 433 were enrolled and randomized (Figure 1). Participants in the two groups had similar characteristics at baseline. As of January 5, 2015, 407 had completed their six weeks postpartum visit or were no longer in care. Analysis of complete data showed that by six weeks postpartum, a lower proportion of participants in the intervention group (17.7%) than the control group (27.0%) were LTFU (unadjusted odds ratio (OR), 0.58; 95% confidence interval (CI), 0.36–0.94). Similarly, a higher proportion of participants in the intervention group (70.0%) than the control group (54.5%) attended all scheduled visits and accepted proposed services (OR=1.91; 95% CI, 1.21–2.87). Results were similar after adjusting for marital status, age and education (Table 1). Among newly diagnosed HIV‐infected women, small, incremental cash incentives resulted in increased retention along the PMTCT cascade and adherence to available services. The overall effects of these incentives on HIV‐free survival and cost‐effectiveness warrant further investigation. Abstract TUAD0202–Figure 1. Participants tree. Abstract TUAD0202–Figure 1. Participants tree. Abstract TUAD0202–Table 1. Effect of conditional cash compensation Study group Odds ratio (95% CI) Overall n (%) Intervention n (%) Control n (%) Unadjusted p Adjusted p Loss to follow‐up Yes 91 (22.36) 36 (17.73) 55 (26.96) 0.58 (0.36, 0.94) 0.0255 0.58 (0.36, 0.93) 0.0235 No 316 (77.64) 167 (82.27) 149 (73.04) Attendance of each clinic visit and received services Yes 254 (63.41) 142 (69.95) 112 (54.90) 1.91 (1.27, 2.87) 0.0017 1.97 (1.30, 2.97) 0.0013 No 153 (37.59) 61 (30.05) 92 (45.10) 10.7448/IAS.18.5.20389 © 2015 Yotebieng M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: yotebieng.2@osu.edu Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) partnered with the Children's Investment Fund Foundation (CIFF) and Zimbabwe Ministry of Health and Child Care (MOHCC) to roll out the WHO 2010 and later 2013 prevention of mother‐to‐child HIV transmission (PMTCT) guidelines. EGPAF, MOHCC and CIFF developed a “critical path” with a prioritized set of performance indicators, with population‐based targets, that are the main drivers of impact. The indicators are reviewed quarterly, as they largely draw on routine monitoring data. If performance is lagging in a particular indicator, a diagnosis is undertaken to identify the reason and corrective action explored. Critical path indicators and results for quarter 2, 2012 are in Figure 1. The EGPAF‐CIFF goal was to reduce mother‐to‐child transmission (MTCT) of HIV from about 25% in 2009 to less ~9% by 2015. Health facilities (HFs) were supported to implement the guidelines through training and mentoring during site support visits, among other assistance. PMTCT data were collected quarterly from all supported HFs, and performance of each indicator compared with established targets during data‐driven programme reviews held by EGPAF, partner programme officers and MOHCC district staff. Reasons for under‐performance and improvement strategies were identified and implemented in subsequent quarters through mentoring and coaching of HF staff to improve service provision and patient follow‐up. By October 2014, EGPAF was supporting 1480 out of 1560 sites to provide WHO 2013 PMTCT guidelines (Option B+). Service uptake in all critical path indicators increased significantly (p<0.001) from 2009/10 to 2013/14 as follows: ANC bookings 68–100%, HIV testing 85–98%, AZT prophylaxis 32–91%, CD4 testing 41–67%, ART initiation for pregnant mothers 18–85%, EID 13–71%, mothers’ adherence on ARV prophylaxis 34–77%. The national MTCT rate fell to ~9.0% in 2013. Through use of the critical path cascade, EGPAF and CIFF supported the MOHCC to achieve a rapid scale‐up of PMTCT services. There is a need to maintain coverage and quality PMTCT services and ensure that children needing ART are actively identified, started and maintained on treatment. EGPAF is intensifying support in these new areas. Abstract TUAD0203–Figure 1. PMTCT critical path. Abstract TUAD0203–Figure 1. PMTCT critical path. 10.7448/IAS.18.5.20390 © 2015 Musarandega R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rmusarandega@pedaids.org Attrition from antiretroviral treatment (ART) services is an important determinant of HIV treatment outcomes. This study assessed factors associated with attrition among pregnant and non‐pregnant patients initiating ART following adoption of Option B+ (universal ART eligibility for HIV‐infected pregnant women) in October 2012 in Haiti. Electronic medical records of adult patients initiated on ART from October 2012 to August 2014 at 73 health facilities (HF) from 8 of 10 Haitian administrative departments were analyzed. Within a survival analysis framework, attrition was defined as the first instance of failure to attend a HF visit for 90 days after a missed clinical or pharmacy‐dispensing appointment, or an officially‐recorded programme discontinuation, whichever came first. Known transfers to alternative HF were treated as censored observations, not attrition cases. ART initiations during or within 12 weeks after pregnancy were deemed Option B+ cases. The Kaplan‐Meier method and Cox proportional hazards regression, stratified by HF, were used to determine attrition and associated factors. Among 17,084 patients who initiated ART, 7719 (45.2%) were non‐pregnant women, 5920 (34.7%) were men and 3445 (20.2%) were pregnant women. At six months, attrition was 15.6% (95% confidence interval (CI): 14.8–16.4) for non‐pregnant women, 17.0% (16.1–18.0) for men and 30.1% (28.5–31.7) for pregnant women. At 12 months, attrition was 31.8% (95% CI: 30.6–33.0), 34.5% (33.2–35.9) and 50.8% (49.0–52.6) respectively. Adjusted for patient‐level factors and HF, attrition risk was 63% higher among pregnant women and 16% higher among men, compared to non‐pregnant women (p<0.001). Significant protective factors included: receiving psychosocial counselling (hazard ratio (HR): 0.84, p<0.001); cotrimoxazole prophylaxis (HR: 0.83, p<0.001); tuberculosis treatment (HR: 0.88, p<0.001) before ART initiation; having an HIV‐positive household member (HR: 0.80, p<0.05); living in the same commune as the HF (HR: 0.94, p<0.05), and greater duration of pre‐ART enrolment (HR: 0.99 for each 30‐day increase, p<0.001). Following adoption of Option B+, ART attrition in Haiti was higher than that described in published reports from other resource‐limited settings. Early, sustained and tailored interventions are urgently needed to reduce ART attrition in Haiti, particularly among pregnant women. 10.7448/IAS.18.5.20391 © 2015 Domercant J W et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: viw5@cdc.gov The Cameroon Ministry of Public Health began implementation of life‐long antiretroviral treatment (ART) for HIV‐positive pregnant and breastfeeding women (Option B+) in 2013. This evaluation assesses early ART acceptability, retention and Mother‐to‐child‐transmission. Results will guide subsequent phases of the national rollout. From October, 2013, to June, 2014, we recruited participants from 22 purposefully selected health facilities in the Northwest and Southwest Regions for an observational cohort evaluation. HIV‐positive pregnant and breastfeeding women, not currently on antiretrovirals (prophylaxis or treatment), were eligible to participate in the assessment. Option B+ was offered to all eligible participants, and a descriptive analysis was performed. Of 1267 HIV‐positive pregnant or breastfeeding women identified, 669 (53%) were eligible for the evaluation. Of those who were offered Option B+, 666 (99%) accepted life‐long ART and 3 (<1%) accepted ART only during pregnancy and breastfeeding. As of October 2014, 569 (85%) women remained alive and on treatment; 8 (1.2%) died, 17 (3%) discontinued ART and 34 (5%) were lost to follow‐up (LTFU). Fifty‐six (8%) did not return for their first refill after ART initiation; this percentage varied from 2 to 8% between facilities. The six month retention for monthly cohorts of women initiating Option B+ was 77–91% (Figure 1). Of 409 infants born to the 669 women enrolled, 8 (2%) died, 3 (7000 community meetings and engaged>27,000 individuals in dialogues at Community Days, identifying and addressing barriers, misperceptions and harmful gender norms. The proportion of women attending ANC≤20 weeks’ gestation across the three countries increased by 36% from baseline; this trend was significant across the quarters observed (p<0.0001). Attendance during the first trimester (≤12 weeks) also increased, from 11.7% (84/719) to 14.1% (102/721) in Swaziland (p=0.163), and from 3.4% (24/705) to 12.0% (97/809) (p<0.0001) in Zimbabwe (Uganda data not available). Community dialogues actively focused on the benefits of early ANC and addressed norms of waiting until the woman “shows” before seeking ANC. In our study, community based interventions have resulted in significant greater than one‐third increase in ANC≤20 weeks’ gestation in three African countries. On‐going data analysis will provide data on the full potential of open community dialogues by trained community leaders to change community norms and health‐seeking behaviours such as early access to ANC and MCH/PMTCT services. Abstract TUAD0206LB–Table 1. Change in gestational age at first antenatal care Gestational age at first ANC Baseline July–September 2013 (January–March 2014, Uganda) n=5071 6–12 months of implementation October–December, 2014 n=4799 p‐value ≤20 weeks 1532 (30.2%) 1975 (41.2%) p1 year) individuals recruited in Cape Town, South Africa. Recognition of both MPER and V3/glycans was associated with increased breadth and potency. MPER‐recognizing sera neutralized 4.62 more panel viruses than MPER‐negative sera (95% prediction interval (PI) 4.41, 5.20), and V3/glycan‐recognizing sera neutralized 3.24 more panel viruses than V3/glycan‐negative sera (95% PI 3.15, 3.52). In contrast, V2/glycan site‐recognizing sera neutralized only 0.38 more panel viruses (95% PI 0.20, 0.45) than V2/glycan site‐negative sera and no association between V2/glycan site recognition and breadth or potency was observed. Despite autoreactivity of many neutralizing antibodies recognizing MPER and V3/glycans, antibodies to these sites are major contributors to neutralization breadth and potency in this cohort. This suggests that the autoreactivity effect is not critical and that the MPER and the V3/glycans should remain high priority vaccine candidates. The V2/glycan site result is surprising because broadly neutralizing antibodies to this site have been repeatedly observed. It may therefore be appropriate to focus on developing immunogens based upon the MPER and V3/glycans. Abstract WEAA0102–Table 1. Broad/potent neutralization and target recognized Category Less potent (geo mean ID50220) Relative risk (95% CI) p (X2) Less broad (neutralizes5). Based on residues 114 and 116, B*35:01/08/14/16/17/20/43 were classified as PY, and B*35:02/03/12 as Px. Ranking HLA‐B*35 alleles according to median pVL or CD4 count showed a wide spectrum of associated HIV disease outcomes. B*35:01 (PY) and B*35:12 (Px), which are not considered disease‐susceptible alleles, were associated with higher pVL and lower CD4 count (p<0.05, q46,000 probe sets per chip). Validations of microarrays were performed by real‐time PCR and/or flow cytometry. HIV‐DNA integration was measured by nested real‐time PCR. Functional validations were performed using RNA interference (Amaxa). Among 15,303 “present calls,” 1538 and 1285 probe sets were modulated by RA in CCR6‐ and CCR6+ T‐cells, respectively (p<0.05; fold change cut‐off 1.3). Gene Set Variation Analysis (GSVA), Ingenuity Pathway Analysis (IPA) and Gene Ontology tools were used to identify pathways/individual transcripts specifically induced by RA in CCR6+ versus CCR6‐ T‐cells. This signature included an increased expression of gut homing markers (a4β7, CCR9), HIV‐1 coreceptors (CCR5, CXCR6) and also pathways linked to the regulation of T‐cell activation (CD38, Lck, PTPN13 and MAP4K4), glucose metabolism (Glut1, Glut8), cell cycle (GADD45G), HIV replication via CCR5 expression (KLF2) and multidrug resistance (MDR1/ABCB1). In addition, the transcriptome of RA‐treated CCR6+ T‐cells showed decreased expression of known HIV‐1 resistance factors (PPAR‐g, CCL3 and CCL3L1). Our studies demonstrate that RA‐mediated imprinting for gut‐homing is associated with HIV permissiveness in CCR6+ but not CCR6‐ T‐cells and reveal molecular mechanisms underlying these differences. These findings will orient the discovery of new therapeutic strategies aimed at limiting HIV permissiveness, and subsequently the size of HIV reservoirs, specifically in gut‐homing Th17 cells. 10.7448/IAS.18.5.20397 © 2015 Planas D et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: delphine.planas@gmail.com Infants bear a high burden of HIV‐1 and tuberculosis (TB) infections, especially in sub‐Saharan Africa. We previously demonstrated that the double auxotroph Mycobacterium tuberculosis (Mtb) strain mc26435, engineered to co‐express SIV Gag, was safe and immunogenic in neonatal macaques. Here, we tested the efficacy of an oral mc26435 prime/intramuscular MVA‐SIV boost regimen to protect against repeated low‐dose oral SIVmac251 challenge in infant macaques. The study included 75 infant rhesus macaques. Mock‐vaccinated infants (n=15) received saline. Vaccinated animals (n=60) received attenuated auxotroph Mtb‐vaccines with or without SIV gag/env inserts (n=53) orally, or BCG (n=7) intradermally at birth at nine weeks, infants were exposed to a once‐weekly low‐dose oral SIVmac251 challenge regimen. Plasma viraemia was determined by real‐time PCR. Cellular immune activation was determined by flow cytometric analysis in blood and tissues, soluble plasma markers were measured with a Procarta 37plex. Statistical analysis for risk‐per‐SIV exposure was determined by SAS and Kaplan‐Meier plots; immune parameters were analyzed using Kruskal‐Wallis with multiple Dunn's comparison. A single administration of the mc26435 vaccine at birth induced persistent immune activation that was associated with oral SIV acquisition after fewer challenges compared to mock‐vaccinated infants. The human BCG vaccine resulted in similar enhanced acquisition of SIV, and BCG‐vaccinated infants showed higher peak viraemia compared to mock‐ and Mtb‐vaccinated infant macaques. The potential for enhanced oral SIV acquisition was independent of the mycobacterial vaccine strain, immunization route and boost regimen. Analysis of blood and tissue samples revealed that both Mtb and BCG vaccines induced immune activation of myeloid cell populations and CD4+ T cells, potential target cells of SIV. Immune activation was detected as early as three weeks post‐vaccination and persisted for several months. Our results in the infant macaque model are consistent with BCG‐induced immune activation of CD4+ T cells in human infants, reports of persistent monocyte activation in BCG‐vaccinated human adults, and increased HIV‐1 infection rates in human CD4+ T cells exposed to Mtb complex in vitro. Thus, in areas of high HIV‐1 prevalence, TB vaccines need to be tested for their risk of enhancing HIV‐1 susceptibility in human infants. 10.7448/IAS.18.5.20555 © 2015 Jensen K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: abelk@med.unc.edu Early initiation of long‐term antiretroviral therapy (ART) may lead to viral control after treatment discontinuation. Recent evidence indicates that ART initiated within seroconversion limits the HIV‐1 reservoir size. Insight into the reservoir in patients with different timings of ART as well as those who can control HIV‐1 without therapy should further inform new treatment strategies. A cross‐sectional study of HIV‐1 reservoir size (total and integrated HIV‐1 DNA) and dynamics (2‐LTR circles and cell‐associated HIV‐1 unspliced RNA (usRNA)) was performed in peripheral blood mononuclear cells (PBMCs) in 84 HIV‐1 infected patients from four cohorts in two clinical centres (London, UK and Ghent, BE): long‐term treated patients with ART initiated during seroconversion (SRCV on ART; n=25) or chronic infection (Chronic ART; n=32), long‐term non‐progressors (LTNP; n=17) and ART‐naïve recent seroconverters (Recent SRCV; n=10). Total HIV‐1 DNA, 2‐LTR and usRNA were measured by ddPCR and integrated HIV‐1 DNA by Alu‐HIV PCR. Clinical parameters including time on ART and aviremia, CD4 count and CD4/CD8 ratio were collected. Median total HIV‐1 DNA copies were: 92, 48, 137 and 1901 c/106 PBMCs in SRCV on ART, LTNP, Chronic ART and Recent SRCV, respectively. Significantly lower levels of total (p=0.041) and integrated HIV‐1 DNA (p=0.003) were detected in early as compared to chronically treated patients, however these were higher than those found in LTNP (Figure 1a and 1b). Interestingly, similar levels of integrated HIV‐1 DNA were found in Recent SRCV compared to the Chronic ART cohort (p=0.104), confirming very fast seeding of the reservoir (Figure 1b). Levels of usRNA were significantly lower in early compared to chronically treated cohort (p=0.007), indicating a lower transcriptional activity in early treated patients and similar to LTNP (p=0.615). Furthermore, early treated patients exhibited a higher CD4/CD8 ratio as compared to chronically treated patients (p=0.009), suggesting lower levels of residual immune activation. Our data demonstrate that long‐term early treated patients have smaller reservoir size as compared to patients treated during chronic infection, however not reaching levels found in LTNP. Interestingly, the reservoir dynamics in terms of 2‐LTR and usRNA as well as the CD4/CD8 ratio in early treated patients are comparable to LTNP. Abstract WEAB0101–Figure 1. Total HIV‐1 DNA (a) and integrated HIV‐1 DNA (b) levels in four patient cohorts. Data is shown as log10 copies/million (c/M) PBMC and significant p‐values are indicated by *. Differences between the cohorts were determined by Wilcoxon Signed Rank test. Abstract WEAB0101–Figure 1. Total HIV‐1 DNA (a) and integrated HIV‐1 DNA (b) levels in four patient cohorts. Data is shown as log10 copies/million (c/M) PBMC and significant p‐values are indicated by *. Differences between the cohorts were determined by Wilcoxon Signed Rank test. 10.7448/IAS.18.5.20398 © 2015 Malatinkova E et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: eva.malatinkova@ugent.be Non‐reactive HIV serology may be a marker of low HIV viral burden. We examined the evolution of HIV antibody in a cohort of individuals treated during acute HIV infection (AHI). Between April 2009 and December 2014, adults attending voluntary HIV testing in Bangkok, Thailand, were screened for AHI, by either pooled nucleic acid testing (NAT) of 4th generation immunoassay (4G IA) non‐reactive samples or by 3rd (3G) or 2nd generation (2G) enzyme immunoassay (EIA) of 4G IA reactive samples. Immediate antiretroviral therapy (ART) was offered. Western blot and p24 quantification were performed for Fiebig staging. HIV serology at baseline, weeks 12 and 24 were performed. Two hundred and thirty‐three Thai adults were enrolled from 130,164 samples screened; three individuals did not initiate ART and were excluded from analysis. The median age of the volunteers was 27 years, and 95% were male. Median time from history of HIV exposure to enrolment was 18 days, and median time from enrolment to ART initiation was one day. Of 207 baseline 2G EIA non‐reactive subjects, results were available for 150 at week 12 and 135 at week 24 (Table 1). At week 12, 34% were non‐reactive by 2G, 3% by 3G and 20% by 4G IA; at week 24, 39% were non‐reactive by 2G, 5% by 3G and 18% by 4G. Baseline HIV RNA350 cells/µL (p=0.01) and Fiebig stage 1 or 2 (p=0.03) were predictive of non‐reactive 2G EIA at week 24. Lower AUC0–24 week for HIV RNA was also associated with non‐reactive 2G EIA at week 24 (p≤0.001, Figure 1). Seroreversion was uncommon. One of 23 individuals with reactive 2G EIA at baseline was non‐reactive at week 24; 11 of 207 demonstrated transient 2G EIA reactivity at week 12. Approximately 40% of individuals who initiated treatment in AHI maintained non‐reactivity to 2G EIA after 24 weeks of ART. Rapid ART initiation and HIV RNA decline as well as low HIV RNA and high CD4 at baseline predicted subsequent serological non‐reactivity. HIV serologic non‐reactivity is likely due to low viral burden, further supporting the benefits of early initiation of ART. Abstract WEAB0102–Figure 1. Plasma viral load by 2G EIA reactivity. Abstract WEAB0102–Figure 1. Plasma viral load by 2G EIA reactivity. Abstract WEAB0102–Table 1. Non‐reactivity to enzyme immunoassay Non‐reactivity to HIV enzyme immunoassay, N (%) Baseline (N=207) Week 12 (N=150) Week 24 (N=135) 2nd generation EIA 207 (100) 51 (34)a 53 (39)a 3rd generation EIA 99 (48) 5 (3)a 7 (5)a 4th generation IA 43 (21) 30 (20) 24 (18) aMcNemar's test, p<0.001, compared to baseline (Note: no significant difference between week 12 and 24). McNemar's test, p<0.001, compared to baseline (Note: no significant difference between week 12 and 24). 10.7448/IAS.18.5.20399 © 2015 Fletcher J L K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: james.f@searchthailand.org The goal of HAART, in established HIV infection, is to obtain virological success (plasma HIV‐RNA level (pVL)107) and mean CD4 count 479/mm3 (77–1003). Patients were mostly infected with subtype B HIV‐1 (n=30, 54%). Due to the evolution of treatment recommendations over the 10‐year study period, nine different combinations of HAART were used, including mostly TDF/FTC (n=38, 69%) and a protease inhibitor as third agent (n=49, 89%). At W24, 44/55 (80%) patients had pVL80%), however, self‐reported ART coverage among HIV‐positive FSW was just 39% (Figure 1). After adjusting for time since HIV diagnosis, women who had intimate partners and had not disclosed their HIV status to them were over 50% less likely to be on ART than FSW not in relationships (Table 1). Mothers and women with fewer clients per month were also statistically significantly less likely to be on treatment than non‐mothers or FSW with more clients in the adjusted analyses. Among treatment eligible FSW not on ART, 16/61 (26.2%) had previously been initiated but were no longer taking ART. HIV testing was common among FSW in this setting, and awareness of HIV status was relatively high, however, efforts are needed to improve ART uptake and retention in this population. Though viral suppression data were not available, this likely represents additional fall‐out from the care cascade. Disclosure to partners and family appear to be key barriers to treatment uptake. Building HIV disclosure skills and efficacy may help to improve health outcomes for FSW living with HIV and prevent onward transmission. Abstract WEAC0106LB–Figure 1. Engagement of South African FSW in the HIV care cascade. Abstract WEAC0106LB–Figure 1. Engagement of South African FSW in the HIV care cascade. Abstract WEAC0106LB–Table 1. Predictors of ART use among ART‐eligible FSW Prevalence ratio [95% CI] p‐value Adjusted prevalence ratio [95% CI]† p‐value Age (REF≥30 years) 18–29 years 0.78 [0.60–1.02] 0.069 0.87 [0.66–1.16] 0.346 Number of clients past 30 days 0–10 REF 0.074 REF 11 or more 1.24 [0.98–1.57] 0.074 1.29 [1.02–1.63] 0.032 Partnership and disclosure No non‐paying intimate partner REF – REF – Disclosed to some or all intimate partners 0.87 [0.69–1.09] 0.219 0.86 [0.69–1.08] 0.188 Has not disclosed to intimate partners 0.41 [0.19–0.87] 0.021 0.47 [0.23–0.95] 0.036 Mother No REF REF Yes 0.82 [0.62–1.08] 0.156 0.76 [0.58–0.99] 0.047 †Univariate analyses also assessed age, race, education, mobility, violence and depression. The adjusted model includes variables statistically significant at p<0.20 in univariate analyses, including variables listed, age and time since HIV diagnosis. Univariate analyses also assessed age, race, education, mobility, violence and depression. The adjusted model includes variables statistically significant at p12 months, suppressed viral load) were referred to CACs. Kaplan‐Meier methods estimated time to outcomes among CACs stratified by gender and age (youth: 15–24 years of age and older patients: >25 years of age). Long‐term follow‐up (LTFU) was compared between CACs and facility‐based care using proportional hazards models with time‐varying covariates and inverse probability weights of CAC participation. Of the 2113 patients (68.8% female, 7.4% youth) decentralized to a CAC, 94% were retained on ART after 12‐months. After the first CAC visit, LTFU among CAC patients was 5.6 and 6.4% at 12‐months (Figure 1a) and viral rebound 2.2 and 1.5% (Figure 1c), for men and women, respectively. LTFU was higher in CACs among youth compared to older patients (Figure 1b). Youth were twice as likely to be LTFU ((adjusted hazard ratio) aHR: 2.17, 95% CI 1.26–3.73) and experience viral rebound (aHR 2.24, 95% CI 1.00–5.04) in a CAC compared to older patients. Overall, CAC participation reduced LTFU by 67% (aHR: 0.33, 95% CI 0.27–0.40) compared to facility‐based care, and this reduction persisted when stratified by patient demographic and clinic characteristics. Patients initiating ART most recently, in 2010 or 2011, had a 90% reduction in LTFU in a CAC compared to facility‐based care (95% CI 0.05–0.21). Youth were the only sub‐set of patients that did not have a significant decrease in risk of LTFU in CACs compared to the community health centre (CHC) (aHR 0.68, 95% CI 0.37–1.22). Community‐based Adherence Clubs appear to be associated with a decreased risk of LTFU compared to facility‐based care. More research is needed on how to expand the role of community‐based ART services and what components of these delivery models support long‐term retention. Abstract WEAD0101–Figure 1. Kaplan‐Meier plots over the first 18‐months in a Community‐based Adherance Club: (a) LTFU by gender, (b) LFTU by age, (c) Viral rebound by gender, (d) Viral rebound by age. Abstract WEAD0101–Figure 1. Kaplan‐Meier plots over the first 18‐months in a Community‐based Adherance Club: (a) LTFU by gender, (b) LFTU by age, (c) Viral rebound by gender, (d) Viral rebound by age. 10.7448/IAS.18.5.20407 © 2015 Grimsrud A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: agrimsrud@gmail.com Successful treatment for HIV infection requires sustained viral suppression (SVS). Patients with undetectable HIV‐RNA levels have a significantly lower risk of clinical disease progression. And at community level viral suppression is important to reduce HIV transmission and the emergence of resistant strains. The study aimed to analyze the frequency and duration of viral suppression (VS) in the first cohort of people living with HIV/AIDS (PLWHA) under treatment. We retrospectively evaluated data from all PLWHA uninsured adults who initiated HAART through the National Program during 2004–2006 and followed‐up until 2012. Patients with complete records in the National Laboratory Reporting System Data Base were included. The duration of VS was analyzed using survival analysis (Kaplan‐Meier) in PLWHA who achieved viral suppression. Survival time was measured between the first control with viral load ≤400 copies/ml until the presence of first interruption or failure of viral suppression (FSV) with viral load>400 copies/ml. Persons lost to follow up and those without FSV were censored. R Software 3.0.3.was used. During the study period a total of 6289 PLWHA had access to health care settings for initial evaluation and only 5142 received HAART. Of these, 4530(88%) achieved VS for variable time (responders) and 612 never presented VS (non‐responders). Cumulative survival rate was analyzed in responders: 91.1% maintained VS up to one year, 84.6% up to two years, 80.2% to three years, 77.1% to four years, 74.1% to five years and 70.1% to six years. According to survival analysis, Kaplan‐Meier curves presented lower duration of VS in young adult patients, females, persons in prisons and those who did not increase their CD4 above baseline. No differences were observed with baseline CD4 and viral load (p<0.05). This findings suggest that SVS as a programme indicator is feasible and useful for monitoring health care settings and ranking them like a control quality measure. SVS could also be included as another parameter in cascade of treatment measures. 10.7448/IAS.18.5.20408 © 2015 Caballero P et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: zcaballeron@unmsm.edu.pe In a Universal Test and Treat (UTT) strategy, entry into care soon after HIV diagnosis is crucial to achieve optimal population‐antiretroviral treatment (ART) coverage. We evaluated the rate of, and factors associated with, entry into care following home‐based HIV testing in a cluster‐randomized trial of the effect of immediate ART on HIV incidence in rural KwaZulu‐Natal, South Africa. From March 2012 to May 2014, individuals ≥16 years in ten (2×5) clusters were offered home‐based HIV testing; those ascertained HIV‐positive were referred to TasP trial clinics and were offered universal and immediate ART (intervention clusters) or according to national guidelines (control clusters). Entry into care was defined as attending a TasP clinic within three months of referral among adults not actively in HIV care (no visit to local HIV programme within past 13 months). Associated factors were identified separately by sex, using multivariable logistic regression. Overall, 1205 adults (72.6% women) not actively in HIV care were referred to a TasP clinic. Of these, 405 (33.6%) attended a TasP clinic within three months (no difference between trial arms): 32.5% of women, 36.7% of men. Participants who ever visited the local HIV programme (n=360) were more likely to enter into care than those who didn't (women: adjusted odd‐ratio (aOR) 1.76, 95% Confidence Interval (1.26–2.45); men: 2.07 (1.18–3.64)). In women (n=875), those less likely to attend a TasP clinic within three months had completed some secondary school (0.51 (0.33–0.79)) or at least secondary school (0.47 (0.29–0.76)) versus below primary school; were living 1–2 km from a TasP clinic (0.43 (0.30–0.62)) or 2–5 km (0.40 (0.27–0.61)) versus 90 days apart. cART use was prescription of a regimen of ≥3 active antiretroviral agents in a year. Viral suppression was HIV‐1 RNA<200 copies/mL at last measurement in the year. cART use and viral suppression denominators were subjects with ≥1 visit in the year. Multivariable modified Poisson regression models were used to assess temporal trends and predict percentages meeting each indicator in each year, adjusting for age, sex, HIV transmission mode, cohort, calendar year and total time in care. Among 18,799 individuals contributing to retention analyses, 14,380 to cART use analyses and 13,330 to viral suppression analyses, there were differences between those meeting indicator definitions versus not by most characteristics (Table 1). There were significant improvements in the indicators from 2003 to 2012: from 63 to 80% retained, 74 to 91% using cART, and 53 to 82% virally suppressed (p<0.05, each). Predicted values from adjusted models revealed similar trends (Figure 1). Female sex (risk ratio (RR)=0.96; 95% confidence interval (CI): 0.93, 0.99 vs. males) and injection drug use (IDU) as HIV transmission mode (RR=0.84; 95% CI: 0.74, 0.94 vs. male sexual contact with males (MSM)) were associated with lower retention, but unrelated with cART use or viral suppression. MSM transmission (RR=0.96; 95% CI: 0.92, 0.99) decreased probability of cART use versus heterosexual transmission. HIV Care Continuum outcomes have improved over time. However, efforts must be made to improve retention, particularly among females and IDUs, and cART use must be improved among MSM. Additional research is needed to sustain progress by identifying impediments to achieving positive Care Continuum outcomes, and their causes, in these settings. Abstract WEAD0104–Table 1. Person‐years contributed and characteristics Characteristic Not Retaineda Retaineda p* Not on cARTb On cARTb p* Not virally suppressedc Virally suppressedc p* Total 22,386 67,171 <0.01 11,565 57,312 <0.01 19,369 41,271 <0.01 Age (years) 33.9 (28.2, 40.6) 36.4 (30.0, 43.9) <0.01 32.5 (27.1, 39.3) 35.5 (29.6, 42.4) <0.01 33.5 (27.7, 40.4) 36.0 (30.1, 42.9) <0.01 Male sex 14,238 (25.1) 42,487 (74.9) 0.35 8119 (16.5) 40,982 (83.5) <0.01 13,493 (31.0) 29,981 (69.0) <0.01 Female sex 8148 (24.8) 24,684 (75.2) 3446 (17.4) 16,330 (82.6) 5876 (34.2) 11,290 (65.8) MSM HIV risk 7050 (27.6) 18,503 (72.4) <0.01 5079 (18.6) 22,225 (81.4) <0.01 7537 (31.4) 16,489 (68.6) <0.01 IDU HIV risk 820 (52.7) 735 (47.3) 203 (15.1) 1141 (84.9) 349 (29.3) 842 (70.7) Hetero HIV risk 8443 (29.2) 20,495 (70.8) 4800 (16.1) 24,945 (83.9) 8921 (34.4) 17,044 (65.6) Other/unk. HIV risk 6073 (18.1) 27,438 (81.9) 1483 (14.2) 9001 (85.9) 2562 (27.1) 6896 (72.9) Individual years in care 7 (4, 9) 7 (4, 9) <0.01 6 (3, 8) 8 (5, 10) <0.01 6 (4, 9) 8 (5, 10) <0.01 Abstract WEAD0104–Figure 1. Figure in HIV care continuum outcomes in CCASAnet. Abstract WEAD0104–Figure 1. Figure in HIV care continuum outcomes in CCASAnet. 10.7448/IAS.18.5.20410 © 2015 Rebeiro P F et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: p.rebeiro@vanderbilt.edu Despite known clinical and prevention benefits, ART is typically delayed by weeks‐to‐months after HIV diagnosis to allow linkage to care, HIV education, social stabilization and laboratory evaluation. The UCSF/San Francisco General Hospital (SFGH) RAPID programme aimed to eliminate this delay by providing same‐day/observed ART even as HIV care was being established. We investigated consequences of the RAPID treatment initiation strategy. RAPID eligibility included new HIV diagnosis with acute/recent infection, active opportunistic infection or CD4 <200/mm3. At referral, all RAPID‐eligible or ‐ineligible patients with new diagnosis received a standard package of multidisciplinary services for social support, education, risk and stigma reduction; labs were drawn; and regular provider follow‐up was arranged. The RAPID intervention consisted of 1) same‐day access to an on‐call provider; 2) a five‐day ART supply facilitated by and 3) an accelerated process for insurance benefits. Focusing on a July 2013–December 2014 programme period, survival analysis was used to compare time to achieving viral load (VL) <200 copies/mL between patients receiving and not receiving the RAPID intervention, and also between these patients and historical controls from two eras of ART provision at SFGH: pre‐RAPID universal (2010–2013) and CD4‐guided (2006–2009). We studied 227 newly diagnosed outpatients receiving RAPID (n=39), universal (n=149) or CD4‐guided (n=39) ART. No patients had private insurance and 27% were homeless; mean (range) CD4 was 381(2–1031)/mm3 and VL 4.6 (1.6–7.0) log10 cp/mL. Time to VL <200 cp/mL was significantly faster in RAPID patients versus both contemporaneous and historical controls (p<0.001; see Figure). Median (IQR) time to VL <200 for RAPID ART was 56(40–87) days versus 119(58–201) days for universal and 283(128–777) days for CD4‐guided ART. After three months of ART, 75% RAPID versus 38% non‐RAPID patients achieved a VL <200 cp/mL; after six months, 95% RAPID versus 70% non‐RAPID patients achieved VL <200 cp/mL. Among the first 39 patients receiving RAPID ART and followed for 5–18 months, only two (5%) had toxicity‐related regimen changes, none discontinued ART and 35 (90%) remain engaged in care. Combined with patient education and psychosocial support, same day‐observed initiation of ART at the time of HIV diagnosis was feasible and associated with substantially faster sustained viral suppression. Abstract WEAD0105LB–Figure 1. Viral suppression over time by ART initiation strategy. Abstract WEAD0105LB–Figure 1. Viral suppression over time by ART initiation strategy. 10.7448/IAS.18.5.20557 © 2015 Pilcher C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: cpilcher@php.ucsf.edu Health systems offer infant HIV testing as part of prevention of mother‐to‐child HIV transmission (PMTCT) programs, but are not built to systematically diagnose HIV infection in older children before symptomatic illness. Offering HIV‐infected adults attending HIV treatment programs targeted testing in home or clinic may increase early diagnosis of paediatric HIV. HIV‐infected parents attending HIV care clinic at Kenyatta National Hospital (KNH) in Nairobi, Kenya were asked about their children's HIV status. Adults with untested children≤12 years old chose to test children either at home (HBT) or in a clinic (CBT). Multinomial relative risk regression was used to identify cofactors of testing acceptance. During the 9‐month period when targeted testing was routinely offered, approximately four times as many children were tested per month as in the previous 10‐month period (13.6 vs 3.5 per month, RR: 3.9, 95% CI: 2.8–5.5). Among 116 enrolled adults, 23 (20%) chose HBT and had 46 children tested, 48 (41%) chose CBT and had 58 children tested, and 45 (39%) did not complete testing. More adults chose CBT than HBT (p=0.003), but more children were tested per adult by HBT (2.0 vs. 1.2, p<0.001). HIV prevalence among 104 tested children was 8% overall; six infected children were identified by CBT and two by HBT (median age: 8 years (IQR: 2–11)). Compared to adults who chose CBT, adults who chose HBT were more likely to have higher income, more education, be male, have a partner, have an unemployed partner and have a partner known to be HIV negative (p<0.05), while adults who did not test their children were more likely to have higher income and have a partner who was known to be HIV negative or of unknown HIV status (p<0.05). In multivariate analyses, income and partner status remained significantly associated with testing choice. Targeting HIV‐infected parents in care increased the rate of paediatric testing and found high prevalence of paediatric HIV. CBT was preferred over HBT at this urban referral hospital. Efforts to increase paediatric HIV testing and to understand parental characteristics are important to provide timely diagnosis and linkage to care. Abstract WEAD0201–Figure 1. Active referral increases paediatric HIV testing. Abstract WEAD0201–Figure 1. Active referral increases paediatric HIV testing. 10.7448/IAS.18.5.20411 © 2015 Wagner A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: anjuliwagner@gmail.com WHO recommends PITC to all in high‐burden countries. Symptom screening algorithms have been used widely for other diseases like tuberculosis. Prompt identification of undiagnosed HIV infection remains a priority in Southern Africa. We previously proposed a simple algorithm where a child is asked to respond to any of the four questions, namely, whether child 1) has previously been admitted to hospital, 2) has had recurring skin problems, 3) is a single or double orphan 4) has experienced poor health in the past three months which can be asked by any cadre at primary care level for screening older children at risk of HIV infection and requiring an HIV test. The objective of this study was to validate the performance of this algorithm in a primary care setting. All previously untested children, aged 6–15 years attending seven selected Primary Health Care Clinics of Harare, Zimbabwe, with parental/guardian consent were tested for HIV infection and asked to respond to four algorithm questions. Each positive response was scored as one. A total of 6102 (74%) children with median age 9 (IQR: 7 to 11) years, 3138 (51%) of them male, consented to an HIV test. HIV prevalence was 4.8% (95% CI: 4.2–5.3) and positivity increased successively as the score increased with those who scored zero, 55/3830 (1%); scored one, 110/1609 (7%); scored two, 80/489(16%); scored three, 26/96 (27%); scored four, 10/16(63%). A child with a score of one or more had eight times odds (95% CI: 6–11) of testing HIV positive with a sensitivity of 80% (95% CI: 75–85), specificity of 66% (95% CI: 64–67). Sensitivity was higher in those aged 10 years or more (86% vs. 70%, p=0.001). Overall, we needed to test 11 children to identify one HIV positive. The algorithm maintained its integrity and demonstrated that it is a sensitive tool screening older children at risk of HIV infection. The algorithm can be used by lower cadre healthcare workers and can help prioritize limited resources. 10.7448/IAS.18.5.20412 © 2015 Bandason T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: tbandason@brti.co.zw In 2013, it was estimated that 193,500 of children under 15 years were living with HIV in Uganda and 83% would be eligible for treatment according to WHO guidelines; recommending lifelong treatment for all children under five years and all older patient based on clinical or immunologic staging. However, despite efforts to scale up paediatric treatment, coverage remained low at 22% in 2013. Programmatic barriers to ART initiation in children include the perception that paediatric ART is complicated, unavailability of CD4 testing and difficulty in accurate clinical staging. In September 2013, Uganda adopted a “test and treat” antiretroviral therapy (ART) policy for all HIV infected children under 15 years of age to simplify recommendations and remove programmatic barriers to ART initiation in children. The MOH launched and disseminated these guidelines to all stakeholders though three day health facility based trainings and mentoring during the period January to December 2014. To evaluate the impact of this new policy a comparison was made between the number of children initiated between June and December 2013 and those initiated between January and June 2014. By December 2014, 1340 (84%) of 1600 ART providing health facilities and 17,238 health workers were trained on the new guidelines. There was 1.4‐fold increase in the number of HIV infected children newly initiated on ART from 5540 in June–Dec 2013 to 9145 in Jan–June 2014. The increase was greater among children aged 5–14 years and 2–4 years (2.4 and 1.4 fold, respectively); however, there was no change among the under two year old's (see Figure 1). Pregnant adolescents constituted 2.5% (229/9145) of children less than 15 years of age enrolled on ART in Jan–June 2014. Paediatric ART coverage has increased from 22% (43,481/193,500) in December 2013 to 27% (51,305/193,500) in June 2014. Expanding eligibility criteria increases initiation of older children on ART but to enrol those who are at higher risk of disease progression/mortality, more work needs to be done to improve early infant diagnosis (EID) and early case detection. Abstract WEAD0203–Figure 1. Children 0–14 years newly initiated on Antiretroviral therapy (July 2013 to June 2014). Abstract WEAD0203–Figure 1. Children 0–14 years newly initiated on Antiretroviral therapy (July 2013 to June 2014). 10.7448/IAS.18.5.20413 © 2015 Elyanu P et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: eleanormagongo@gmail.com Perinatally HIV‐infected children are more susceptible to vaccine preventable infections and vaccine induced immunity is less robust than in healthy children because of precocious waning of protective immunity. For this high risk population it is important to design specific vaccine schedules to define correct dosing and to set accurate correlates of protection. This survey was performed to give an overview of current vaccinations practice among paediatricians looking after vertically HIV‐infected children. An online questionnaire regarding vaccination practices in HIV‐infected children was completed by investigators from the PENTA network. Data were collected between November 2013 and March 2014. A total of 88 experts in the management of paediatric HIV‐infection from 46 different units looking after 2465 patients completed the questionnaire. The majority of units (72%) did not perform routine childhood immunizations in HIV centres. Vaccination histories were incomplete for 40% of the studied population. Influenza, pneumococcal conjugate vaccine and human papilloma vaccine immunizations are widely administered (93, 89 and 83% of units, respectively). Varicella and Rotavirus vaccinations are less recommended (61 and 24% of the units, respectively). Monitoring of vaccine responses is employed in 72% of centres. Serology appears to be the most feasible assay among the different centres (90%), mostly performed with immune‐enzymatic assays. Vaccination practices for perinatally HIV‐infected children still vary widely between countries. A crucial issue is the incomplete adherence to varicella vaccine. Indeed only in few countries varicella vaccination is universally recommended for children at national. More efforts should be made to standardize mandatory and recommended vaccinations, as well as to guide timing of serological assays. The majority of units carry out immuno‐enzymatic tests to evaluate specific antibody levels. However, methods vary with different cut‐offs of protection and units of measurement employed. Moreover, especially in high risk groups (e.g. children who started late HAART or performed vaccinations before treatment), researches on the development of novel methods to assess protective immunity and accurate correlates of protection are needed. The ultimate goal will be to design individualized vaccine schedules, developed on therapeutic and immunological features of individual patients, optimizing the chances of them gaining robust long‐term vaccine induced protection. 10.7448/IAS.18.5.20414 © 2015 Manno E C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: emma_m@hotmail.it Although rates of pregnancy and HIV infection are high among Kenyan adolescent women, their engagement in Prevention of Mother‐to‐Child HIV Transmission (PMTCT) services is poorly characterized. We hypothesized that adolescent women show lower engagement in the PMTCT cascade than adult women, from antenatal care (ANC) attendance to HIV testing and antiretroviral (ARV) uptake. We conducted a nationally representative cross‐sectional survey of mothers attending 120 maternal child health clinics selected by probability‐proportionate‐to‐size‐sampling in Kenya in July–December 2013, with a secondary survey oversampling HIV‐positive mothers in 30 clinics. Self‐report questionnaires verified by clinic booklets recorded ANC attendance, HIV testing, ARV use and maternal characteristics. Data were compared between adolescent (age<20) and adult mothers. Differences in maternal characteristics were assessed by Chi‐square test. Logistic regression was used to analyze ANC attendance and HIV testing among all women and ARV uptake among HIV‐positive women. Among 2521 mothers surveyed, 278 (12.8%) were adolescents. Adolescents were less likely than adults to have above primary education (25.0% vs. 42.9%, p<0.001), intended pregnancy (40.5% vs. 58.6%, p<0.001) and a current partner (73.1% vs. 90.9%, p200 cells/mm3; <200 cells/mm3). Our study included 941 individuals with at least one year follow‐up (median age 40, 21% female) and with a CD4 count obtained between September 1st, 2006 and March 31st, 2011. Individuals with CD47 days), had costs more than double the low cost cluster (N=147; $6811($13,592)). Individuals with CD4>200 were best classified in four clusters. The high cost cluster (N=74; $15,831($19,180)) was characterized by non‐HIV ER hospitalizations (100%≥1 day, 55.4%>7 days) and high prevalence of mental health issues. The second highest cost cluster (N=60; $5058($5152)) was characterized by short‐term non‐HIV elective hospitalizations (48.3%=1 day). The two lower cost clusters both had no hospitalizations; the higher (N=425; $3378($6454)) with much more frequent physician visits and medication use than the lowest cost cluster (N=167; $1291($7969)). Even within relatively homogeneous cohorts in terms of disease progress at time of linkage to HIV care, individuals were found to have heterogeneous HRU patterns. Identifying classes of individuals according to HRU can help inform clinical response, as well as the design of public health interventions to optimize HIV care. 10.7448/IAS.18.5.20415 © 2015 Krebs E et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: ekrebs@cfenet.ubc.ca HIV prevalence is declining in all key affected populations in Armenia (people who inject drugs, men who have sex with men, prisoners and female sex workers); however, there are increases among labour groups who seasonally migrate to countries of higher HIV prevalence. We conducted a modelling study to assess the impact of optimizing the national strategic plan to minimize HIV incidence and AIDS‐related deaths by 2020. We determined optimal funding levels for all programs to best achieve the strategic plan and, in particular, examined the outcomes required for migrant programs to warrant increased funding. We used the Optima model to perform epidemiological and economic analyses. Demographic, epidemiological, behavioural and HIV programme cost data were obtained for Armenia from 2000 to 2014 and used to inform the model. Through internal and external consultations, assumptions were generated on what coverage levels among targeted populations could be attained for different investments, as well as their expected outcomes. A sensitivity analysis on migrant HIV testing and counselling programs was conducted around assumptions based on observed data. According to Optima's optimization algorithm, shifts in funding allocations are required to minimize incidence and deaths by 2020. The largest emphasis should be on antiretroviral therapy (ART), as optimal allocations nearly doubled the investment in treatment from 17 to 24% of the total budget. This is projected to avert almost 25% of new infections and 50% of AIDS‐related deaths by 2020 compared to levels if 2013 spending were maintained. We show that funding for seasonal migrant programs should be maintained through to 2020 at 5% of the total budget. Sensitivity analysis demonstrated that these programs are cost‐effective to fund if the coverage threshold for HIV testing and counselling for seasonal migrants, as illustrated in Figure 1B, can be achieved. Optimization of HIV/AIDS investment in Armenia could significantly reduce HIV incidence and AIDS‐related deaths by 2020, particularly by focusing more on antiretroviral therapy. We have also identified thresholds for programme performance, prior to their scale‐up, which can be used to evaluate whether they should be scaled‐up or down in the future. Country of research: Armenia Key Population: People living with HIV (PLHIV), Migrants/displaced persons/mobile populations Abstract WEAD0302–Figure 1. (a) Optimized spending to minimize HIV incidence and AIDS‐related deaths by 2020 in Armenia, (b) Sensitivity analysis of cost‐coverage for seasonal migrant HIV testing and counselling program in Armenia. Abstract WEAD0302–Figure 1. (a) Optimized spending to minimize HIV incidence and AIDS‐related deaths by 2020 in Armenia, (b) Sensitivity analysis of cost‐coverage for seasonal migrant HIV testing and counselling program in Armenia. 10.7448/IAS.18.5.20416 © 2015 Kelly S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: skelly@gmail.com As performance‐based financing (PBF) gains global traction, evidence around its effectiveness to accelerate the elimination of HIV is needed. We evaluated the impact of a PBF programme implemented by Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), on the provision of HIV, PMTCT and MCH services. We also examined the temporal effects of PBF to better understand its lifecycle both in terms of onset and duration of effect. Finally, we evaluated the impact of PBF on non‐incentivized services. The impacts of PBF in Gaza (South) and Nampula (North) provinces were analyzed using a retrospective observational study design in which PBF provinces were matched with control provinces Eighteen indicators related to HIV, PMTCT and MCH services were reviewed. Due to regional heterogeneity, we evaluated the North and South as separate experiments. Beginning January 2011, up to eleven quarters of data from 134 PBF facilities after matching (84 North and 50 South) were used. Data sources include PBF programme data and health management information system data. Our econometric framework employed a multi‐period, multi‐group difference‐in‐difference model on data that was matched using propensity scoring. The regression design employed a generalized linear mixed model with both fixed and random effects, fitted using the seemingly‐unrelated regression (SUR) technique. PBF resulted in positive impacts on MCH, PMTCT, and paediatric HIV programme outcomes. The majority of the 18 indicators responded to PBF (77% North and 66% South), with at least half of the indicators demonstrating a statistically significant increase in average output of more than 50% relative to baseline. Most adult HIV (excluding pregnant women) initiation and retention indicators did not respond to PBF. On average, it took six quarters of implementation for PBF to take effect, and impact was generally sustained thereafter. Indicators were not sensitive to price, but rather inversely correlated to the level of effort associated with marginal output. No negative impacts on incentivized indicators nor spill‐over effects on non‐incentivized indicators were observed. The PBF programme in Mozambique has shown to produce large, sustained increases in the provision of PMTCT, paediatric HIV and MCH and should be considered as a powerful alternative to traditional input‐based financing. 10.7448/IAS.18.5.20417 © 2015 Rajkotia Y et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: yrajkotia@collaborativedev.com At the end of 2013, about 300,000 patients were on second‐line antiretroviral therapy (ART) in sub‐Saharan Africa. The need for second‐line ART may increase substantially with increasing duration of patients on ART and roll‐out of viral load monitoring. We aimed to estimate the need of second‐line ART in sub‐Saharan Africa between 2015 and 2030 under various scenarios. We developed a mathematical simulation model of HIV progression on ART to project second‐line needs up to 2030 for individual countries. The model allows the user to vary key input parameters, including annual numbers of patients starting ART, delay in switching after detection of treatment failure, possibility of treatment interruptions, background mortality and monitoring strategies. We applied the model to all countries in sub‐Saharan Africa assuming 12 scenarios that combine different future ART scale‐up scenarios (accelerated until universal coverage; stable; no future scale‐up), monitoring (routine viral load monitoring in all or only selected countries), and retention and switching (including or excluding possibility of treatment drop‐out and delayed switching). The input parameters were chosen to fit the numbers of patients on first‐ and second‐line ART in 2005–2013 to observed estimates. If the scale‐up of ART is accelerated across the region, patients are retained in care, switching is immediate, and all countries implement routine viral load monitoring, the number of patients on second‐line ART will increase to 4.1 million by 2030 (17% of all patients on ART). In a scenario with a stable scale‐up and realistic drop‐out and switching delay, the corresponding numbers were 2.8 million (15%) with universal routine viral load monitoring, and 2.2 million (12%) with routine viral load monitoring only in selected countries. We expect that by 2030, 2–3 million people will receive second‐line ART in sub‐Saharan Africa, but the number of patients in need may be over four million. Routine viral load monitoring, timely switching and minimizing treatment interruptions will further increase the number of patients on second‐line ART. Abstract WEAD0304–Table 1. Projected number of patients on first‐ and second‐line ART in 2020 and 2030 under various scenarios 2020 2030 Universal routine viral load monitoring Targeted or routine viral load monitoring depending on country Universal routine viral load monitoring Targeted or routine viral load monitoring depending on country Future scale‐up of ART initiation Treatment interruptions and switching 1st‐line 2nd‐line 1st‐line 2nd‐line 1st‐line 2nd‐line 1st‐line 2nd‐line Accelerated scale‐up until universal No interruptions, immediate switching 18,272,800 2,480,100 19,143,300 1,672,400 19,561,700 4,144,300 20,730,300 2,992,200 coverage reached Interruptions included, delayed switching 18,334,300 1,771,300 18,869,600 1,221,200 20,161,000 3,561,500 21,143,100 2,539,400 Stable scale‐up No interruptions, immediate switching 13,306,000 1,899,200 13,807,300 1,387,100 15,717,400 3,239,100 16,397,400 2,555,600 Interruptions included, delayed switching 12,598,600 1,445,300 12,970,000 1,056,600 15,892,600 2,758,100 16,462,900 2,166,900 No future scale‐up No interruptions, immediate switching 7,655,600 1,397,200 7,447,200 987,100 7,305,900 1,757,000 7,082,000 1,352,300 Interruptions included, delayed switching 7,697,300 1,186,700 8,009,900 872,700 7,314,800 1,569,200 7,619,000 1,262,700 Abstract WEAD0304–Figure 1. Expected number of patients on first‐ and second‐line ART in four selected, unnamed, sub‐Saharan African countries. We assumed universal routine viral load monitoring, stable scale‐up of ART initiation, and included treatment interruptions and delay in switching. Curves show the model projections and the points the observed numbers. Black/grey curves and points show the total number of patients, blue curves/points the patients on first‐line ART and red/pink curves/points the patients on second‐line ART. Abstract WEAD0304–Figure 1. Expected number of patients on first‐ and second‐line ART in four selected, unnamed, sub‐Saharan African countries. We assumed universal routine viral load monitoring, stable scale‐up of ART initiation, and included treatment interruptions and delay in switching. Curves show the model projections and the points the observed numbers. Black/grey curves and points show the total number of patients, blue curves/points the patients on first‐line ART and red/pink curves/points the patients on second‐line ART. 10.7448/IAS.18.5.20418 © 2015 Estill J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: olivia.keiser@ispm.unibe.ch The private sector is a key HIV service provider in Kenya, but few data on the cost of private service provision are available. The lack of cost data has inhibited the design of reimbursement mechanisms and health insurance packages, as well as policy decisions on private sector financing. This study estimated unit costs for private sector HIV services disaggregated by facility type and level, as a contribution to ongoing efforts to implement health insurance products covering HIV services. Cost and service volume data were collected from 149 private sector facilities in 2013 as part of a nationwide systematic sampling of public and private healthcare costing study supported by GIZ, the USAID‐funded Strengthening Health Outcomes Through the Private Sector (SHOPS) Project Kenya, and the Ministry of Health. The MASH (Management Accounting System for Hospitals) tool was used to analyze data. Multiple facilities were eliminated due to lack of complete data with only 60 used. Average unit costs per inpatient day and per outpatient visit were generated by sector and facility levels 2–4 (as defined by Kenya Norms and Standards 2006). HIV specific unit costs estimated included for HIV counselling and testing (HCT) services and provision of ART. The authors estimated operational costs, but were unable to estimate capital costs following lack of data. Average outpatient visits ranged from Ksh. 689 to 1036 in level 2 and level 4, respectively. ART visit costs ranged from Ksh. 1575 to 3660 across the facilities sampled. HCT visit services ranged from Ksh. 537 to 1151 across level 2 and 4 facilities, respectively. The study contributed to health financing policy discussions in the provision and financing of HIV services in Kenya. Data generated was presented to insurers and providers who expressed intentions of using it for decision making. Possible applications include design of HIV care inclusive insurance products and advising reimbursement decisions regarding the same. Providers offering HIV services can also use it to benchmark their efficiency. Due to poor record keeping in most facilities, only 60 of the 149 facilities had enough data for analysis. There's a need to support facilities to improve record keeping. 10.7448/IAS.18.5.20419 © 2015 Chuma B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: bensonchuma@gmail.com A total of $29.5 billion has been allocated by PEPFAR from 2007 to 2014 through the annual country operational plan (COP) process. COPs serve as a planning tool for activities of US government and in‐country partners funded by PEPFAR. Historically, utilizing data from COPs has been difficult due to their inflexible PDF/RTF format hindering the ability to query and manipulate data, create graphical representations of the financial data or identify trends in PEPFAR allocations over time. As PEPFAR moves towards greater civil society engagement during COPs’ development, it is increasingly important that COPs’ data are readily accessible, categorizable and interpretable for civil society organizations (CSOs). Utilizing standard open source tools, amfAR – funded by MAC AIDS – created a navigable database and website of all allocation data contained in published COPs from 2007 through 2014. Data are categorized and can be graphically represented and disaggregated by year, primary partner, host country, strategic area, budget code and organizational type of recipient. Text narratives of individual budgetary mechanisms captured directly from the COPs are also included in the database and provide users with detailed information for specific allocations. In addition, epidemiological profiles and PEPFAR targets are available by country to provide context for the public health impact of investments. From 2007 through 2014, $29.5 billion was allocated through the COPs process. By organizational type, the primary recipients of PEPFAR funds were NGOs ($8.3 billion), private contractors ($5.4 billion) and universities ($3.5 billion). Another $5.5 billion was not allocated to an identifiable partner or programme. Trends varied substantially by country. In Rwanda, resources shifted dramatically to Rwandan government agencies (from 7.6% of PEPFAR resources in 2011 to 34.2% of PEPFAR resources in 2013). Comparatively, PEPFAR 2013 host government funding was lower for Kenya (10.72%), Malawi (3.66%), Nigeria (2.64%) and South Africa (0.8%). amfAR's COPs database provides corresponding financial and graphical information about progress towards country ownership and gives the most granular view to date of PEPFAR budgets. The database will be an invaluable tool to help CSOs and others digest and utilize PEPFAR budgetary information. The database is available at http://copsdata.amfar.org Abstract WEAD0306LB–Figure 1. Host Country Government Agency Allocations. Abstract WEAD0306LB–Figure 1. Host Country Government Agency Allocations. 10.7448/IAS.18.5.20559 © 2015 Honermann B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: brian.honermann@amfar.org A putative case of transmission of an X4 HIV strain from a CCR5wt/wt donor to a homozygous CCR5Δ32/Δ32 recipient was retrospectively identified in the Vancouver Injection Drug Users Study. We collected longitudinal intrahost deep‐sequence data and applied ancestral phylogenetic reconstruction methods to characterize HIV transmission and evolution in this rare event. Pairwise genetic distances separating donor and recipient bulk plasma HIV gag, pol, nef and env‐V3 sequences were the lowest in the cohort (e.g. 0.0027 substitutions/nuc site in Gag vs. cohort median 0.06), identifying them as a putative transmission pair. The estimated transmission date (ETD), calculated as the midpoint of the recipient's last HIV‐negative and first positive dates, was Aug/01. Donor plasma/Peripheral blood mononuclear cells (PBMCs) were available at −13, −7, −1 and +35 months from ETD; recipient plasma/PBMCs were available +5, +6 and +12 months from ETD. Env‐V3 from plasma‐RNA and PBMC‐DNA were triplicate amplified, pooled equally and deep‐sequenced (Roche 454). BEAST and HyPhy were used to reconstruct phylogenies, estimate multiplicity of infection and reconstruct transmitted/founder (T/F) viruses from plasma‐derived deep sequences from donor and recipient. Despite infection with the same X4 HIV strain, donor CD4 count was 20 cells/mm3 within 1.5 years of infection whereas the recipient's remained >270 cells/mm3. Donor/recipient plasma viral loads were comparable (~4.5 Log). All 10 ancestral reconstructions were consistent with transmission of a single X4 T/F virus between May and August 2001. The estimated T/F virus sequence was identical to the co‐dominant variant (36%) observed in the recipient's first (+5 month) timepoint. This sequence was also observed in 0.09% of donor plasma and 33.5% of PBMC at month −1, suggesting minority variant transmission. In the donor, reversion of ~60% of the total plasma virus population to an R5 phenotype occurred by 50 months post‐infection; in contrast, the recipient's dominant V3 sequence steadily diversified over time but remained consistently X4. Results highlight the utility of phylogenetic reconstruction applied to deep‐sequence data to characterize T/F viruses and intra‐host evolution in transmission pairs. Differential CD4 depletion and V3 evolution in these individuals, despite acquisition of a near‐identical X4 strain, underscores the critical role of host genetics on HIV evolution/pathogenesis. 10.7448/IAS.18.5.20420 © 2015 Le A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: qal@sfu.ca Genetic stratification within specific populations may explain differences in HIV control. We explore the influence of genetic diversity on HIV disease progression in a cohort of mestizo individuals with different proportions of European (EUR), Amerindian (AMI) and African (AFR) genetic ancestry components. We estimated individual ancestry proportions in a cohort of 565 HIV clade‐B infected, antiretroviral treatment‐naïve Mexican individuals using a panel of 128 ancestry informative markers. HLA alleles and KIR genes were genotyped for each participant in order to control for already known associations with HIV control and to describe putative novel associations in different genetic context. The mean ancestral component proportions in the study cohort were 0.594 AMI, 0.38 EUR and 0.026 AFR, as previously observed in Mexican mestizo populations. We observed a negative correlation between the proportion of AMI ancestry component (p=0.0014) and a positive correlation between the proportion of EUR ancestry component (p=0.0004) and CD4 T cell counts. To try to explain these observations, we evaluated differences in frequency and effects on CD4 T cell counts of specific HLA alleles, KIR genes or HLA‐KIR combinations in EUR 60% vs. AMI 60% individuals. A*31:01, B*39:05, B*44:03 and C*07:02 showed protective effects in individuals with high EUR component, but risk effects in individuals with high AMI component (p<0.05). Most KIR genes were more protective for EUR individuals than for AMI individuals. KIR+HLA‐Bw4 combinations were more frequent in individuals with EUR component (p<0.05) while KIR+HLA‐C1 combinations were more frequent in AMI individuals (p0.2% of total sequence reads. An identical sequence found at both pre‐alloHSCT timepoints accounted for 9/31 (29%) of independent VOA sequences. This sequence grouped with the plasma and CSF viral rebound sequences in a monophyletic clade with high sequence homology. Despite 100% donor chimerism in peripheral blood, ART interruption led to HIV rebound in plasma and CSF. Rebound virus was identical to a pre‐alloHSCT isolate which compromised nearly 1/3 of the latent CD4+T‐cell reservoir sampled. This unique case suggests that recipient cells persist at early time‐points after alloHSCT and that a single viral population latent in resting memory CD4+T cells can re‐establish infection. Abstract MOPDA0105–Figure 1. ML Tree. Abstract MOPDA0105–Figure 1. ML Tree. 10.7448/IAS.18.5.20424 © 2015 Capoferri A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: alongwi2@jhmi.edu Viral outgrowth assay (VOA) is a widely used culture assay to measure the latent HIV‐1 reservoir harbouring replication‐competent HIV‐1 in resting CD4+ T cells in patients on HAART. However, the assay is costly, and both labour and resource intensive. To overcome some of these issues with the VOA, we designed an assay using ultra deep sequencing (UDS), which directly analyzes the number of different sequences of the induced viruses to score the number of latently HIV‐infected resting CD4+ T cells. In this study, we tested the premise whether the viral sequences derived from two different proviruses are genetically distinct, since the assay involves a bulk culture. To analyze viruses derived from different VOA culture wells scored as p24 positive, the viral samples derived from different culture wells were assigned with a specific Barcode and subjected to sequence analysis of the V1–V3 region of env sequences using the Primer ID‐based paired‐end MiSeq platform. A total of nine patient samples, two acute and seven chronic, were analyzed by UDS. Phylogenetic trees were generated by using consensus sequences created from sequences with the identical Primer ID and were used to detect distinct viral lineages present in the individual culture supernatant. For chronic patient samples, IUPM values were determined by using distinct viral lineages detected and the adjusted number of patient‐derived resting CD4+ T cells used for VOA. Approximately 50% of the viral lineages derived from each chronic patient were distinct. In contrast, all viral lineages derived from each acute patient were homogeneous. When IUPM values determined by UDS analysis were compared to the IUPM values obtained from VOA, we observed approximately twofold higher IUPM values than the IUPM values determined by VOA. We also observed a significant positive correlation between the number of viral lineages observed per well and the number of resting T cells present per well. The results suggest that approximately 50% of the viral lineages induced from different cells derived from chronic patients were distinct. Thus, the UDS assay is applicable for samples derived from chronic patients. The multiplexing ability of the assay improves the efficiency for the throughput capacity. 10.7448/IAS.18.5.20560 © 2015 Lee S‐K et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: sooklee@med.unc.edu Bacterial vaginosis (BV) is associated with an increased risk of HIV transmission, and intravaginal practices (IVP), the practice of cleansing the vagina for hygienic, health or sexuality reasons, is the primary risk factor for developing BV. This study examines the relationship between BV, IVP and lower genital HIV shedding in HIV infected women in Zambia. Participants were HIV‐1 infected women, older than 18 years and living in Lusaka, Zambia. Participants completed audio computer administered self‐interviews questionnaires assessing demographic, sexual risk factors and IVP. BV was diagnosed by gram stain of vaginal secretions using Nugent criteria. HIV‐1 plasma viremia and genital shedding was assessed by measuring HIV‐1 RNA in plasma and cervico vaginal lavages using real time PCR. One hundred and twenty‐eight HIV‐1 infected women were enrolled. Mean age was 37 years (range 24–60). Most had a stable male sex partner (126; 98%), and the majority of male partners had HIV infection (86; 67%). About one third (44; 34%) reported more than one partner in the prior year. All participants had engaged in IVP in the prior month, and over 90% used IVP daily. Ninety‐eight participants (76%) had abnormal vaginal flora (Nugent score of 4–10); and 80 (62%) had BV (Nugent score 7–10). HIV‐1 plasma viremia was detected in 26 participants (20%) (median=8.4 log copies/mL, range=3.9–14.5). HIV‐1 genital shedding was detected in 18 participants (14%) (median=6.7 log copies/mL, range=3.6–12.7). In multivariate analysis, daily IVP were associated with BV (OR=7.9, CI=1.54–40.8, p<0.01) and plasma viremia was associated with HIV‐1 genital shedding (OR=7.23, CI=2.43–21.37, p150. STD screening was done in all cases. Demographic information collected included: age, CD4, ARV at insertion and purpose of IUD (contraception vs. cycle control). Data was reviewed from 44 sequential women given IUDs from 2009 to 2014 with ages 17– 48. CD4 count 160–1230 (median 590); 32/44 (73%) had viral loads <40 c/ml, 9 women had detectable VL between 89–126,908 c/ml. 7 were not on ARV therapy. 2 were on ARV but struggled with adherence and were detectable. 3/44 had a copper IUD. 40/44 had a hormonal IUD. 1 had a hormonal followed by a copper IUD. 3 IUDs were inserted for menorrhagia. 1 IUD was for combined therapeutic and contraceptive purposes. 5 requested the hormonal IUD removed not related to reproductive plans. 1 refused reinsertion when the expired hormonal IUD was removed. Complications included four IUD expulsions (9%) (three spontaneous; one partial within the cervix). The rate of expulsion in general population is 6%. One IUD was removed by hysteroscopy due to upward migration of strings and myometrial embedment. One IUD accidentally pulled out during intercourse and required emergent reinsertion of a new device. No IUD related infections or other serious complications occurred, regardless of CD4 count. In this small series of HIV+ women, IUDs were safe and well tolerated. This method of contraception should remain an option for HIV+ women if close follow up of short and long term complications can be followed. 10.7448/IAS.18.5.20426 © 2015 Vicol L A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: lvicol@cw.bc.ca Ensuring safe, effective contraception for women with HIV‐1 is a public health imperative. Some data suggest that antiretroviral therapy (ART) may diminish the effectiveness of certain contraceptive methods, particularly implants. Combining data from 5282 HIV‐infected women participating in three longitudinal studies (Partners in Prevention HSV/HIV Transmission Study, Couples Observation Study and Partners PrEP Study) from seven countries in Africa between 2004 and 2012, we calculated incident pregnancy rates among women using different contraceptive methods (implant, injectable and oral) and compared those to rates among women using no contraception. Multivariable Cox regression models controlled for confounding factors, and the interaction between each contraceptive method and ART use was tested to assess if ART diminished contraceptive effectiveness. During follow‐up (median 1.8 years, IQR 1.2–2.3), 9% of women ever used implant, 41% used injectables (primarily depot medroxyprogesterone acetate (DMPA)), 15% used oral pills and 47% never used hormonal contraception. Additionally, 31% of women ever used ART during follow‐up, including 23% using nevirapine and 5% using efavirenz. Among women not using contraception, pregnancy rates were 13.2 and 22.5 per 100 women‐years for those on and not on ART, respectively. Use of implants reduced the risk of pregnancy by more than 90%, both among women on ART (aHR 0.06, 95% CI 0.01–0.45) and not on ART (aHR 0.05, 95% CI 0.02–0.11). Likewise, injectables reduced pregnancy risk (aHR 0.18, 95% CI 0.09–0.35 on ART and aHR 0.20, 95% CI 0.16–0.24 not on ART), as did oral contraceptives by a lesser degree (aHR 0.37, 95% CI 0.15–0.91 on ART and aHR 0.36, 95% CI 0.28–0.47 not on ART). We found no statistical evidence that ART use diminished contraceptive effectiveness, including for nevirapine and efavirenz, although sample size was limited for assessing specific ART agents. In this large prospective evaluation of three studies, modern contraceptive methods were highly effective in reducing pregnancy risk in HIV‐infected women, including those concurrently using ART. While limited evidence from other studies suggests that some ART agents could diminish the effectiveness of contraceptive implants, these data emphasize that implantable contraception is highly effective compared to no contraception and more so than shorter‐acting methods such as injectables and oral pills. Abstract MOPDB0103–Table 1. Contraceptive effectiveness, by ART status and type Progestin use ART Use # Pregnancies Person‐years Incidence rate (per 100 person‐years) aHR* (95% CI), reference no contraception p‐value for interaction term No contraception On ART 111 843.5 13.2 – – No contraception No ART 1067 4733.6 22.5 – – Implant On ART 1 94.1 1.1 0.06 (0.01, 0.45) 0.73 Implant No ART 7 507.8 1.4 0.05 (0.02, 0.11) Injectable On ART 11 332.8 3.3 0.18 (0.094, 0.35) 0.79 Injectable No ART 111 2100.2 5.3 0.20 (0.16, 0.24) Oral pills On ART 5 81.2 6.2 0.37 (0.15, 0.91) 0.97 Oral pills No ART 63 573.1 11.0 0.36 (0.28, 0.47) Total 1376 9266.3 14.8 – – 10.7448/IAS.18.5.20427 © 2015 Pyra M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mpyra99@uw.edu A large and increasing number of HIV‐infected women are conceiving while taking antiretrovirals (ARVs) globally. In resource‐limited settings, surveillance systems, if present, often are limited to the initial birth exam. We used pre‐randomization data from May 2011 to December 2014 from an ongoing clinical trial of infant cotrimoxazole prophylaxis in Botswana. Enrolments of live‐born infants of HIV‐infected women occurred after delivery, so long as the mother consented to infant participation and no infant life‐threatening conditions were identified at birth. Infants were examined by study staff at delivery, and monthly in the first three months of life, and congenital anomalies were documented. We present a descriptive analysis of anomalies identified after the initial birth exam. Of 2935 HIV‐infected women enrolled in the Mpepu study who delivered live‐born infants, newborn exams were documented on 2900 (99%) infants. ART from conception was documented for 1088 (38%) women; 1147 (40%) started ARVs during pregnancy; 442 (15%) women received AZT monotherapy; and 223 (7%) received no ARVs during pregnancy. A total of 28 congenital anomalies were identified, and 8 (29%) were first diagnosed at a visit after the initial birth exam (Table 1). No differences were identified in the number of infants with or without congenital abnormalities by ARV exposure group in pregnancy, but the study was underpowered to detect differences in rare outcomes. Identification of congenital anomalies after the birth exam occurred either because the anomaly was not readily apparent at birth (e.g. biliary atresia), or because an externally‐identifiable anomaly was overlooked at birth but subsequent parental concern led to documentation and management of the anomaly. ARV use in pregnancy warrants ongoing surveillance monitoring for teratogenicity, particularly for regimens such as EFV/FTC/TDF with insufficient safety data in pregnancy. Nearly one third of birth anomalies detected in this cohort of well children were diagnosed after the initial birth exam. Our findings highlight the importance of incorporating, where possible, longitudinal assessment and reporting for detection of congenital anomalies that may not be identifiable at the birth exam. Abstract MOPDB0104–Table 1. Congenital anomalies Case # Description of congenital anomaly Presenting symptom Timing of diagnosis from birth 1 Anovestibular fistula Stool in urine 42 days 2 Biliary atresia Jaundice at birth 48 days 3 Biliary atresia Jaundice at birth 38 days 4 Congenital Lymphedema Bilateral leg swelling 15 days 5 Jejunal atresia Failure to pass stool with abdominal distension and vomiting 5 days 6 Macrocephaly Widening of fontanelle and increasing head size 85 days 7 Pyloric stenosis Projectile vomiting 25 days 8 Talipes equino valgus Concern expressed by mother about position of foot 60 days 10.7448/IAS.18.5.20428 © 2015 Ajibola G et al; licensee International AIDS Society Published 22 July 2015 While community mobilization (CM) is a powerful tool to increase and sustain demand for HIV testing services, few rigorous trials of CM interventions have been conducted. We implemented a theory‐driven CM intervention in order to improve HIV outcomes in 22 communities participating in a community randomized trial (CRT) in a rural area of Mpumalanga Province, South Africa. The mobilization activities were designed to improve community collaboration to address HIV and inequitable gender norms. Cross‐sectional surveys were conducted with 50–55 residents ages 18–35 in each village prior to (n=1181; 2012) and following (n=1174; 2014) two years of intensive intervention activities in half of the villages. Intervention activities mapped onto six domains of CM: 1) shared concern around HIV, 2) community consciousness, 3) organizational structures, 4) leadership, 5) community cohesion and 6) collective action. Validated domain measures were included in the surveys and mean community CM scores were computed and used to predict HIV testing in the past year for each domain and for total CM scores. We used GEE logistic regression analysis to assess the effect of village level CM domain scores on individual‐level testing outcomes and included interaction terms to assess intervention effects at follow‐up. The overall CM score as well as three of six CM domains, including consciousness, concerns, collective action, were significantly associated with HIV testing following the intervention and interacted with intervention assignment. For example, for every standard deviation increase in community consciousness, the odds of HIV testing increased for intervention village participants (OR: 1.36, p=<0.01) but not for control village participants. Similar findings for total CM score (OR: 1.51), shared concerns (OR: 1.62) and collective action (OR: 1.45) indicate that the intervention successfully improved HIV testing. Leadership, presence of organizations and community cohesion were not significantly associated with HIV testing at end line. To our knowledge this is the first CRT assessing a theory‐based CM intervention including quantitative measures of CM domains over time. While not all of the six domains were associated with HIV testing uptake, we found clear evidence that communities can be mobilized and that CM measures are associated with improved engagement in HIV testing. 10.7448/IAS.18.5.20429 © 2015 Lippman S A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: sheri.lippman@ucsf.edu Despite widespread availability of antiretroviral therapy (ART), demand for HIV testing remains low across southern Africa. HIV testing may be viewed as a signal of HIV status. Those who seek an HIV test may be rejected by potential sexual partners who fear contracting HIV. This could discourage HIV testing and encourage travel far from home for HIV testing to avoid being seen. Such stigma may be exacerbated by unawareness of the public benefit of ART, that is, its capacity to reduce HIV transmission by 96%. We evaluated an information experiment designed to increase HIV testing rates by reducing stigma. We conducted a cluster‐randomized controlled trial in Malawi. We held community health information meetings in all villages. In control villages (n=62), we provided information on the private benefits of ART, including its potential to prolong life and reverse AIDS symptoms. In intervention villages (n=60), the public benefit of ART was discussed in addition to the control message. Among those aged 15–49, there was a significantly larger uptake of HIV testing in the intervention villages (intervention 2.6% vs. control 1.6%; p=0.0035), according to routinely collected data from 18 health facilities over a period of three months after the intervention. This effect was significant for men and women, and larger when corrected for spill‐overs. The intervention led to a large shift in beliefs about ART, as measured by a survey five months after the intervention. Respondents in intervention villages were more likely to report accepting attitudes towards sexual partners on ART. High beliefs about the public benefit of ART were associated with significantly more tests at nearby clinics. HIV testing decisions were predicted by a respondent′s perception of his/her community's beliefs about ART. These observations strongly suggest that the effect of the intervention on HIV testing uptake is mediated by a reduction in stigma. The results demonstrate that stigma between sexual partners is a significant barrier to HIV testing, and that providing new information on the effect of ART on HIV transmission can increase testing uptake. 10.7448/IAS.18.5.20430 © 2015 Derksen L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: l.c.derksen@lse.ac.uk HIV self‐testing has the potential to increase HIV testing and thereby decrease the time persons living with HIV are unaware of their status, but the absence of counselling may result in increased risk of HIV acquisition. In Seattle, Washington, we randomly assigned 230 HIV‐negative men who have sex with men (MSM) at high risk for HIV acquisition in a 1:1 ratio to have access to HIV self‐testing using the OraQuick ADVANCE Rapid HIV‐1/2 Antibody Test on oral fluids or to testing as usual for 15 months. Men randomized to self‐testing were trained to use the test and provided a self‐test at baseline; they could contact the study for additional tests as needed up to once a month. All participants were advised to test quarterly, offered testing reminders and could test through any existing HIV testing source. The primary outcome was self‐reported number of HIV tests during follow‐up. To evaluate potential adverse effects of self‐testing, we compared the following between the two arms: non‐concordant condomless anal intercourse (CAI) and number of male CAI partners in the last three months (measured at 9 and 15 months) and diagnosis with a bacterial sexually transmitted infection (STI) at the final study visit (15 months). Men randomized to self‐testing reported significantly more HIV tests during follow‐up (mean=5.3, 95% CI=4.7–6.0) than those in the control arm (3.6, 3.2–4.0; p<0.0001), representing an average increase of 1.7 tests per participant over 15 months. Men randomized to self‐testing reported using an average of 3.9 self‐tests during follow‐up. Self‐testing was non‐inferior to clinic‐based testing with respect to markers of HIV acquisition risk. At the final study visit, 5.4% of MSM randomized to self‐testing were diagnosed with a bacterial STI compared with 12.2% of control participants (risk difference=−6.8%; 95% CI=−16 to +1.6%). There were no significant differences between the two arms in the proportion of men reporting non‐concordant CAI or the reported number of male CAI partners in the last three months at 9 and 15 months. Access to free HIV self‐testing increased testing frequency among high risk MSM and did not impact sexual risk behaviour or STI acquisition. Abstract MOPDC0103–Figure 1. Distribution of self‐reported HIV tests by arm. Abstract MOPDC0103–Figure 1. Distribution of self‐reported HIV tests by arm. 10.7448/IAS.18.5.20431 © 2015 Katz D et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: dkatz7@u.washington.edu Transgender women are the population most impacted by HIV in the United States, with prevalence approximately 40 times higher than the general population. The rates of HIV antibody testing in the transgender community are not commensurate with risk. Development of alternative testing strategies to ensure early detection, care and prevention of infection is critical. We conducted a pilot study to explore feasibility and acceptability of offering home‐based, self‐conducted HIV testing for transwomen. Fifty HIV‐negative transwomen in San Francisco were provided with OraQuick oral HIV self‐test kits and asked to utilize the tests once a month for three months. Survey data were collected at baseline, one month and three months. In‐depth‐interviews (IDIs) were conducted with 11 participants at their final visit to learn more about self‐testing experiences, barriers to self‐testing and how the self‐test might fit into an expanded pool of testing options. Self‐testing was both feasible and acceptable: following the first test 94% reported the test easy to use; 93% said the results were easy to read; and 91% said they would recommend the self‐test to others. Acceptability remained high at three months. Approximately 25% used the test kit with others present and 68% reported preference for self‐tests versus clinic‐based testing. IDIs revealed tension between a desire for the privacy afforded by self‐testing and a desire for the social and resource support offered at health facilities. While most participants were comfortable accessing services and had been tested recently (88% in the past year), IDIs revealed apprehension about being seen at HIV‐testing clinics. Qualitative data also indicated that partner testing was of interest and that the cost of the kits could discourage future utilization. The home‐based, self‐conducted HIV test provides a viable option for populations who prefer to avoid the clinic environment. To increase acceptability, enhanced linkage strategies to social and resource support should be considered. The current price point is inaccessible for populations that experience disproportionate economic marginalization. Interest in partner testing could represent an opportunity to package tests in pairs and an expanded opportunity for testing uptake. Additional research should focus on expanding delivery options and implementation strategies. 10.7448/IAS.18.5.20432 © 2015 Lippman S A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: sheri.lippman@ucsf.edu HIV self‐testing (HIVST) can potentially increase uptake of testing in a low‐cost, confidential and non‐stigmatizing manner. Rigorous evaluation of instructional materials for accurate self‐testing has rarely been conducted. In preparation for implementation and scale‐up of HIVST in Zimbabwe, we have adapted and iteratively refined instructional materials to support self‐testing. Here we present results from our evaluation of these materials through supervised self‐testing. Participants were recruited at an HIV testing clinic using convenience sampling. They were given the instructional materials and left alone to complete their self‐test and record the result. Confirmatory rapid testing after HIVST, and pre‐ and post‐test questionnaires to evaluate their experience were conducted. The testing process was video recorded and videos analyzed using checklists. Data were evaluated weekly and IEC materials iteratively refined accordingly to optimize accuracy. We conducted 172 supervised self‐tests among participants in urban Harare, with mean age of 30 (range 18–70), 53% female and 20% first‐time testers. Overall 93% read their result accurately, in some cases despite failing to follow instructions as determined by video. Six percent were unable to determine their result. One percent got inaccurate results, including one HIV+ individual on antiretroviral therapy (ART) who followed instructions correctly as determined by video. While most (88%) reported the test was not hard to use, 23% said some instructions were unclear, resulting in modifications to the materials. Common sources of confusion were in interpreting results, the purpose of the test kit desiccant and unclear images/language. Low literacy was associated with unsure/invalid results, prompting revision of the materials for a rural, less literate setting. There, among 29 participants, 3% were unable to determine their results and 31% got an inaccurate result. Materials have been further revised making them almost entirely pictorial, and supervised self‐testing is ongoing. Though there is little published research on optimizing HIVST materials, we found that thorough evaluation of materials through supervised self‐testing has been critical to optimizing accuracy. Numerous revisions were required, and evaluation in different settings yielded differing results. Rigorous development and testing of HIVST supportive materials appropriate to country and setting is recommended prior to implementation of HIVST programs. Abstract MOPDC0105–Table 1. HIV results among 172 participants in Harare Participant‐read HIVST Staff‐read HIVST Confirmatory test HIV negative 146 150 (146+3 unsure+1 transcription error*) 156 (149+7 invalid HIVST) • 160/172=93% got an accurate HIVST result • 2/172=1% got an inaccurate HIVST result* • 10/172=6% unable to decipher their HIVST result. 7 (4%) of these had performed the test incorrectly, 3 (2%) could not interpret their result HIV positive 16* 15 16 HIV unsure 5 0 0 HIV invalid 5 7 0 *One was a participant transcription error – she was clear in her post‐HIVST interview that she thought she was HIV negative. The second was someone on ART who tested negative via self‐test and positive in confirmatory testing. One was a participant transcription error – she was clear in her post‐HIVST interview that she thought she was HIV negative. The second was someone on ART who tested negative via self‐test and positive in confirmatory testing. 10.7448/IAS.18.5.20433 © 2015 Mavedzenge S N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: smavedzenge@rti.org Partner notification (PN) for control of sexually transmitted infections (STIs) is a public health strategy which notifies the partners of infected individuals of their possible exposure to disease. PN has rarely been used in sub‐Saharan Africa as an HIV prevention intervention. In Cameroon, patients newly diagnosed with HIV do not usually receive assistance in notifying their sex partners leading to low partner disclosure and poor partner involvement in prevention of mother‐to‐child transmission (PMTCT). In 2012, the World Health Organization issued new guidelines in PMTCT including Option B+which recommends that all HIV positive pregnant women (PW) be placed on antiretroviral treatment for life irrespective of CD4 count. PN was integrated into PMTCT at 22 pilot Option B+sites as a strategy to increase male partner disclosure, notification, testing and linkage to care. Beginning in March 2013, Trained Health Advisors (HA) at the 22 B+sites interviewed consenting HIV‐positive PW about their sexual partners in the last two years and facilitated disclosure or confidentially informed their partners that they had been exposed to HIV. The HAs pre‐test counselled the partners and offered HIV testing in the clinic, their home or other location. They then educated both index cases and their partners on HIV prevention and risk reduction and linked all HIV positive partners to care and treatment. During the 18 months, uptake was monitored monthly and 823 PW tested HIV positive at the 22 option B+sites (Figure 1). Of the 840 partners they identified, 693 (82.5%) were traced and notified of their exposure to HIV. Of the 693 notified, 421 (60.8%) did their HIV test and received results. A total of 139 (33.0%) of those tested were HIV positive and 138 (99.3%) were linked to appropriate C&T services. HIV negative partners (67.0% of those tested) were counselled on risk reduction. Male partner involvement increased greatly at seven of ten sites monitored. PN is a feasible HIV prevention strategy in resource‐limited settings which can identify and test many partners of HIV positive PW. PN can be integrated into Option B+PMTCT programs to identify HIV positive partners who are placed on treatment alongside the HIV positive PW. Abstract MOPDC0106–Figure 1. Uptake of PN services at 22 B + sites. Abstract MOPDC0106–Figure 1. Uptake of PN services at 22 B + sites. 10.7448/IAS.18.5.20434 © 2015 Muffih P T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: piustih@cbchealthservices.org Eastern Europe and Central Asia face a rapidly escalating HIV epidemic driven by injection drug use (IDU). We evaluate the role of opioid substitution treatment (OST) in engaging HIV‐infected people who inject drugs (PWID) in care and the effect of OST on utilization of medical services. Cross‐sectional study of healthcare utilization in the past six months among 296 randomly sampled HIV‐infected opioid‐dependent PWID conducted in healthcare clinics in 2010 across Ukraine. Participants categorized as therapeutic on OST if on OST for at least three consecutive months prior to the past six months or as not taking OST if not on any OST in the past nine months. Based on this criterion, 24 individuals were excluded. The 65% on OST (177/272) were less likely to be below the poverty line or live alone and more likely to be married or have gone to prison (p<0.05). The two groups did not differ significantly in terms of age, gender, or education. Those on OST had more years of opioid injection but were less likely to have injected in the past 30 days, to have engaged in poly‐substance abuse, or to have ever overdosed on drugs (p<0.01). In the past six months, those on OST were less likely to seek emergency care (72% vs. 84%, p<0.05) and had fewer mean emergency care visits (2.77 vs. 4.57, p<0.02) with no significant differences in mean ambulatory visits (1.78 vs. 0.59, p=0.11) or hospitalizations (0.53 vs. 0.34, p=0.36). Those on OST were more likely to be engaged in HIV care, as evidenced by higher rates of antiretroviral therapy ART (37% vs. 26%, p=0.08), recent CD4 testing (82% vs. 60%, p<0.01), and recent TB testing (95% vs. 71%, p<0.01). Number of self‐reported symptoms was higher in the non‐OST group compared to those on OST (10.46 vs. 7.75, p<0.01). Limitations include cross‐sectional design and potential for recall and social desirability biases. Despite higher rates of incarceration and more years of opioid injection, those therapeutic on OST were less likely to seek emergency care than those not on OST and more likely to be engaged in HIV care with fewer overall symptoms. 10.7448/IAS.18.5.20435 © 2015 Bachireddy C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: chet86@gmail.com Prior studies indicate that opioid substitution treatment (OST) reduces the risk of mortality and improves the odds of accessing highly active antiretroviral therapy (HAART), however the relative effects of these treatments for injection drug using people living with HIV/AIDS (PLHIV) are unclear. We aim to determine the independent and joint effects of OST and HAART on mortality, by cause, within a population of injection drug using PLHIV initiating HAART. We used a linked population‐level administrative database for British Columbia, Canada (1996–2010) to form a cohort of injection drug using PLHIV. We selected all individuals identified as HIV‐positive and either having a history of OST at initial HAART receipt, as indicated by methadone or buprenorphine dispensation records in the BC PharmaNet database or having an indication of injection drug use before HIV infection, as indicated in the HIV testing database. We employed time‐to‐event analytic methods, including competing risks models, proportional hazards models with time‐varying covariates, and marginal structural models, to identify the independent and joint effects of OST and HAART on all‐cause, as well as drug‐ and HIV‐related mortality, controlling for covariates. Among 1727 injection drug using PLHIV, 493 (28.5%) died during a median 5.1 years (interquartile range: 2.1–9.1) of follow‐up: 18.7% due to drug‐related causes, 55.8% due to HIV‐related causes, and 25.6% due to other causes. Standardized mortality ratios were 12.2 (95% CI: 9.8, 15.0) during OST, and 30.0 (27.1, 33.1) during periods out of OST. Both OST (adjusted hazard 0.34 (95% CI: 0.23, 0.49)) and HAART (0.39 (0.31, 0.48)) decreased the hazard of all‐cause mortality; however, individuals were at lowest risk of death when these medications were used jointly (0.16 (0.10, 0.26)). Both OST and HAART independently protected against not only HIV‐related death, but also drug‐related death and death due to other causes. While both OST and HAART are life‐saving treatments, there is an urgency to ensure joint administration to protect against both drug and HIV‐related mortality. 10.7448/IAS.18.5.20436 © 2015 Nosyk B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: bnosyk@cfenet.ubc.ca Mexico's innovative 2009 “narcomenudeo” law decriminalized small‐scale drug possession, mandating drug treatment diversion in lieu of incarceration and reframing drug policy to facilitate HIV prevention. However, the US‐Mexico Border region continues to experience elevated HIV risk related to syringe sharing, while evidence‐based addiction treatment and other prevention services targeting people who inject drugs (PWID) remain critically under‐resourced. We designed a longitudinal cohort study to assess the implementation of this structural intervention among at‐risk PWID in Tijuana. This mixed‐methods research programme integrated a structured questionnaire and laboratory testing with qualitative interviews assessing legal knowledge, police encounters, drug and sex risk behaviours, and infectious disease status. At baseline, 737 PWID were recruited in Tijuana; 32 participated in qualitative interviews. Between 2010 and 2013, only 11% of PWID respondents reported being aware of drug decriminalization; virtually none experienced drug treatment diversion or the law's other operational components. Interviews underscored the law's irrelevance to PWID; 699 (98%) characterized police practices as typically inconsistent with formal law. Instead of diversion to addiction treatment, multivariate modelling suggested that police encounters are independently associated with increased HIV risk behaviours such as syringe sharing (OR=1.26; 95% CI=1.09–1.46) and poly‐drug use (OR=2.11; 95% CI=1.38–3.22). Qualitative data underscored the dissonance between the formal legal standards for drug and syringe possession, treatment diversion and other public health‐oriented legal provisions on the one hand, and the lived experience of drug users on the other. Interviews mapped out a number of pathways by which arbitrary police enforcement severely undermine drug users’ ability to engage in protective HIV behaviours. Mixed‐methods findings reveal that, just as housing instability can aggravate HIV risk, the lack of predictability in one's legal environment—also known as a “weak rule of law”—can compound HIV risk. Formal drug policy reform may be necessary in many settings to reduce HIV risk among PWID, but appears insufficient as a stand‐alone intervention. As policy interventions intended to facilitate HIV prevention gain global momentum, ancillary structural reforms such as police training to improve the rule of law are needed to unlock their public health potential. Operational partnerships with law enforcement are discussed. 10.7448/IAS.18.5.20437 © 2015 Beletsky L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: lbeletsky@ucsd.edu In 2011, the government of Tanzania established methadone assisted therapy (MAT) to combat the dual epidemic of HIV and injection drug use. However, enrolment of females who inject drugs into MAT has lagged behind that of males. To address this inequity, the methadone clinic at Mwananyamala Regional Referral Hospital (MRRH) introduced low threshold services for females in January 2013, allowing women to bypass the historically required attendance at community‐based organizations prior to enrolment. Furthermore, existing female clients were encouraged to recruit their peers and one‐day of the week was set aside for enrolling female clients only. We conducted an interrupted time‐series study to evaluate the impact of implementing low threshold services for females enrolling into MAT, using de‐identified, routinely collected data from November 2012 to October 2014 at MRRH. Prais‐winsten regression models were utilized to estimate the mean change in the proportion of clients that were female and the weekly number of females enrolling, adjusting for male enrolment and a period of MAT enrolment interruption form July–November 2013. Overall, 759 clients enrolled into the methadone clinic during the study period. Of those enrolling, the mean age was 34 years. The mean number of people enrolling into methadone during the study period was 8 clients (95% CI: 7, 9) per week. After implementation of low threshold services, the proportion of female clients increased from 14% (95% CI: 13%, 15%) to 24% (95% CI: 23%, 25%; p=0.001), but after the enrolment interruption, the proportion of female methadone clients decreased slightly to 22% (21–22%). Adjusting for male enrolment, the mean number of females enrolling per week was 2 (95% CI: 1–3; p=0.001) people per week higher as compared to before implementation. Following the enrolment stoppage, the average number of female enrollees was comparable to pre‐intervention (mean change: 0; 95% CI:–1, 1; p=0.442). Implementation of low threshold services improved enrolment into the methadone programme among women, thereby increasing the proportion of female methadone clients. However, the gains in enrolment were attenuated after an enrolment interruption, highlighting the importance of programme stability with this group of clients. Abstract MOPDD0104–Figure 1. Lowess smooth of the percentage of female methadone clients. Abstract MOPDD0104–Figure 1. Lowess smooth of the percentage of female methadone clients. 10.7448/IAS.18.5.20438 © 2015 Lambdin B H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: blambdin@pgaf.org Among illicit drug users, renewed efforts to reduce high levels of HIV/AIDS‐related morbidity and mortality and curb rates of viral transmission rely, in part, on earlier initiation of antiretroviral therapy (ART). However, there are concerns that starting treatment prior to immunosuppression for members of harder‐to‐treat groups could contribute to lower levels of treatment adherence and lead to impaired virologic response. Thus, we sought to evaluate trends in CD4 cell count at ART initiation over time and rates of subsequent virologic response among HIV‐positive illicit drug users during a community‐wide Treatment‐as‐Prevention campaign in Vancouver, Canada. We used data from the ACCESS study, an ongoing longitudinal cohort of HIV‐positive illicit drug users linked to comprehensive HIV clinical monitoring and pharmacy dispensation records. In this retrospective study, we included all individuals who initiated ART from 2005 onwards. We used multivariable logistic regression to evaluate differences in mean CD4+ cell count at initiation by year of initiation. To estimate time to plasma HIV‐1 RNA viral load <50 copies/mL by CD4 cell count at ART initiation, we used Kaplan–Meier and Cox proportional hazards methods. Between 2005 and 2013, 357 individuals initiated ART. Median CD4 at initiation increased from 130 cells/mL (interquartile range: 60 – 205) in 2005 to 330 (205 – 430) in 2013. In a linear regression analysis adjusted for age, gender and ancestry, year of initiation was positively associated with CD4 cell count at initiation (b = 30.82 cells per year increase, p < 0.001). Among 357 initiates, 184 (52%) reached non‐detectable plasma VL within 360 days. In an adjusted Cox proportional hazards model, CD4 cell count at initiation was positively associated with time to viral suppression (adjusted hazard ratio: 1.21 per 100 cell/mL increase; 95% confidence interval: 1.13–1.29). We observed substantial increases in CD4 cell count at initiation over time coincident with a community‐wide TasP‐based initiative. Individuals initiating ART earlier in the disease course exhibited higher rates of optimal virologic response. These findings support earlier initiation of ART among illicit drug users to reduce levels of HIV/AIDS‐associated morbidity and mortality and rates of viral transmission. 10.7448/IAS.18.5.20564 © 2015 Milloy M‐J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: uhri‐mjsm@cfenet.ubc.ca Since the association between high HIV‐RNA replication in central nervous system and immune activation/inflammation has not yet been established, we aimed to investigate the inflammatory milieu in CSF and peripheral blood of HIV+ antiretroviral‐naïve subjects with high CSF viremia compared to those with low CSF viremia, in the attempt to identify biomarkers that might be used as diagnostic tools. A total of 150 HIV+ cART‐naïve pts underwent to lumbar puncture for CSF HIV‐RNA quantification and were tested for peripheral T‐cell immune‐phenotypes (CD38/CD45RA/CD45R0/CD127 on CD4/CD8; flow cytometry). In a subgroup of 64 patients CSF/plasma TNF‐a, IL‐6, sCD14, IFNg, MCP‐1, IP‐10, neopterin, S100beta (ELISA, Luminex) were measured. We defined: high CSF HIV‐RNA ≥10,000 cp/mL (H‐CSF), low CSF HIV‐RNA 1 log10 cp/mL. Statistical analyses: Chi‐square, Mann–Whitney test and univariate/multivariate logistic regression. 48/150 pts (32%) resulted H‐CSF. VE was found in 5/150 pts (3%). No differences in gender, risk exposure categories, viral hepatitis co‐infections, HIV duration, age and CD4+ nadir were found between L‐CSF and H‐CSF. H‐CSF pts displayed higher plasma HIV‐RNA (p=0.002) and VE (p=0.019). The univariate logistic regression showed that H‐CSF are characterized by lower central memory CD127+CD4% (p=0.026) and naïve CD8+CD45RA% (p=0.017) and higher activated CD8+CD38% (p=0.08) and memory activated CD8+CD38+CD45R0% (p=0.021). In multivariate analysis, lower proportion of CD8+CD45RA% was the only parameter independently associated with H‐CSF (AOR 0.934, IC 95% 0.877–0.995, p=0.035), adjusting for plasma VL, CD4/CD8 ratio, CD127/CD4%, CD8/CD38%. Within the CSF, we found that H‐CSF displayed significantly higher sCD14 (p<0.0001), neopterin (p=0.006), IL‐6 (p=0.002) and IP‐10 (0.035) and no differences in TNFa, MCP‐1 and S100beta. Similarly, H‐CSF showed higher circulating sCD14 (p<0.0001), but not TNFa, IL‐6 and IFNg. The low percentage of naïve CD8+ T‐cells, independently associated with higher CSF Viral Load, might be included in a panel of biomarkers useful to identify patients at major risk of high CSF replication, if confirmed by larger studies. Besides, the finding of higher peripheral and CSF activation/inflammation in H‐CSF group indicate a more complex scenario, where both districts cooperate in maintaining the inflammation within CNS, possibly affecting neuronal function, and therefore deserves further investigations. 10.7448/IAS.18.5.20439 © 2015 Merlini E et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: esther.merlini@unimi.it Dysregulated type I interferon (IFN) responses contribute to immunopathology in chronic HIV infection, therefore it is critical to dissect the molecular mechanisms underlying HIV‐stimulated IFN production. We examined the spatiotemporal regulation of IFN secretion by plasmacytoid dendritic cells (pDC), specialized cells that secrete high levels of IFN upon HIV recognition by Toll‐like receptor (TLR) 7. We showed previously that intracellular trafficking of HIV to early endosomes is associated with potent IFN secretion but minimal NF‐kB signalling, resulting in suboptimal pDC maturation; however, how HIV trafficking is determined and the causal link between HIV subcellular localization and differential TLR signalling are currently unknown. Human pDC were purified from peripheral blood and were stimulated with GFP labelled: HIV, HIV pseudotyped with influenza hemagglutinin envelope (HA‐HIV), and PR8 influenza. TLR7 expressing HEK NF‐kB reporter cells, stably transfected with CD4 mutants with cytoplasmic tails directing trafficking to early endosomes (EE) or lysosomes, were activated with HIV and controls. Analysis included ELISA, flow cytometry and florescent microscopy. Cells were imaged using the Advanced Precision imaging system and images were analyzed using ImageJ. We compared the effects and spatiotemporal trafficking in pDC of HIV, influenza and HA‐HIV. We demonstrate that HA‐HIV strongly activates maturation pathways (NF‐kB) in pDC and traffics rapidly to lysosomes, similarly to influenza but unlike HIV, suggesting that viral envelope directs trafficking and resultant phenotype of ssRNA virions in pDC. We studied HIV‐CD4 interactions in a HEK reporter cell system expressing TLR7 with functional NF‐kB signalling, which we co‐transfected with CD4 mutants whose cytoplasmic tails either directed CD4 trafficking to EE or lysosomes. We show that wild type (WT) CD4 localizes to EE, whereas CD4 mutated with either DEC‐205 or LAMP1 tail localizes to lysosomes. HIV traffics to EE in WT CD4 expressing TLR7 HEK cells and fails to stimulate NF‐kB signalling, whereas HIV traffics to lysosomes in DEC‐205/LAMP1 expressing TLR7 HEK cells and stimulates NF‐kB signalling, suggesting that rerouting of HIV (via CD4) to lysosomal compartments triggers NF‐kB rather than IFN pathways. CD4 receptor mediated endocytosis targeting early endosomes determines HIV intracellular localization and observed interferon‐producing phenotype of HIV‐activated pDCs. 10.7448/IAS.18.5.20440 © 2015 O'Brien M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mpowersobrien@yahoo.com Plasmacytoid dendritic cells (pDCs) constitute a major source of type‐I interferon (IFN‐I) production during acute HIV infection. Their activation results primarily from TLR7‐mediated sensing of HIV‐infected cells. BST2/Tetherin is a restriction factor that suppresses HIV release by cross‐linking virions at the cell‐surface. HIV‐1 overcomes BST2 antiviral activity through Vpu, which partially downregulates BST2 cell‐surface expression. Apart from its direct antiviral activity, BST2 was shown to bind the ILT7 pDC‐specific inhibitory receptor and repress IFN‐I production by activated pDCs. Here, we examined whether Vpu‐mediated BST2 antagonism could modulate innate sensing of HIV‐infected cells by pDCs. PBMCs or isolated pDCs were co‐cultured with T cells infected with wild type or Vpu‐defective HIV‐1 and innate sensing was evaluated by monitoring IFN‐I production. BST2‐mediated activation of ILT7 signalling was analyzed using an ILT7‐reporter cell system. We show that Vpu attenuates the production of IFN‐I during sensing of HIV‐1 infected cells by pDCs. This control of innate sensing by Vpu could be prevented by: 1) depletion of BST2 from infected donor cells; 2) depletion of ILT7 in pDCs; or 3) blocking BST2‐ILT7 interaction using anti‐BST2 antibodies or soluble ILT7. Using a BST2 mutant that cannot cross‐link budding virions but yet retains the capacity to repress IFN‐I production by pDCs, we show that virion trapping on infected donor cells prevents BST2 from eliciting an inhibition of IFN‐I production by pDCs. Interestingly, confocal microscopy analysis of virus producing cells reveals that in presence of Vpu there is a residual pool of surface BST2, which is excluded from viral budding sites and thus potentially accessible for interaction with ILT7 on pDCs. Lastly, using an ILT7 reporter cell system, we provide evidence that Vpu‐mediated BST2 antagonism modulates the levels of available surface BST2 capable of engaging and activating ILT7 upon cell‐to‐cell contact. Overall, this study sheds light on a novel Vpu‐BST2 interaction that allows HIV to control innate sensing of infected cells by pDCs via the negative signalling exerted by the ILT7‐BST2 pair. This mechanism of innate immune evasion is likely to be critical for efficient viral dissemination and establishment of viral reservoirs during acute infection. 10.7448/IAS.18.5.20441 © 2015 Bego M G et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: eric.cohen@ircm.qc.ca HIV‐1 latency is a multifactorial process resulting by the interplay between cellular transcription factors and the viral regulatory protein Tat. We have previously described the interferon‐inducible restriction factor TRIM22 as a suppressor of basal and phorbol ester‐dependent LTR‐mediated transcription independently of NF‐kB and of Tat/TAR interaction. As basal HIV‐1 transcription is mainly driven by the binding of the cellular transcription factor Sp1, we have investigated whether TRIM22 could interfere with such Sp1‐driven transcriptional activation of HIV‐1 LTR. 293T cells, lacking of endogenous TRIM22, were co‐transfected with a TRIM22‐expressing plasmid together with reporters vectors driven by the HIV‐1 promoter containing either wild‐type or mutated Sp1 binding sites or lacking of either one or two sites; reporter expression was assessed 48 hours post‐transfection. Endogenous TRIM22 was knocked‐down (KD) in SupT1 cells that were subsequently infected with HIV‐1 molecular clones engineered to be dependent on an incorporated Tet‐On gene expression system for activation of transcription while being independent of Tat/TAR interaction. Virus replication was monitored up to 32 days post‐infection. Cell extracts from TRIM22‐transfected 293T was subjected to 1) immunoprecipitation, 2) Western blotting, 3), DNA pull‐down and 4) chromatin immunoprecipitation (ChIP). TRIM22 overexpression suppressed Sp1‐driven transcription of HIV‐1, as its inhibitory activity was lost in the absence of Sp1 binding sites. In contrast, TRIM22 KD increased the replication of infectious clones that were exclusively dependent upon Sp1 binding to the promoter. Furthermore, immunoprecipitation experiments showed that TRIM22 and Sp1 can interact physically although this interaction does not affect the level of expression of endogenous Sp1 or its phosphorylation state. TRIM22 did not directly bind to the HIV‐1 LTR by either in vitro pull‐down experiments or in ChIP experiments, however TRIM22 expression drastically prevented the binding of Sp1 to the HIV‐1 LTR. TRIM22 inhibits Sp1‐dependent transcription by interacting with Sp1 and preventing its binding to the HIV‐1 LTR. Our findings bear relevance for the discovery of new pharmacological approaches aimed at targeting the reservoir of cells latently infected with replication‐competent proviruses. 10.7448/IAS.18.5.20442 © 2015 Turrini F et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: turrini.filippo@hsr.it Tripartite motif‐containing protein 22 (TRIM22) is an E3 ubiquitin ligase with activity against HIV‐1: high levels of TRIM22 expression are associated with reduced viral set‐point following acute HIV‐1 infection. The TRIM22 gene has been greatly shaped by positive selection, and its expression is sensitive to retroviral infection, Type I and Type 2 interferon. The mechanism by which TRIM22 exerts its antiviral effect is poorly understood. Further, the impact of TRIM22 genetic variation in the context of HIV‐2 disease is unknown. To test the hypotheses that TRIM22 expression antagonizes HIV‐2 infection and that polymorphisms in TRIM22 significantly modulate this effect, we conducted three studies. Firstly, TRIM22 was genotyped in 60 HIV‐2 patients, comparing viral controllers and rapid progressors, and a similar number of age and sex matched controls from the same community in rural Guinea‐Bissau. Using regression modelling, polymorphisms were analysed alongside immunological and virological data. Secondly, a model of TRIM22 was constructed using computational methods and the polymorphisms observed in vivo were mapped and analysed. Finally, baseline cDNA and protein levels of TRIM22 from C8166 cells were measured using quantitative RT‐PCR and flow cytometry respectively. The cells were subsequently infected with HIV‐2, and measurements repeated to determine whether TRIM22 gene expression is sensitive to HIV‐2 infection. The data show that TRIM22 polymorphisms rs1063303 and rs7935564 are significantly associated with HIV‐2 acquisition and disease progression. Further, polymorphisms observed in vivo cluster in functional regions that our modelling studies suggest may interact with the HIV‐2 capsid. Finally, we show that TRIM22 gene expression is upregulated in the presence of HIV‐2, in a lymphocyte cell line. Taken together, our data show that TRIM22 expression is sensitive to HIV‐2 infection and that polymorphisms in TRIM22 genes are significantly associated with HIV‐2 acquisition and disease progression. Further the study has computationally characterized positively selected polymorphisms observed in vivo and the data show that these polymorphisms have the potential to significantly alter protein structure and function. These data provide the first analysis of TRIM genetic variation in the context of HIV‐2 infection. 10.7448/IAS.18.5.20443 © 2015 Simpson S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: shmona.simpson@trinity.ox.ac.uk During chronic viral infections, high antigenic load continually stimulates T cells resulting in T‐cell exhaustion. Exhausted T cells increase the expression of negative checkpoint inhibitors such as PD‐1, which raise the threshold for activation and contribute to suppressed immune responses. Another recently discovered immune checkpoint receptor, TIGIT, is upregulated on T cells in neoplasms and chronic LCMV infection. We hypothesize that TIGIT functions as a negative checkpoint receptor marking dysfunctional T cells during SIV infection and that modulation of TIGIT would restore anti‐SIV‐specific T‐cell responses. Spleen, lymph node (LN) and PBMCs from SIV‐naïve and SIV‐infected rhesus macaques (RMs) were examined for surface expression of TIGIT. In vitro cytokine production was assessed via intracellular cytokine staining. Proliferative capacity was determined through CFSE dilution assays in the presence of antibodies blocking TIGIT and PD‐1 pathways (anti‐TIGIT mAb and anti‐PD‐L1 mAb). TIGIT expression was significantly upregulated on CD8+ T cells derived from the spleen and LN but not on PBMC in SIV‐infected animals. The frequency of TIGIT+ CD8+ T cells in the LN significantly correlated with SIV viral load, and TIGIT expression was driven primarily by g‐chain cytokines such as IL‐2. TIGIT was expressed on approximately 40% of SIV‐specific CD8+ T cells, even in animals with full cART suppression of viral replication. While Ki‐67 expression did not differ between TIGIT+ and TIGIT− CD8+ T cells, TIGIT‐ CD8+ T cells produced significantly more IFN‐g compared to TIGIT+ CD8+ T cells. Single and dual blockade of TIGIT and/or PD‐1 signalling pathways restored proliferative capacity of SIV‐specific T cells in vitro. TIGIT is a negative checkpoint receptor that marks a novel population of functionally exhausted SIV‐specific CD8+ T cells and is associated with SIV disease progression. The enhancement of virus‐specific T‐cell proliferative responses in the presence of single or dual blockade of TIGIT and/or PD‐1 suggests that targeting the TIGIT pathway is a viable therapeutic approach to reverse T‐cell dysfunction. Given the high sequence homology of rhesus and human TIGIT, this provides a platform to further investigate TIGIT, along with other checkpoint inhibitors, as potential targets for mediating a functional cure for HIV. 10.7448/IAS.18.5.20561 © 2015 Webb G M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: moring@ohsu.edu Prolongation of the QTc interval (QTc) increases the risk of cardiovascular events (CVE). The incidence of CVE is higher in HIV‐infected (HIV+) patients compared with the general population. The impact of different antiretroviral therapies (ART), co‐medication and HIV‐infection on the electrical activity of the heart is rarely investigated in large HIV+ cohorts. We compare QTc of HIV+ outpatients of the HIV HEART study (HIVH) and of controls of the population‐based Heinz Nixdorf Recall study (HNR), both recruited from the German Ruhr area since 2000. HIVH cases were age‐ and sex‐matched with HNR controls in a 1:2 ratio. QTc was measured and corrected using the Bazett's formula. We used crude and adjusted linear mixed models to account for the matched design and adjusted for QTc interval prolonging medication (QTc‐PM, no ART). Differences in QTc between HIV specific factors and ART were evaluated using ANOVA in the HIVH subpopulation. All analyses were stratified by sex. 496 HIVH participants (83.3% male, aged 54.5±6.7) were matched with 992 HNR controls. We observed a longer QTc in HIVH subjects compared with HNR controls: 424±23 ms versus 411±15 ms for male and 435±20 ms versus 416±17 ms for female subjects (p440 ms, female >460 ms) was pathologic in 22.8% versus 3.9% of HIVH and HNR males and in 12.1% versus 1.8% of the females. No differences in the QTc were observed within the HIVH population for different ART medications, for the clinical and immunological HIV status and for the route of HIV infection in both sexes. HIV+ patients have longer mean QTc and more often pathological prolonged QTc compared with age‐ and sex‐matched controls from the general population even after adjustment for intake of non‐antiretroviral QTc‐PM. ART, HIV stage and HIV transmission route are not associated with QTc prolongation. 10.7448/IAS.18.5.20444 © 2015 Esser S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: stefan.esser@uk‐essen.de Efavirenz has been associated with reductions in vitamin D (25[OH]D) and Tenofovir with increased bone turnover, reductions in bone mineral density (BMD) and renal tubular dysfunction (RTD). We hypothesized that switching from Atripla to Darunavir/Ritonavir monotherapy (DRV/r) might increase 25[OH]D, and improve BMD and RTD. Patients with HIV RNA <50 copies/mL on Atripla for ≥ six months were randomized 1:1 to receive ongoing Atripla or DRV/r (800/100 mg once daily) for 48 weeks. Primary endpoint was change from baseline in 25[OH]D at week 48. Secondary endpoints included changes in BMD, bone turnover markers and RTD. Linear regression estimated the mean difference in 25[OH]D in patients on Atripla versus DRV/r. Secondary endpoints were expressed as the mean (95% CI) observed between‐arm difference from baseline. 70 subjects (86% male, 66% white, mean (SD) CD4 cell count 537.3 (191.5) per mm3) were randomized, of whom 26 (DRV/r) and 31 (Atripla) completed the 48 week study on the allocated treatment. The mean (SD) difference between baseline and week 48 25[OH]D was 5.0 (5.9) ng/mmol for DRV/r and 1.2 (6.0) for Atripla. After adjustment for baseline 25[OH]D and demographics, at week 48 DRV/r monotherapy was associated with a +3.5 (95% CI: 0.5, 6.4) ng/mmol increase in 25[OH]D compared to Atripla (p=0.02). Subjects in the DRV/r arm experienced increases in BMD (mean between‐arm difference (0.02 (0.003, 0.04) g/cm2 at the lumbar spine, p=0.03, and 0.03 (0.006, 0.06) g/cm2 at the neck of femur, p=0.02), and reductions in parathyroid hormone (PTH) (−20.4 (−38.8, −2.0) ng/l, p=0.03), bone‐specific alkaline phosphatase (−7.1 (−9.7, −4.5) IU/L, p<0.0001) and serum type 1 pro‐collagen (−16.9 (−26.5, −7.4) ug/L, p=0.0008), as compared with subjects on Atripla. No significant difference in RTD (urine retinol‐binding protein/creatinine ratio and phosphate reabsorption) was observed. Reasons for discontinuation in the DRV/r arm included side effects (n=4) and virus load rebound (n=2), all of which resolved with DRV/r discontinuation or regimen intensification. A switch from Atripla to DRV/r resulted in significant improvements in 25[OH]D and PTH, and a 2–3% increase in BMD. DRV/r monotherapy provides a bone‐friendly treatment option to patients with osteoporosis or increased fracture risk. 10.7448/IAS.18.5.20445 © 2015 Hamzah L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: lisa.hamzah@kcl.ac.uk Accelerated bone mineral density (BMD) loss occurs during the first two years of ART. Few studies have evaluated subsequent BMD changes, especially compared to uninfected controls. ACTG A5318 performed one follow‐up site‐specific dual‐energy x‐ray absorptiometry (DXA) in HIV‐infected individuals who had received baseline and follow‐up DXAs during the randomized treatment trial A5202/A5224s. As controls, we obtained DXA results from uninfected participants enrolled in BACH/Bone and WIHS cohorts. Repeated measures analyses compared BMD change rate between HIV‐infected and uninfected, adjusting for age, sex, race and body mass index (BMI). In the HIV‐infected group, we performed multivariable analyses evaluating association of HIV‐specific (baseline and time‐updated CD4 and viral load), HIV treatment‐related (randomized ART regimen, cumulative tenofovir (TDF) exposure) and non‐HIV related factors (age, sex, race, relevant concomitant medication use, BMI, total lean body mass) on BMD change rate. Baseline characteristics between HIV infected (n=97) and HIV‐uninfected (n=630) participants were generally similar: median age, 40 versus 46; % female, 14 versus 14; % black, 34 versus 35; median BMI, 24 versus 29; and median years between first and last DXA, 7.5 versus 6.9. Seventy‐one percent of HIV‐infected participants were on TDF at last DXA. Compared to controls, HIV‐infected individuals had significantly greater adjusted BMD decline rate at lumbar spine (LS) and total hip (TH) during the first 96 weeks of ART (both p<0.001). Subsequently, on follow‐up DXA, HIV infection remained significantly associated with greater adjusted BMD decline rate at LS (−0.29%/year; 95% CI: −0.49, −0.09; p=0.005) but not at TH (p=0.63). In the HIV group, the rate of BMD decline slowed after the first 96 weeks of ART (0–96 weeks vs. Late Change: LS: −0.75%/year vs. −0.19%/year, p=0.04; TH: −1.29%/year vs. −0.30%/year, p<0.001). During the late period, no HIV‐related characteristic was associated with BMD loss, but lower total lean body mass (and not BMI) was associated with greater BMD loss at LS and TH (both p30 U/L or AST >50 U/L) within past 12 months were enrolled. Adolescents with history of hepatitis B/C co‐infection or significant alcohol consumption were excluded. The assessments included liver ultrasonography (USG‐evaluation of fatty liver); transient elastography (TE‐evaluation of liver stiffness), serum liver function test. Aspartate aminotransferase‐to‐platelet ratio index (APRI‐biomarker of liver fibrosis) was calculated. Liver stiffness was defined as any liver fibrosis. (TE ≥5.1 kPa) and significant liver fibrosis (TE ≥7.4 kPa). APRI >0.5 and >1.5 were defined as mild/moderate fibrosis and advanced fibrosis, respectively. Correlation of APRI and TE result was assessed. From August to December 2014, 39 adolescents were enrolled. Median (IQR) age was 17.2 (14.6–19.4) years; 47% were male. Median (IQR) duration of ART was 7.8 (4.4–11.2) years, of which 54% currently received non‐nucleoside reverse transcriptase (NNRTI)‐based regimen. Median (IQR) current CD4 cells count was 691 (535–979) cells/mm3. Fatty liver was observed in 6 (15%) adolescents, of which 2 (5%) had severe fatty liver (Table1). Seventeen (46%) adolescents had any liver fibrosis and 6 (15%) had significant liver fibrosis (Table 1). Median (IQR) of ALT and AST were 30 (21–39) and 25 (20–31) U/L, respectively. Four (11%) had mild/moderate fibrosis by APRI. The APRI was moderately positively correlated with liver stiffness evaluated by TE (Pearson's correlation coefficient=0.51; p=0.001). About one‐third of perinatally HIV‐infected adolescents with a history of transaminitis met criteria of fatty liver or liver fibrosis. Longitudinal follow‐up to monitor for progression and provide appropriate interventions in a timely manner is needed. This study is funded by CIPHER Grants (2014), International AIDS Society. Abstract TUPDB0104–Table 1. Characteristics of perinatally HIV‐infected adolescents with non‐alcoholic fatty liver disease or liver fibrosis Sex Age (yrs) BMI (kg/m2) ALT (U/L) AST (U/L) Fatty Liver by USG TE (kPa) APRI M 23 36.2 160 87 Severe 14.0 0.63 F 17 21.3 36 24 Severe 5.7 0.21 M 15 17.6 36 42 Mild 5.9 0.39 F 12 15.4 36 31 Mild 5.7 0.42 F 20 17.8 46 35 Mild 4.3 0.47 F 20 20.5 71 33 Mild 3.3 0.33 M 17 25.8 50 45 Normal 8.6 0.60 F 18 19.4 23 25 Normal 8.0 0.34 M 14 17.8 23 32 Normal 7.9 0.27 M 18 18.5 29 22 Normal 7.8 0.17 F 23 18.0 19 18 Normal 7.7 0.34 M=male; F=female; BMI=body mass index; ALT=alanine aminotransferase; AST=aspartate aminotransferase; USG=ultrasonography; TE=transient elastography; APRI=aspartate aminotransferase‐to‐platelet ratio index; The bold text indicates abnormal values for each test. M=male; F=female; BMI=body mass index; ALT=alanine aminotransferase; AST=aspartate aminotransferase; USG=ultrasonography; TE=transient elastography; APRI=aspartate aminotransferase‐to‐platelet ratio index; The bold text indicates abnormal values for each test. 10.7448/IAS.18.5.20447 © 2015 Sudjaritruk T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: tavitiya@gmail.com The incidence of insulin resistance (IR) and diabetes mellitus in HIV‐patients, both contributing to cardiovascular morbidity and mortality, has been associated with antiretroviral therapy (ART). Only limited data exists on metabolic effects of regimens including newer drugs such as fixed dose combination drugs, particularly concerning IR. In this prospective, open‐label, randomized phase‐I‐study we investigated the effects of the recently available fixed dose combination of tenofovir disaproxil fumarate, emtricitabine, elvitegravir and cobicistat (TDF/FTC/EVG/cobi, group I) on IR, in comparison to established ART with TDF/FTC+lopinavir/ritonavir (LPV/r, group II) and TDF/FTC+darunavir/ritonavir (DRV/r, group III). N=30 healthy, male volunteers were randomly assigned into one of the 3 study arms. IR was measured using golden standard method of hyperinsulinemic eugylcemic clamp before and 14 days after initiation of study medication. Briefly, a constant insulin infusion (2 mIU/(kg*min)) was infused over two hours, glucose infusion was adjusted as necessary to achieve stable glucose levels (target 90±5 mg/dl). All volunteers took the study medication, as verified by pill counting. IR was evaluated using the mean glucose disposal rate normalized to body weight (MBW, (mg glucose/min*kg)), as calculated during the clamp. To test for statistical significance of global and pairwise differences in IR, analyses of variances and the Student's t‐test was used. To test for significant changes in IR within study arms, the paired t‐test was used. The enrolled volunteers were young, non‐obese, healthy males; no significant differences were detected concerning baseline characteristics (Table 1). Mean IR did not differ between the groups before treatment (I vs. II vs. III: 11.2±3.2 (SD, standard deviation); n=10 vs. 12.5±3.3; n=9 vs. 11.6±2.5; n=9). The medication was well tolerated; 2 patients were excluded from analysis due to medical (hypothyroidism) and technical (insulin pump error) reasons. TDF/FTC+LPV/r significantly affected IR after 14 day of treatment as compared to baseline (9.2±1.8 vs. 12.5±3.3; p=0.037), but neither TDF/FTC/EVG/cobi (11.3±2.5 vs. 11.2±3.2; p=n.s.) nor TDF/FTC+DRV/r (11.3±2.4 vs. 11.6±2.5; p=n.s.) did. Our study shows for the first time that neither treatment with the fixed dose combination TDF/FTC/EVG/cobi nor with TDF/FDC+DRV/r affects IR as compared to the established regimen TDF/FTC+LPV/r. Abstract TUPDB0105–Table 1. Baseline characteristics Group/parameter (Mean±SD) I: TDF/FTC/EVG/cobi II: TDF/FTC + LPV/r III: TDF/FTC + DRV/r Age (years) 26.3 (±4.8) 27.3 (±4.8) 27.2 (±2.3) Weight (kg) 75.3 (±4.8) 70.2 (±8.3) 72.3 (±7.6) Body height (cm) 183.5 (±4.2) 178.9 (±5.7) 180.0 (±5.5) BMI (kg/m2) 22.4 (±1.1) 21.9 (±2.2) 22.3 (±1.5) Fasting blood glucose (mg/dl) 82.0 (±5.1) 82.3 (±6.7) 83.3 (±6.0) 10.7448/IAS.18.5.20448 © 2015 Spinner C D et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: christoph.spinner@tum.de New diagnoses of HIV‐1 infections among people who inject drugs (PWID) increased in Athens metropolitan area, Greece during 2011. Our aim was to identify potential cross‐group transmissions between PWID and other risk groups using molecular methods. HIV‐1 subtypes were determined for 711 HIV‐1(+) PWID sampled during 2011–2014. Cross‐group transmissions among the PWID were those that originated from other groups as estimated by phylogenetic trees. Specifically cross‐group transmissions corresponded to viral lineages from PWID that didn't fall into the outbreak transmission networks or the PWID recombinants. Further phylogenetic analyses were conducted for the sequences from cross‐group transmissions. Among the 711 HIV‐1(+) PWID, 630 (88.6%) sequences fell within four IDU transmission networks belonging to CRF14_BG (n=356, 50.1%), CRF35_AD (n=123, 17.3%), subtype B (n=106, 14.9%) and A (n=45, 6.3%); 48 (6.8%) were recombinants consisting of partial regions originating from the PWID‐specific clades. On the other hand, sequences from 33 (4.6%) PWID didn't belong either to the PWID transmission networks or the recombinants, suggesting that they are evidence of potential cross‐group transmissions. Phylogenetic analyses (n=28) for subtypes A and B detected most frequently among the cross‐group transmissions suggested that most of these infections originated from non‐PWID transmission networks in Greece and the former Soviet Union countries (AFSU). Specifically we found that nine (75.0%) of the subtype B infections originated from Greece, whereas eight (50.0%) and seven (43.8%) of subtype A strains were of AFSU and Greek origin, respectively (Figure 6). The gender distribution didn't differ significantly between those infected within PWID networks (F: n=99; M: n=579) or the cross‐group transmissions (F: n=7; M: n=26). During the four year period of the HIV‐1 outbreak among the PWID in Athens metropolitan area, we estimated that 33 (4.6%) of the infections in this group are due to cross‐group infections. Notably, half of these cross‐group infections due to subtype A originate from the large IDU epidemic in Eastern Europe (AFSU). For subtype B, however, the majority of cross‐group infections originated from Greece. Abstract TUPDC0101–Figure 1. Phylogenetic tree of subtype A sequences from PWIDs with evidence for cross‐group transmissions plus sequences from the Greek epidemic sampled during 1999–2013 and a randomly selected global sample. Abstract TUPDC0101–Figure 1. Phylogenetic tree of subtype A sequences from PWIDs with evidence for cross‐group transmissions plus sequences from the Greek epidemic sampled during 1999–2013 and a randomly selected global sample. 10.7448/IAS.18.5.20449 © 2015 Paraskevis D et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: gknikolopoulos@gmail.com In Pakistan, people who inject drugs (PWID) have a high HIV prevalence (~27%), and the prevalence among sex workers (SW) has recently increased. There is considerable geographic heterogeneity of HIV prevalence, which may reflect multiple subepidemics with unique trajectories, characterized by specific risk contexts, behaviours and sexual or syringe‐sharing networks. This study uses genetic clustering to identify and characterize these HIV subepidemics of ongoing transmission. Mapping and integrated behavioural and biological surveillance took place among 16,756 PWID and male (MSW), hijra (HSW) and female (FSW) SW across Pakistan in 2011. Of the 1637 persons who tested HIV positive (9.8%), we were able to analyze gp41 sequences from 1153. These sequences were aligned to a reference sequence: HXB2. We identified sequences that were highly similar (≤1% pairwise Tamura Nei 93 genetic distance) and deemed these persons potential transmission partners. Transmission clusters were constructed by connecting persons who share potential transmission partners. Clusters were characterized in terms of high risk population group membership and city. Logistic regression was used for tests of statistical significance. The prevalence of HIV was determined to be 27.3%, 5.2%, 1.6% and 0.6% among PWID, HSW, MSW and FSW, respectively. Of the 1153 sequences, 652 were clustered (56.5%) in 87 unique clusters ranging in size from 2 to 96 sequences. Average cluster size was 7.5 (s.d.=15), although clusters of two predominated. Compared with MSW, PWID were more likely to be clustered (odds ratio=1.6, p=0.01). Larger clusters were more likely to span multiple cities and include SW, with an average mixed PWID/SW cluster size of 23.6, compared with cluster sizes of five or two for clusters composed entirely of PWID or SW, respectively. Most PWID who were in clusters were in large clusters of nine or more individuals, whereas HSW and MSW tended to be in clusters of diverse sizes. A comprehensive understanding of HIV transmission in Pakistan will be critical to design strategically targeted HIV prevention programs. Clusters may be indicators of ongoing transmission, and thus an effective strategy for prevention programs could be to target the cities and population groups with high clustering. 10.7448/IAS.18.5.20450 © 2015 Thompson L H et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: laura.thompson@alumni.utoronto.ca The HIV epidemic among men who have sex with men (MSM) is expanding at an alarming rate in Asia. Understanding the dynamics of HIV‐1 transmission among MSM through viral sequence analyses may provide essential information on the origin of viral lineages and the characteristics of disease spread. We determined transmission networks of HIV‐1 among MSM across countries in East and Southeast Asia. A total of 1856 HIV‐1 polymerase gene sequences were obtained from TREAT Asia Studies to Evaluate Resistance‐Monitoring (TASER‐M) sites in Hong Kong, Thailand, Malaysia and the Philippines between 2006 and 2011. Time‐stamped sequence datasets of HIV‐1 subtype B (n=144) and CRF01_AE (n=186) from antiretroviral‐naive MSM were identified and subjected to spatiotemporal analysis using Bayesian phylodynamic methods. A transmission network was defined as a phylogenetic cluster (≥2 isolates) supported by >90% bootstrap values and Bayesian posterior probability value of 1 at the tree node. Phylogenetic reconstructions showed that 68% of HIV‐1 subtype B and 46% of CRF01_AE sequences were grouped in 50 transmission networks of various sizes (mean size=5.6, range=2–32 sequences), with subtype B sequences having a higher tendency to form a network (p1 sex partner. IPs named 283 partners, 278 had complete date: 59% are spouses. Of 192 people tested, 103 (53.6%) tested after APS at four weeks. Of 103 HIV positive diagnoses, 55 (53.4) were reported at eight, but not four, weeks, suggesting APS‐assisted identification of new HIV infections. APS appeared to increase both partner HIV testing and identification of HIV‐infected partners across a range of subgroups (Table 1). The magnitude of impact varied. In multivariate analysis, APS appeared more effective among persons in ongoing sexual relationships and less effective among persons with multiple sex partners, a group in whom partner testing and HIV identification remained relatively low. APS significantly improves HIV testing uptake and case‐finding among current sex partners: those in monogamous pairs benefit most. These findings suggest that the model of APS piloted in Mozambique might be most profitably focused on persons in ongoing partnerships and highlights the need for better interventions for persons with multiple sex partners. Abstract TUPDD0104–Table 1. Factors associated with uptake of assisted partner services for HIV testing and HIV diagnosis N=278 Tested Prior to APS # (%) Total Tested at 8 weeks # (%) OR testing Post v Pre APS* (Univariate) OR testing Post v Pre APS** (Multivariate) HIV+ Prior to APS # (%) Total HIV+ at 8 weeks # (%) OR HIV+ Post v Pre APS* (Univariate) OR HIV+ Post v Pre APS** (Multivariate) Male partner (ref: female) 59 (28.8) 142 (69.3) 1.61 (0.91–2.84) 33 (15.8) 78 (38.1) 1.51 (0.76–2.99) Live together 66 (43.4) 124 (81.6) 1.07 (0.67–1.70) 36 (23.7) 71 (46.7) 1.67 (0.92–3.03) IP has >1 sex partner 37 (27.4) 73 (54.1) 0.43 (0.26–0.72) 0.52 (0.31–0.89) 19 (13.6) 33 (24.4) 0.28 (0.15–0.52) 0.39 (0.20–0.77) Has continuing sexual relations 78 (35.3) 172 (77.8) 2.78 (1.44–5.33) 2.09 (1.04–4.17) 43 (19.3) 94 (42.5) 3.36 (1.27–8.93) 1.92 (0.70–5.53) IP reason for HIV testing: symptoms 20 (23.8) 52 (61.9) 0.99 (0.58–1.70) 9 (10.6) 24 (28.6) 0.74 (0.39–1.39) IP reason for HIV testing: prenatal 44 (37.0) 96 (80.7) 1.61 (0.97–2.67) 21 (17.2) 54 (45.4) 2.34 (1.30–4.21) 1.66 (0.91–3.03) Total 89 192 48 103 Results from logistic regression models using the (cluster) option in STATA. 95% CI presented in parentheses. *Results from univariate models. **Results from multivariate models. Results from logistic regression models using the (cluster) option in STATA. 95% CI presented in parentheses. Results from univariate models. Results from multivariate models. 10.7448/IAS.18.5.20457 © 2015 Feldacker C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: golden@u.washington.edu Testing partners for HIV in the antenatal period is an effective way to bring HIV services to couples. Leveraging antenatal HIV testing with point of care (POC) diagnostics for other sexually transmitted infections (STI) may improve male partner treatment services among couples. We conducted a prospective study among male partners of pregnant women who received home‐based couple HIV testing and education (HOPE) following a first antenatal visit in Kisumu, Kenya. From April to July 2014, rapid POC syphilis testing (SD Bioline Syphilis 3.0) was added to the package of services for men and those with positive results were referred to the clinic for treatment. We assessed men's acceptance of testing and intention to seek clinic‐based treatment and calculated an odds ratio to examine correlation between uptake of syphilis and HIV testing. Data were available for 73 (83%) couples receiving a HOPE visit. Men were on average 26 years of age (IQR: 22, 29). At study entry, most men reported having previously tested for HIV (93%, n=68), of whom 7% reported being of known HIV positive status (n=5) and 80% reported knowing their female partner's HIV status (n=59). Of 73 men, 67 accepted syphilis testing (92%) among whom 64 intended to attend clinic STI treatment if they received a positive syphilis result (95%). HIV prevalence among the men was14.7% and one man (<1%) was syphilis positive. In this group, 61 (83%) accepted both syphilis and HIV tests. Three men (4%) refused both tests and three men (4%) accepted HIV alone. Six men (8%) accepted syphilis alone, of whom two reported having been previously tested as HIV‐positive. If a man accepted HIV testing, he was 10‐fold as likely to accept syphilis testing, compared to a man who refused HIV testing (OR: 10.2; 95% CI: 1.05–89.3; p=0.02). In a high HIV and low syphilis setting, home‐based education and POC syphilis testing of male partners during pregnancy is highly acceptable when coupled with HIV testing and may encourage men to seek clinic‐based STI services. Integration with HIV testing appears feasible, and syphilis test uptake is highly correlated with HIV test uptake. 10.7448/IAS.18.5.20458 © 2015 Mark J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jmark55@uw.edu Understanding factors influencing ART adherence is needed to optimize treatment responses for HIV infected men who have sex with men (MSM) and Hijra/transgender women (TGW) in India. The objective of this formative study was to determine rates of ART uptake and adherence and explore potential factors associated with adherence in Indian MSM and TGW. We conducted a cross‐sectional survey in Hindi among all HIV positive MSM and TGW on ART accessing support services at a LGBT community based organization in Mumbai between July and September 2014. Non‐adherence was measured by self‐report and defined as missing any doses (i.e. <100% adherent) in the past one month and three months. Potential correlates of adherence assessed were sociodemographics, medication side‐effects, depression (CESD‐10), self‐efficacy (GSE), internalized homophobia/stigma and medication beliefs using chi‐square or t‐tests. Of the 300 individuals registered in the organization's HIV support programme, 28.3% (85/300) were eligible for ART by current country standards (e.g. CD4=350 or having an OI) with 22% (65/300) currently on ART. Of those on ART, 83% (54/65) were MSM and 17% (11/65) TGW; 40% (25/65) were married to women, and most (97%) received free ART through government clinics. Overall, 32% (21/65) were non‐adherent in the past one month and 45% (29/65) in past three months. Correlates (p<0.05) of non‐adherence were similar for one month and three months and were associated with younger age, non‐Kothi identity (MSM subgroup), alcohol use, having sex with women, feeling healthy and negative medication beliefs but was not directly associated with depression, internalized homophobia, or medication self‐efficacy. In one of the first studies of adherence among MSM and TGW in India, ART treatment uptake and adherence were suboptimal. Modifiable factors associated with adherence may serve as targets for interventions to support adherence. Further work is however needed to verify self‐report measures with biological outcomes and confirm findings in other samples of Indian MSM and TGW. 10.7448/IAS.18.5.20459 © 2015 Pina C et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: christopher.pina@med.einstein.yu.edu The development of a preventative HIV‐1 vaccine will most likely require induction of broadly neutralizing antibodies (BCN). Neutralizing antibodies develop in almost all HIV‐1 infected individuals, however they develop months following HIV‐1 infection and they are strain‐specific. The development of BCN antibodies occurs only in 20–30% of HIV‐1 infected individuals. However, the mechanism that leads to the development of BCN is unknown and not all epitopes have been identified. The aim of the study was to evaluate pathways and mechanisms that lead to the development of broadly neutralizing antibodies. Twenty individuals with acute HIV‐1 infection were identified and followed longitudinally for three years in Durban, KwaZulu‐Natal. A panel of 18 viruses (6 subtype A, 6B and 6C) was used to screen the patients for neutralizing antibodies at 2–3 years post‐infection using the TZM‐bl neutralization assay. The patients that developed broadly neutralizing antibodies were followed up longitudinally at 8, 10, 14, 16, 18, 71, 88, 100, 124, 150, 200 weeks to determine the timing of emergence of the BCNs. Specificity of BCNs was determined using single point mutagenesis at 3 years post‐infection. Three out of 20 individuals (AS3‐268, AS2‐1037, AS2‐358) developed broadly neutralizing antibodies. AS3‐268 developed potent BCN activity peaking at three years post‐infection and it targets N276A glycan on the CD4 binding site of gp120. AS2‐1037 developed potent broadly neutralizing activity peaking at two years post‐infection and it targets N332A glycan on the V3 loop of gp120. AS2‐358 developed BCNs peaking at two years post‐infection and it did not map to any known specific epitope. Broadly neutralizing antibodies could be detected at approximately one year post‐infection and they targeted different epitopes on the viral envelope. Work is currently in progress to assess the maturation of breadth and to assess antibody‐virus co‐evolution. 10.7448/IAS.18.5.20460 © 2015 Ndlovu B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: bongiwendlovu4@ukzn.ac.za The MRKAd5 Gag/Pol/Nef vaccine increased the risk of HIV acquisition. However, the Step study suggested an HLA‐specific benefit in viral setpoint to vaccinees who subsequently became infected. The Phambili trial, using the same MRKAd5 vaccine, presented an opportunity to investigate the existence of an HLA‐specific effect in a genetically distinct South African population. Gag‐specific CD8 T‐cell responses restricted by protective South African HLA alleles such as HLA‐B*57 are associated with successful control of infection, while disease‐susceptible alleles such as HLA‐B*58:02 present non‐Gag epitopes and are associated with rapid progression. We hypothesized that the MRKAd5 Gag/Pol/Nef vaccine might redirect responses towards Gag in HLA‐B*58:02+ Phambili subjects who would not target it naturally. Viral loads (VL), CD4 T‐cell counts, HLA types and ELISpot anti‐HIV CD8 T‐cell responses were analyzed in subjects blinded to vaccine/placebo assignment. All data analyzed were from ART‐naïve subjects. HLA‐B*58:02 was the most prevalent allele (population frequency 23%). HLA‐B*58:02+ vaccinees (n=7) had lower viral setpoints than placebo‐recipients (n=7) (25,670 vs. 215,500, p=0.03), a 0.8log lower VL calculated using all longitudinal pre‐ART data via a mixed effects model (p<0.001, Figure 1a), reached CD4<350 cells/µl slower (p=0.002, Figure 1b) and showed an increase in Gag breadth in ELISpot assays (p=0.04) compared to HLA‐B*58:02+ placebo‐recipients. In addition to the known increased risk of HIV acquisition resulting from the MRKAd5 Gag/Pol/Nef vaccine, these current data suggest a therapeutic effect of the same vaccine in subjects expressing HLA‐B*58:02, an African HLA allele strongly associated with rapid progression in natural HIV infection. HLA‐B*58:02+ vaccinees showed a lower viral setpoint and slower time to CD4<350 cells/µl, associated with increased Gag‐specific ELISpot responses. Caveats to the study include limitation of ELISpot assays to only 60 of 100 study subjects, selected based on cell availability; and of HLA typing to 79 subjects, based on material availability. These factors potentially introduced unintended selection bias effects. Nonetheless, these data on ART‐naïve subjects are consistent with Step studies, indicating a beneficial therapeutic MRKAd5 HLA‐specific effect that in South Africa includes the most prevalent HLA‐B allele, HLA‐B*58:02. Abstract WEPDA0102–Figure 1. (a) Graphical presentations of patient longitudinal pre‐ART data and regression lines obtained from a variable intercept linear mixed effects model showing longitudinal VL differences in infected B*58:02+vaccinees (blue, n=7) and placebo‐recipients (red, n=7); ANOVA. (b) Kaplan‐Meier curves showing time to CD4<350 cells/µl in infected HLA‐B*58:02+vaccinees (blue, n=7) and placebo‐recipients (red, n=7); log rank test. Abstract WEPDA0102–Figure 1. (a) Graphical presentations of patient longitudinal pre‐ART data and regression lines obtained from a variable intercept linear mixed effects model showing longitudinal VL differences in infected B*58:02+vaccinees (blue, n=7) and placebo‐recipients (red, n=7); ANOVA. (b) Kaplan‐Meier curves showing time to CD4<350 cells/µl in infected HLA‐B*58:02+vaccinees (blue, n=7) and placebo‐recipients (red, n=7); log rank test. 10.7448/IAS.18.5.20461 © 2015 Leitman E M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: ellen.leitman@st‐hughs.ox.ac.uk HIV‐1 subtype C accounts for about 50% of the global HIV‐1 infections. It is the predominant subtype in India, Ethiopia and countries in southern Africa. However, virological attributes to this unique epidemiological pattern have not yet been fully defined. A total of 207 HIV‐1 positive plasma or established strains were cultured and expanded to higher titre stocks by culturing in PBMCs from HIV‐1 negative donors. Near full‐length genome (NFLG) sequences were obtained by amplifying two overlapping half genomes. The newly obtained sequences were aligned to the HIV‐1 whole genome reference sequences for subtyping. Viral genome copy numbers, tissue culture infection doses (TCID) and p24 concentrations were determined for virus stocks and compared via linear regression among major subtypes. Mann‐Whitney U tests were used for the infectivity comparisons at the alpha 0.05 level. Analysis of NFLG sequences showed that these viruses belonged to subtype A1 (16), subtype B (48), subtype C (53), subtype D (10), CRF01_AE (12), other subtypes and CRFs (F1, F2 G, CRF02, and CRF022; each with ≤8 sequences) and URFs (45). Only subtypes with ≥10 NFLG sequences were subjected to further analysis. No biologically relevant differences (a 0.5 log10 difference) among all compared subtypes were observed for three measurements: viral genome copy numbers, TCID, and p24 concentrations. The only exception was that the TCID of subtype C was 0.51 log higher than that of CRF01 (p=0.04). The infectivity per viral genome (TCID/RNA copy) was the highest for subtype C (0.00452 TCID/RNA copy) and was significantly higher than those of all four compared subtypes (A1, B, D and CRF01_AE; p=0.0286, p=0.0004, p<0.001 and p=0.0205, respectively). The p24/RNA copy ratios of subtypes C and B (0.13 and 0.12 pg/RNA copy, respectively) were the highest and were significantly higher than those of subtypes A1 and D (p<0.05), but similar to that of CRF01_AE. The high infectivity of HIV‐1 subtype C may give it more replication advantages and allow it to disseminate faster in HIV‐1 infected populations in some geographic areas compared to other subtypes. High infectivity may play a critical role in the global epidemic of subtype C. 10.7448/IAS.18.5.20462 © 2015 Demarco T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: todd.demarco@dm.duke.edu The HIV‐1 accessory protein Nef is essential for HIV‐1 pathogenesis and progression to AIDS. By hijacking the cellular trafficking machinery Nef is able to alter T cell activation, increase viral replication and permit viral immune evasion via downregulation of the cell‐surface receptors CD28, CD4 and MHC I, respectively. However, only recently have these functions been studied outside of laboratory‐adapted strains of HIV‐1. This proposal aims to investigate how the high degree of HIV‐1 genetic diversity impacts Nef function. An HIV‐1 based lentiviral expression system was used to express Nef proteins from 10 group M subtypes (A1, A2, B, C, F1, F2, G, H, J and K) in the context of an HIV‐1 infection. T cell lines were infected with pseudoviruses encoding Nef proteins and analyzed for surface levels of CD28 and MHC‐I using fluorescent antibody staining and flow cytometry. Alternatively, CD4 cell surface levels were measured by transfecting CD4+ HeLa cells with expression plasmids encoding Nef‐GFP fusion proteins followed by fluorescent antibody staining and flow cytometry. Nef expression was determined by a combination of western blot analysis and flow cytometry to measure fluorophore fused Nef proteins. Our results demonstrate that MHC I, CD28 and CD4 are differentially downregulated between HIV‐1 subtypes. Notably, subtype C Nef, the most common subtype globally, was significantly less efficient at downregulating MHC I and CD28 when compared to the laboratory strain NL4.3. Subtype G Nef, found predominantly in Central and West Africa, was significantly less efficient at downregulating all three cell surface receptors. Differences in downregulation efficiency for all three receptors were attributed to variations in Nef protein expression. This study represents a comprehensive analysis of Nef function among 10 HIV‐1 subtypes and adds to the growing evidence that HIV‐1 genetic diversity impacts viral protein function. Due to the pathogenic role Nef plays in an HIV‐1 infection, these results may help explain recent studies that show differences in disease progression in individuals infected with different HIV‐1 subtypes. Finally, these findings support further study of all major HIV‐1 subtypes and emphasize the need to consider subtype differences when developing alternative treatment options. 10.7448/IAS.18.5.20463 © 2015 Johnson A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: aaronjohnson13@gmail.com Viral diversity provides a major challenge in the development of a vaccine against HIV‐1. A potential target for HIV‐1 vaccines is gp120 envelope protein, which is involved in viral entry and is a target of the host immune system. It has been shown that Envelope characteristics have a role to play in disease progression. However some studies have demonstrated conflicting results. In this study, we aim to analyze HIV‐1gp120 characteristics, specifically: potential N‐ glycosylation sites, amino acid sequence length and net electric charge in cell associated and cell free RNA derived from recently and chronically infected individuals in Botswana. This was a retrospective study using stored samples collected from treatment naïve HIV‐1C infected cohorts at Botswana Harvard AIDS Institute Partnership, representing recently infected and long term infection as determined by serological assays for recency and longitudinal follow up. A 1200 base pairs fragment of V1 to V5 region of gp120 was amplified by nested PCR and sequenced on both strands using Big Dye Technology in proviral DNA and cell free RNA. Potential N‐glycosylation sites were determined using Los Alamos HIV sequence database while subtype was assigned using REGA HIV subtyping tool. There was a significant increase in amino acid sequence length of V2 (p=0.027) and V4 (p=0.0099) in proviral DNA in the chronic stage as compared to the recent stage of infection. Similar changes were also observed in cell free RNA in V4 (p=0.0074). In addition, the number of potential N‐linked glycosylation sites in proviral DNA was significantly increased in chronic infection in V4 (p=0.0253). No significant changes in net electric charges were observed. There was an association between viral load and V4 region (p<0.001). All samples were classified as subtype C. The increase in amino acid sequence length and potential N‐Glycosylation sites in the V2 and V4 region may be essential in disease progression. The changes observed in V2 and V4 warrant further investigation. A clear understanding of envelope characteristics is important for development and design of new vaccine and therapeutics. 10.7448/IAS.18.5.20464 © 2015 Mohammed T et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: tmohammed@bhp.org.bw Follicular T helper cells (Tfh), a subset of CD4 T lymphocytes, are essential for B‐cell activation and provide help to B cells in the production of antigen‐specific antibodies. Although several studies have analyzed the dynamics of Tfh cells in the context of AIDS by analyzing peripheral blood and LNs of HIV‐infected patients, paradoxically, none of these studies in HIV/SIV infection have addressed the role of Tfh cells in the primary organ of B‐cell activation, the spleen. To address these questions, we have infected rhesus macaques with SIVmac251 (20 AID50). Animals were killed at different time points post‐infection and lymphoid organs were recovered. Tfh cells (PD‐1highCXCR5+) and CD4+ T cell subsets were monitored by flow cytometry. Concomitantly, B‐cell subsets were also analyzed. CD4 T‐cell subsets were sorted and SIV DNA was quantified by RT‐PCR. Herein, we demonstrated for the first time that the percentages and numbers of splenic Tfh cells decrease early during the acute phase in macaques infected with SIV. This profound loss and abnormal differentiation of Tfh is also associated with the loss of memory B‐cell subsets. Moreover, SIV DNA is detected in splenic Tfh cells early after infection. Finally, our results showed that the frequency of splenic Tfh and memory B cells are higher in slow‐progressor compared to rapid progressor RMs at the chronic phase. Altogether, our results demonstrate the drastic depletion of splenic memory B cells, which might be related to the loss of fully maturated Tfh cells. 10.7448/IAS.18.5.20562 © 2015 Moukambi F et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: felicien.moukambi@crchudequebec.ulaval.ca Point‐of‐care or “rapid” serologic assays for HIV are widely used in resources‐limited setting. Their evaluation in the field carried out independently of the fabricant is crucial to assess their capability to accurately detect non‐B subtypes or circulating recombinant form (CRF) of HIV‐1. Our objective was to evaluate the HIV‐1/HIV‐2 INSTI® test (distributed by Nephrotec, Rungis, France) for the diagnosis of non‐B subtypes and CRF of HIV‐1 circulating in Gabon, a country of wide genetic diversity. A panel of 250 HIV‐positive and 250 HIV‐negative plasmas was prospectively collected after informed consent in adult patients attending the Laboratoire National de Référence des MST et du SIDA, Libreville, as recommended by the WHO (Service delivery approaches to HIV testing and counselling: A strategic policy framework; 2012). The reference HIV serology consisted of ImmunoComb II HIV1&2 BiSpot (Inverness Medical Innovations, Yavne, Israel) as screening test followed by confirmatory Western blot (New Lav Blot I, Bio‐Rad, Marnes‐la‐Coquette, France). All HIV‐positive plasma were furthermore subjected to HIV genotyping by pol nested PCR, amplicons sequencing, and analysis of resulting FASTA sequences by Genotyping software from NCBI. A subgroup of 1 out of 10 patients was also tested in parallel with finger‐stick whole blood INSTI® test. All HIV‐1 belong to HIV‐1 group M with broad HIV‐1 genetic diversity as assessed using pol sequences (CRF02_AG (53%), CRF14 (18%), CRF15 (12%), CRF01_AE (8%), A1 (4%), G (2%), K (2%), B (1%)). Among 250 HIV‐infected and 250 HIV‐negative plasmas, 250 and 249, respectively, were positive or negative by INSTI®. Thus, INSTI® test sensitivity and specificity were 100% and 99.6%, respectively; positive and negative predictive values in Gabon were 91.5% and 100%, respectively. For the major subtype CRF_02AG, sensitivity and specificity were 100%. Finally, all 50 patients tested in parallel using plasma and capillary blood and were identified similarly. HIV‐1/HIV‐2 INSTI® test is highly reliable for the detection of various non‐B HIV‐1 antibodies, both in plasma and capillary blood; and it fulfils the WHO criteria for HIV test prequalification. The rapid INSTI® test could be useful for HIV screening in Gabon, as well as in other sub‐Saharan African countries. 10.7448/IAS.18.5.20465 © 2015 Ndjoyi‐Mbiguino A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: nzenguig@yahoo.fr Roche COBAS Ampliprep/COBAS TaqMan HIV‐1 Qualitative version 2 (TaqMan v2 qual) has recently been released for testing of dried blood spot (DBS) for infants and plasma for adults that are antiretroviral (ARV) naïve; however, ARV status of patients is often unknown. This study evaluated the use of whole blood (WB) for HIV‐1 detection using TaqMan v2 qual. 133 samples (125 EDTA, 8 Virology Quality Assurance (VQA) WB) were used with known HIV‐1 status (positive, n=75; negative, n=58) as per Roche Amplicor HIV‐1 DNA PCR assay v1.5 (Roche v1.5). EDTA samples were split: 1 mL plasma, 100 µL WB and 70 µL DBS. Samples were processed using TaqMan v2 qual according to manufacturer's instructions and results compared to Roche v1.5. Sensitivity and specificity were determined for each sample type and compared to EDTA plasma viral load. Seven WB samples (HIV‐1 positive, n=4; HIV‐1 negative, n=3) were evaluated for reproducibility and precision using the TaqMan v2 qual. Of the 69 Roche v1.5 HIV‐1 positive samples, 68 were detected using TaqMan v2 qual DBS or WB; whereas only 60 were detected using TaqMan v2 qual plasma. HIV‐1 positive samples missed had either a viral load of not detected or <20 RNA copies/mL. The TaqMan v2 qual plasma samples missed 13% of HIV‐1 positive samples. No false positives were observed across the three different matrixes evaluated. Of the 8 VQA WB samples tested on TaqMan v2 qual and Roche v1.5, 100% concordance was observed (n=6, HIV‐1 positive; n=2, HIV‐1 negative). Diagnostic sensitivity and specificity are detailed in the table below. Reproducibility and precision was 100% for all samples tested. TaqMan v2 qual using DBS or WB had the highest sensitivity when compared to Roche v1.5 (98.5%). Plasma samples on TaqMan v2 qual missed 13% of HIV‐1 positive samples. With the increase of microbicide use, pre‐exposure prophylaxis and reported poor disclosure of prior ARV use, this study indicates that plasma samples are not the ideal sample matrix for testing adults when ARV exposure is unknown. The high percentage of adult samples that were missed would have serious implications for decreasing HIV‐1 transmission rates. Abstract WEPDB0102–Table 1. Diagnostic Sensitivity and Specificity of the Roche COBAS Ampliprep/COBAS TaqMan HIV‐1 Qualitative version 2 compared to the Roche Amplicor HIV‐1 DNA PCR assay v1.5 Roche COBAS Ampliprep/COBAS TaqMan HIV‐1 Qualitative version 2 sample type Sensitivity Specificity Whole blood 98.5% 100% Plasma 87.0% 100% Dried blood spot 98.5% 100% 10.7448/IAS.18.5.20466 © 2015 Viana R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: carole.wallis@lancet.co.za Over the past decade of antiretroviral therapy (ART) scale‐up, median CD4 counts at ART initiation have increased and ART initiation is recommended at progressively higher CD4 thresholds. However data on the relationship between CD4 count at ART initiation and loss to follow‐up (LTFU) are limited and conflicting. We investigated the association between higher CD4 counts at ART initiation and LTFU in South Africa (SA). All adults initiating ART between 2008 and 2012 at 3 public sector sites in SA were included. LTFU was defined as no clinic visit in the six months before database closure. The Kaplan‐Meier estimator and Cox's models examined the relationship between CD4 count at ART initiation and 24‐month LTFU. Estimates of corrected LTFU were generated adjusting observed LTFU for unascertained deaths through linkage via identification numbers (IDs) with the SA National Population Register. Final models were adjusted for patient demographics, year of ART initiation, and programme expansion. Among 17,038 patients, the median CD4 at initiation increased from 119 (interquartile range (IQR): 54–180) in 2008 to 257 (IQR: 175–318) in 2012. In unadjusted models, observed LTFU was associated with both CD4 counts<100 cells/mL and CD4 counts≥300 cells/mL compared to those with a CD4 count 150–199 cells/mL. After adjustment, patients with CD4 counts ≥300 cells/mL were 1.35 (95% CI: 1.12–1.63) times as likely to be LTFU after 24 months compared to those with a CD4 count 150–199 cells/mL. Correction for unascertained deaths attenuated the association between CD4 counts 1000 copies/mL accessing care at a large urban HIV Centre in Kampala, Uganda. At IDI VL tests have been available since 2005. Until December 2014 these were reserved for patients with documented immunological or clinical failure. Those patients with detectable VL are managed through a treatment failure path‐way consisting of: 1) review of the results by the clinician, 2) case discussion in the weekly multidisciplinary “switch‐meeting” 3) follow up by a clinician and counsellor based on the decision reached during the “switch‐meeting.” We performed a retrospective audit of a sample of patients on first line ART with VL >1000 in 2014; data was extracted from 95 randomly sampled clinic files and the clinic database. 1093 patients on first line ART were tested for VL in 2014, of which 365 (33.4%) had a detectable VL; of these 95 (26%) clinical files were sampled. Median log10 VL was 4.9 (IQR: 4.7–5.3). The diagram summarizes the action taken for the 95 sampled patients stratified by referral to the treatment failure path‐way. 60/95 (63.1%) were switched to 2nd‐line after a median time of 49 days (IQR: 14–84). Of note an action was taken for all patients referred to the treatment failure path‐way. The majority (65%) of patients with a detectable VL were switched to 2nd‐line, and an additional 28% had an action taken. This is a favourable outcome compared to outcomes in other treatment centres around SSA, and we believe that the “switch meeting” model has helped to ensure that action is taken. We advocate that this additional step be considered in WHO and national guidelines to ensure adherence strengthening and prompt switch to second line in patients failing ART. Abstract WEPDB0104–Figure 1. Action taken for the sampled patients with viral failure stratified by referral to the treatment failure path‐way. Abstract WEPDB0104–Figure 1. Action taken for the sampled patients with viral failure stratified by referral to the treatment failure path‐way. 10.7448/IAS.18.5.20468 © 2015 Nsumba M S et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mnsumba@idi.co.ug In resource limited settings, timely plasma separation and transportation to centralized laboratories is a major challenge to the scale‐up of viral load (VL) testing. Whole blood (WB) collection and testing through either dried blood spots (DBS) or point‐of‐care VL assays are potential solutions. However, there is limited evidence on the performance of WB‐based VL assays. We evaluated three WB VL testing platforms, Alere q HIV‐1/2, DBS Abbott RealTime HIV‐1 and Roche CAP/CTM HIV‐1 (DBS, free virus elution protocol) using routine clinical samples across a wide viral load spectrum chosen from South African public sector patients on combination antiretroviral therapy. Abbott RealTime HIV‐1 was used as gold standard and virological failure (VF) was defined for plasma at 1000 copies/mL. Of the 299 samples selected, 153 (51%) had plasma VL>1000 copies/mL. Abbott DBS VL had the best overall VL correlation with its plasma counterpart (r2=0.76), followed by the Roche DBS VL (r2=0.62) and Alere q HIV‐1/2 (r2=0.46). Among samples with VF, Alere q HIV‐1/2 and Abbott DBS assays were highly sensitive, correctly classified 100% and 98% of the samples, respectively. Roche DBS assay was only able to identify 53% of the VF samples correctly. For samples with plasma VL1000 copies/mL identified by WB VL on both Alere q HIV‐1/2 (81%) and Abbott DBS VL (21%) when compared to the plasma reference, while Roche DBS VL showed 99% agreement in this category. Receiver operating characteristic analysis revealed that the threshold of log10 4.12, 3.43 and 2.60 copies/mL provided the best overall VF classification for Alere q HIV‐1/2 (85%), Abbott DBS VL (94%) and Roche DBS VL (82%), respectively. Variability was noted between the different WB VL assays with difficulties assigning a uniform threshold across all platforms, reflecting the differences in sample treatment/processing (DBS versus fresh blood samples) and sample input volume. The performance at 1000 copies/mL of DBS protocols and point‐of‐care devices remains significantly varied and further development is required to ensure minimal VF misclassification. Abstract WEPDB0105–Table 1. Percent of correct classification of VF by WB HIV VL Abbott RealTime HIV‐1 Plasma VL LDL (lower than detectable limit) Not LDL 10,000 copies/mL N 94 52 52 101 Alere q HIV‐1/2 WB% correct classification 22% 14% 100% 100% DBS Abbott RealTime HIV‐1% correct classification 87% 63% 94% 100% DBS Roche CAP/CTM HIV‐1% correct classification 100% 98% 0% 80% 10.7448/IAS.18.5.20469 © 2015 Khan A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: aabida.khan@nhls.ac.za Migration contributes significantly to new HIVcases in Canada. This study describes geographic origin trends among HIV+ mothers and perinatally infected children and the impact of geographic origin on vertical HIV transmission (VT) rates among HIV+ mother‐infant pairs (MIP) in Canada from 1990 to 2013. The Canadian Perinatal HIV Surveillance Program collects data at 22 centres. The primary focus is on MIP with an infant born in Canada and identified prior to/within three months of birth; MIP with Canadian‐born infants identified after three months and HIV+ children born abroad are also tracked. Data reviewed for this study included: maternal country of origin, clinical characteristics, antiretroviral usage and infant outcome. Logistic regression determined VT rate differences for foreign‐born (FBM) versus Canadian‐born mothers (CBM). Among 3877 MIP, 2089 (53.9%) mothers were FBM. Of 1481 (70.9%) African mothers, 30.7%, 20.1%, 17.7% and 16.7% came from East, Central, Horn and West Africa, respectively. CBM accounted for 66.7% (971/1456) in Western/Central Canada, whereas FBM predominated in Ontario (945/1357, 69.6%; greatest proportion East African, 25.0%) and Quebec (713/1020, 69.9%; greatest proportion Caribbean, 36.2%). The largest numbers of FBM originated from Haiti (12.5%), Ethiopia (8.7%), Congo (7.0%), Zimbabwe (5.4%) and Nigeria (4.6%). In the pre‐cART era (1990–1996), Haiti contributed 29.9% (90/301) of FBM, decreasing to 13.0% (119/918) in 1997–2007 and 6.6% (52/782) in 2008–2013. Since 2008, Ethiopia (80/782, 10.2%), Congo (64/782, 8.2%) and Nigeria (62/782, 7.9%) predominated. VT rate among Canadian‐born children from 1990 to 2013 was 3.8% (3.0% among FBM) and 1.2% from 2008 to 2013 (0.7% among FBM). African mothers had lower risk of VT (1990–2013: OR = 0.45, 95% CI 0.29–0.71; 2008–2013: OR=0.35, 95% CI 0.12–1.08) compared to CBM; no differences were seen for other regions. Of 353 HIV+ children (born in Canada or abroad) with FBM, the greatest numbers came from Haiti (48, 13.6%), Ethiopia (33, 9.3%), Burundi (30, 8.5%) and Congo (15, 4.2%). Geographic origins of HIV+ FBM in Canada have changed over time, shifting from predominantly Haitian in the pre‐cART era to predominantly African more recently. African mothers have lower VT rates than CBM. Understanding country‐specific cultural and obstetrical/paediatric health issues is imperative to providing optimal care. 10.7448/IAS.18.5.20470 © 2015 Brophy J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: jbrophy@cheo.on.ca The Canadian Perinatal HIV Surveillance Program (CPHSP) is an active surveillance programme generating national data HIV+ women and their infants in Canada since 1990. We describe the CPHSP’s evolving methodology and analyze mother‐infant pair (MIP) demographics, antiretroviral treatment and vertical transmission (VT) rates in Canada from 1990 to 2013. MIPs are identified at 22 centres following obstetric or paediatric referral for care. Data is entered via a secure web‐based Oracle database, which is managed and analyzed by the CIHR‐Canadian HIV Trials Network. A nationally representative steering committee provides direction and oversight. Data collected include maternal characteristics, antiretroviral therapy (ART) and infant outcome. VT rates are based on data of MIP delivered in Canada and identified within three months after birth; infants identified beyond three months of birth are tracked separately. Among 2914 MIP from the combination ART (cART) era (1997–2013), the overall VT rate was 2.1% but only 0.7% in MIP receiving cART and 0.1% in women receiving >4 weeks of cART. Of 200 identified HIV+ women giving birth in Canada in 2013, 76% acquired HIV heterosexually, 17% through injection drug use (IDU) and 2% perinatally; 53% of mothers were Black and 23% Aboriginal. The proportion untreated steadily decreased from 20.3% in 1997 to 3.0% in 2013. Aboriginal women (7%) continued to represent the largest proportion of untreated women (7%) in 2013, though this decreased from a peak of over 20% during the period 2005–2009. A similar improvement was seen among IDU, with only 3% untreated in 2013. In 2013, seven (3.5%) women had no antenatal cART or suboptimal treatment, the lowest annual number and percentage in the cART era, resulting in two children becoming infected. The CPHSP allows for comprehensive identification of perinatal HIV exposure and outcome trends in Canada. Ongoing challenges include ensuring all MIPS are captured given Canada’s geographically and demographically diverse population and low HIV prevalence. Despite continued improvement in treatment access for pregnant HIV+ women, VT continues to occur with Aboriginal women being at greater risk of inadequate treatment and VT. 10.7448/IAS.18.5.20471 © 2015 Singer J et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: singerjoel@hotmail.com HIV acquisition among sub‐Saharan migrants living in Europe has long been considered to predominantly occur before migration because of generalized HIV epidemics in sub‐Saharan African countries. Recent evidence suggests that a substantial proportion have acquired HIV while they were living in Europe. In the UK, this proportion was recently estimated at 31% using a CD4‐based modelling approach. Such an estimate is not currently available for France. We estimated the proportion of sub‐Saharan migrants who acquired HIV infection after their arrival in France using life‐event and clinical information on a random sample of HIV‐infected hospital outpatients born in sub‐Saharan Africa in Paris region. We assumed that HIV infection had probably been acquired in France if at least one of the following life‐event criterion was fulfilled: 1) HIV diagnosis >10 years after arrival in France, 2) ≥1 negative HIV test in France, and 3) sexual debut after arrival in France. If none of these criteria was fulfilled, we estimated the duration from HIV infection based on first CD4 count measurement using statistical modelling. Infection was assigned in France if, out of 500 durations estimated for each individual, >50% (median scenario) or >95% (conservative scenario) fell within the period while individuals were living in France. Of the 898 HIV‐infected adults born in sub‐Saharan Africa included in the analysis, we estimated that 49% (95% confidence interval: 45–53) in the median scenario and 35% (31–39) in the conservative scenario acquired HIV while living in France. This proportion was lower for women than men (30% (25–35) vs. 44% (37–51) in the conservative scenario) and increased with duration in France. The proportion of sub‐Saharan African migrants having acquired HIV infection while living in France is high, highlighting the need for improved focused HIV prevention. This requires a better understanding of the determinants of HIV infection in France in this population. Abstract WEPDC0103–Figure 1. Flow chart – assignment of HIV acquisition. Abstract WEPDC0103–Figure 1. Flow chart – assignment of HIV acquisition. Abstract WEPDC0103–Table 1. France HIV acquisition – conservative scenario Men Women N Weighted % 95% CI p value N Weighted % 95% CI p value Overall 348 43.9 37.4–50.6 550 30.0 25.1–35.4 Age at arrival in France <25 yr 84 78.1 65.5–87.1 <0.001 171 54.1 46.5–61.5 <0.001 25–34 yr 139 44.3 35.9–53.2 251 24.5 17.7–32.8 35 yr and more 125 19.8 13.0–28.8 128 8.4 4.4–15.5 Number of years in France 0–2 137 10.3 4.9–20.6 <0.001 254 5.4 3.2–8.9 1 negative HIV test after U.S. arrival. Pol genotypes were available for seven of these 11 cases; for six of these seven, a local case was the nearest phylogenetic neighbour, and two were infected with subtype B virus. This suggests local transmission sources for these six cases. The 42 newly diagnosed individuals identified 47 partners; six (12.8%) partners had been diagnosed with HIV infection prior to the investigation. Thirteen partners were newly HIV tested as a result of index patients’ HIV diagnoses; five (38.5%) were HIV‐infected. Of the 11 partners who were previously positive (6) or newly diagnosed (5), seven were interviewed and six were African‐born. We found substantial evidence of ongoing HIV transmission in the African community of KC. Additional efforts are needed to increase HIV testing and prevention among African immigrants in the U.S. 10.7448/IAS.18.5.20473 © 2015 Kerani R et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: rkerani@uw.edu National and district level HIV prevalence rates may obscure substantial variation of HIV disease burden at the community level. Understanding the extent to which HIV differs across communities and the drivers of disparities and similarities within individual districts may offer opportunities for a more effective, targeted HIV response. HIV prevalence and risk behaviours were assessed among 17,109 individuals (53.8% female vs. 46.2% male) in 40 communities in Rakai District, Uganda between August 2011 and October 2013 through the population‐based Rakai Community Cohort Study. Communities were classified as lakeside fish landing sites (n=4), agrarian (n=27) or trading communities (n=9) based upon occupation analysis. HIV prevalence was geospatially mapped using Bayesian methods and variability across and within community classifications was characterized. Differences in risk behaviours between communities were assessed using modified Poisson regression models. There was large variation in HIV prevalence, ranging from 9 to 43%, across communities (see Figure below). Fish landing sites had a mean HIV prevalence of 41% (range: 37–43%). Mean HIV prevalence in trading communities was 17% with substantial variability (range: 11–22%) and 14% in agrarian communities, also with substantial variability (range: 9–26%). Agrarian and trading communities in close proximity (<18 km) to fishing landing sites had HIV prevalence ranging from 11 to 26%. Overall, HIV prevalence was higher among women than men (p=0.01), and the disparity was greatest in the fish landing sites (49% vs. 34%). The proportion of males and females reporting =4 sex partners in the last year was 6.4 (95% CI: 4.1–11.0) and 3.2 (95% CI: 2.7–3.8) times higher in fishing communities than in the agrarian/trading population, respectively. Levels of consistent condom use with non‐marital partners were significantly lower in the fish landing sites (RR=0.80, 95% CI: 0.69–0.94). Large variations in HIV prevalence and risk factors across communities in rural Rakai underscores the need for a granular approach to HIV prevention and response based on local assessment of HIV burden and risks and locally tailored interventions that may include targeting of high risk groups such as those in fish landing sites. Abstract WEPDC0105–Figure 1. HIV prevalence in each of the 40 RCCS communities. Abstract WEPDC0105–Figure 1. HIV prevalence in each of the 40 RCCS communities. 10.7448/IAS.18.5.20474 © 2015 Chang L et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: mgrabows@jhsph.edu Cryptococcal meningitis (CM) constitutes a significant source of morbidity and mortality in resource‐limited regions. One million cases occur annually, representing 10–30% of HIV‐related death in prevalent regions. Optimal interventions for CM prevention remain unclear. The recently developed serum cryptococcal antigen lateral‐flow assay (CRAG‐LFA) is highly sensitive and specific, and may allow early detection of subclinical cryptococcemia in those at risk of developing CM. We sought to determine the cost‐effectiveness of implementing CRAG‐LFA screening for people living with HIV in Uganda compared to other interventions for CM prevention. A decision‐tree model was constructed to compare three strategies for cryptococcal prevention among people living with HIV (PLWH) with CD4<100: Standard of care (SOC, i.e. no cryptococcal screening), CRAG‐LFA screening followed by evaluation and treatment of cryptococcemia or universal primary prophylaxis (UPP) with fluconazole for all patients and no CRAG‐LFA screening. Primary outcomes were expected costs, DALY’s and incremental cost‐effectiveness ratios (ICERs). In sensitivity analysis, we analyzed the impact of costs, prevalence and alternative clinical algorithms on the cost‐effectiveness of CRAG‐LFA screening. CRAG‐LFA screening was associated with an ICER of $5.88 per DALY averted compared to SOC, and was highly cost‐effective at current willingness to pay thresholds for Uganda. CRAG‐LFA screening dominated the UPP intervention (i.e. both cheaper and more effective). Overall, implementation of CRAG‐LFA screening was projected to cost $1.46 more per person than SOC, and could reduce the relative risk of cryptococcal‐associated mortality by over 40%. When including the cost of lifetime ART, the ICER for CRAG‐LFA screening was $557 compared to SOC and still considered cost‐effective. In sensitivity analysis, prevalence of baseline CM and cost of the CRAG‐LFA influenced cost‐effectiveness. In probabilistic sensitivity analysis, the CRAG‐LFA screening intervention was cost‐effective in 100% of simulations, and cost‐saving in 30% of simulations. CRAG‐LFA screening is extremely cost‐effective with the potential to prevent significant morbidity and mortality from CM in vulnerable populations, and represents excellent value for money as a screening intervention for HIV programs in Uganda. Abstract WEPDD0101–Table 1. Cost‐effectiveness projection results Intervention Total Cost Incremental Cost Incremental Cost (including lifetime ART) DALYs Accumulated Incremental Effectiveness (DALYs averted) Incremental Cost‐Effectiveness Ratio (ICER) Incremental Cost‐Effectiveness Ratio (ICER) including lifetime ART Standard of Care (SOC) 9.12 REFERENCE REFERENCE 8.55 REFERENCE REFERENCE REFERENCE CRAG‐LFA Screening 10.58 1.46 139.48 8.30 0.25 5.88 557.60 Universal Primary Prophylaxis (UPP) 236.23 227.10 332.19 8.35 0.20 1141.96 1660.95 Abstract WEPDD0101–Figure 1. Decision‐analysis model schematic. Abbreviations: SOC‐Standard of care, UPP‐Universal fluconazole primary prophylaxis, CRAG‐LFA–cryptococal antigen lateral flow assay, CM‐cryptococcal meningitis, WTP‐WHO pre‐emptive therapy. Decision‐analytic model schematic. We modeled progression or relapse of CM over a 5 year time‐horizon for a cohort of PLWH with CD4 < 100. In all model arms symptomatic patients at baseline receive evaluation for CM assumed to include a lumbar puncture (LP), and treatment if diagnosed with CM. We assumed ART initiation in all arms. The model explores three interventions for prevention of cryptococcal morbidity for those without a baseline diagnosis of CM: 1) SOC, in which patients receive no CM screening or prophylaxis 2) UPP, in which all asymptomatic patients (and symptomatic patients without CM diagnosis * as noted in the model) receive primary prophylaxis with 200 mg of fluconazole. 3) CRAG‐LFA, in which all patients receive serum CRAG‐LFA screening. Individuals with positive CRAG were assumed to receive the WHO preemptive treatment for cryptococcemia with fluconazole 800 mg for two weeks, followed by fluconazole 400 mg for eight weeks. CRAG‐negative individuals receive no further antifungal therapy. Abstract WEPDD0101–Figure 1. Decision‐analysis model schematic. Abbreviations: SOC‐Standard of care, UPP‐Universal fluconazole primary prophylaxis, CRAG‐LFA–cryptococal antigen lateral flow assay, CM‐cryptococcal meningitis, WTP‐WHO pre‐emptive therapy. Decision‐analytic model schematic. We modeled progression or relapse of CM over a 5 year time‐horizon for a cohort of PLWH with CD4 < 100. In all model arms symptomatic patients at baseline receive evaluation for CM assumed to include a lumbar puncture (LP), and treatment if diagnosed with CM. We assumed ART initiation in all arms. The model explores three interventions for prevention of cryptococcal morbidity for those without a baseline diagnosis of CM: 1) SOC, in which patients receive no CM screening or prophylaxis 2) UPP, in which all asymptomatic patients (and symptomatic patients without CM diagnosis * as noted in the model) receive primary prophylaxis with 200 mg of fluconazole. 3) CRAG‐LFA, in which all patients receive serum CRAG‐LFA screening. Individuals with positive CRAG were assumed to receive the WHO preemptive treatment for cryptococcemia with fluconazole 800 mg for two weeks, followed by fluconazole 400 mg for eight weeks. CRAG‐negative individuals receive no further antifungal therapy. 10.7448/IAS.18.5.20475 © 2015 Ramachandran A et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: aramach7@jhmi.edu Early diagnosis and treatment of HIV improves patient outcomes and minimizes risk of transmission. Provider‐initiated testing and counselling (PITC) is an effective case‐finding strategy, but implementation models vary. Malawi Ministry of Health (MOH) guidelines recommend routine opt‐out PITC, in line with WHO recommendations for countries with generalized epidemics, but little is known about its implementation. Our objective was to assess PITC implementation in Malawi. We conducted a cross‐sectional study of PITC implementation at 118 clinics and wards within 12 MOH facilities in central Malawi during June–July 2014. Qualitative data detailing PITC practices was collected through structured interviews with 71 providers who conduct HIV testing at their facility, and characterized using standardized definitions (Figure 1). Quantitative data describing patient visits and HIV tests recorded during 2013 was abstracted from MOH HIV testing reports. Variable models of PITC were reported across facilities and departments (Table 1). Overall, symptom‐based PITC was most commonly reported. Only antenatal and maternity (20/24) departments reported implementing routine opt‐out testing. Use of a PITC register varied significantly according to department type. Only 7.7% (86,657/1,102,802) of patient visits in 2013 included an HIV test. Subgroup analysis of TB and antenatal clinics with available data demonstrated that HIV status was ascertained in 94.3% (5293/5615) and 86.8% (26,831/30,961) of patients, respectively. Providers most commonly cited test kit shortages (71/71 providers), inadequate physical space (58/71) and inadequate number of HIV counsellors (32/71) as challenges in PITC implementation. Providers from inpatient units cited the inability to test on weekends (8/16). Various models of PITC concurrently exist at MOH facilities in Malawi. Only antenatal and maternity clinics demonstrated high rates of routine opt‐out PITC. The low ratio of facility visits that included an HIV test suggest missed opportunities for HIV testing. However, the high proportion of patients at TB and antenatal clinics with known HIV status suggest routine testing is feasible. These results underscore the need to develop clear, standardized PITC protocols and tools, and to address obstacles of limited health commodities, infrastructure and human resources. Abstract WEPDD0102–Figure 1. Definitions of PITC models. Abstract WEPDD0102–Figure 1. Definitions of PITC models. Abstract WEPDD0102–Table 1. Reported PITC model and use of PITC register Types of PITC reported, n (%) Department type Routine opt‐out Routine opt‐in Symptom‐based PITC register in use, n (%) TB Clinic 5/12 (42) 7/12 (58) 0/12 (0) 12/12 (100) Antenatal clinic and maternity ward 20/24 (83) 4/24 (17) 0/24 (0) 24/24 (100) Family planning clinic 1/11 (9) 7/11 (64) 3/11 (27) 8/11 (73) STI clinic 3/6 (50) 3/6 (50) 0/6 (0) 6/6 (100) Outpatient Department, Under‐5 clinic, and immunization clinic 4/36 (11) 4/36 (11) 28/36 (78) 9/36 (25) Malnutrition clinic 7/10 (7) 2/10 (20) 1/10 (10) 5/10 (50) Adult and paediatric inpatient wards 1/19 (5) 3/19 (16) 15/19 (79) 5/19 (26) Totals 41/118 (35) 30/118 (25) 47/118 (40) 69/118 (59) 10.7448/IAS.18.5.20476 © 2015 Schwarz M et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: monica.ann.schwarz@gmail.com CD4 count is essential to identify antiretroviral treatment (ART) eligibility. For over a decade, Médecins Sans Frontières and the Ministry of Health provides ART in 10 rural health centres (HCs) in Chiradzulu District, Malawi. From June 2013, Alere’s PIMATM CD4 point‐of‐care (POC) test is being implemented in the HCs. Shortage of health care‐ and laboratory staff is an issue in this setting. We assessed task‐shifting of PIMA CD4 test operation to non‐health workers living in the community around the HCs. Four non‐health workers received a one‐week structured training on PIMA CD4 POC operation. Between June 2014 and January 2015, 331 venous blood samples of pre‐ART and ART‐patients attending routine CD4‐testing in two rural HCs were included. Each sample was assessed on site with PIMA by a lab technician (LT) and a trained community worker (TCW), and measured with PartecCyflow® counter at district hospital. Kappa‐coefficient and percent agreement for CD4‐classification below and above relevant thresholds were obtained. Bias and limits of agreement (LOA) were assessed for absolute CD4 counts. PIMA error‐rates and failed runs (2 consecutive errors) were recorded and TCW‐operator acceptability assessed. Three‐hundred‐twenty‐eight venous blood samples (85% ART‐patients, 68.5% female) were included. Median CD4 count (LT PIMA) was 425 cells/µL (IQR: 323, 570). Error rates were low (LT: 1.2% vs. TCW: 2.4%, p=0.34) and no failed runs occurred. Good agreement was achieved for PIMA results by LTs versus TCWs for CD4 threshold 350 cells/µL (91.7% (95% CI: 88.2–94.5); kappa=0.80) and 500 cells/µL (91.1% (95% CI: 87.5–93.9); kappa=0.80). The mean bias (TCW‐PIMA minus LT‐PIMA) was low (−2.2 cells/µL (LOA: 137.4, −141.9)). Bias and LOA comparing PIMA results by LTs or TCW versus Partec was similar (LT‐PIMA minus Partec: −46.4 cells/µL (95.9, −188.8)); (TCW‐PIMA minus Partec: −46.5 cells/µL (118.0 −211.0)). TCWs rated PIMA operation as very easy. Adequately trained community workers delivered CD4 results equivalent to lab technicians with PIMA POC in health centre laboratories. Task shifting of simplified CD4 POC‐technologies to trained non‐health care staff can serve as a key strategy to ensure sustainable provision of CD4‐testing in support of ART‐initiation in rural facilities. 10.7448/IAS.18.5.20477 © 2015 Schramm B et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: birgit.schramm@epicentre.msf.org WHO recommends that all children exposed to HIV be tested within four to six weeks of birth to ensure that all infected infants are identified and initiated on treatment early. One major challenge with early infant diagnosis (EID) of HIV in Nigeria remains the absence of standardized logistic sample transfer systems, resulting in long turnaround times between date of sample collection and date of return of result to the mother. To address this challenge, the USAID‐funded ProACT project implemented by MSH, pioneered the Strengthening the Process and Efficiencies for Early infant Diagnosis (SPEEiD) model, which involves the transportation of dried blood spot (DBS) samples from remote HIV clinics to regional PCR labs using the Nigerian Postal Service (NIPOST) Express Mail Service (EMS) platform, which has a network of over 3900 post offices and agencies spread across the country, ensuring penetrance to remote HIV clinics. The objective of this study was to review the effect of utilizing an innovative DBS transport model in improving DBS transportation. We carried out a retrospective analysis of logistic data from 177 samples transferred from 28 PMTCT sites using the SPEEiD model over a 12 month period from March 2013 to February 2014 in Kwara state, North Central Nigeria. A review of the data showed a reduction in turnaround time for return of results from 3–6 months to 3–4 weeks utilizing the SPEEiD Model. Results were received for 97% of samples (171/177) transported with this model, compared to 51% previously. The average cost of sample transfer was estimated at between $20 and $40 per batch and remains comparatively less expensive to other models by at least 30%. The MSH SPEEiD model remains an indigenous, cost effective, sustainable and time‐sensitive sample transfer model which ensures that exposed infants are able to receive their EID test results quickly. This approach may be easily replicated by other partners working in similar resource limited settings, as it provides a practical solution for DBS sample transfer, which remains one of the major challenges affecting EID of HIV in Nigeria. 10.7448/IAS.18.5.20478 © 2015 Ndulue N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: nndulue@msh.org In Uganda, 39% of HIV‐exposed infants (HEI) were HIV tested within two months and 50% and 1/21 samples slightly 50% INSTI test dot intensity diminished by <50% No change in INSTI test dot intensity 15 early SC, IgM positives 15 8 7 – – 6 early SC, IgM not determined 6 2 3 1 – 5 late SC, IgG 5 – – – 5 Total=26 26 10 10 1 5 10.7448/IAS.18.5.20563 © 2015 Moshgabadi N et al; licensee International AIDS Society Published 22 July 2015 Presenting author email: n.moshg@gmail.com

Mr

Leigh Harty

Research Assistant

Department of Microbiology and Immunology

Mr

Leigh Harty

Contact Leigh Harty

Division

Faculty of Medicine, Dentistry and Health Sciences

Mr

Leigh Harty

Print

Leigh Harty's Short Profile

Enquiries

Contact